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Abstract 
 
Background and Aims: Chronic obstructive pulmonary disease (COPD) is 
emerging as a substantial global health problem, with an estimated annual 
mortality of over 3 million people, which is the third largest disease cause 
worldwide. COPD is an irreversible chronic, slowly progressive airway 
obstructive respiratory disease. Cigarette smoking mainly causes it, primarily 
through small airway fibrosis, narrowing and ultimately obliteration, 
accompanied by more generalized but non-obstructive “chronic bronchitis” 
throughout the airways, and in some individuals complicated by the later 
development of lung parenchymal destruction (emphysema). Approximately 
50% of smokers develop COPD eventually.  
In COPD research, there has been a long-held belief that airway disease 
progression is due to “inflammation.” Although this may be true in the airway 
lumen with innate immunity activated by the effect of smoke or secondary to 
infection, the accurate picture for inflammatory cells in the airway wall, where 
the pathophysiological COPD remodeling occurs, is uncertain and especially 
so in mild to moderate COPD patient’s, i.e., earlier disease. This study follows 
up on a previous finding from our group of possibly decreased cellularity in the 
airway wall of patients with COPD. Thus, in the current studies, along with total 
airway wall cellularity, I evaluated the contribution of the main immune cells 
such as neutrophils, macrophages, mast cells,  CD4  and CD8 cells in the large 
and small airway wall of mild-moderate COPD current (CS) and ex-smokers 
(ES), plus normal lung function smokers (NLFS), and compared them to non-
smoker controls (NC). My studies further delved into the macrophage sub-
populations in smokers/COPD and ascertained whether abnormal differential 
switching occurs in the macrophage population in the small airway wall 
compared to the lumen. I also measured macrophage-related cytokine profiles 
in airway luminal bronchoalveolar lavage fluid (BALF) and investigated whether 
the microenvironment dictated these changes. I evaluated cell dysfunction in 
small airway wall cells by assessing their degranulating potential via expression 
of a degranulating-marker lysosome-associated membrane protein -1 (LAMP-
1).  
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While analyzing the CD68+ population of macrophages, I noticed that many 
cells staining strongly were not macrophages as expected, but spindle-shaped 
cells likely to be a population of fibroblasts; indeed the literature strongly 
suggests that CD68 can also stain fibroblasts, but this has until now been 
ignored in respiratory research.  
I further focused on the non-inflammatory cell components in the airway wall, 
investigated the relationship between alpha-smooth muscle actin+ 
myofibroblasts with an expression of epithelial-mesenchymal transition 
markers (a focus of our group for several years), key extracellular matrix 
proteins (collagen I and fibronectin) and airway wall thickness. I also related 
abnormalities to lung function disturbance in COPD.  
In the final phase of my Ph.D. studies, I also managed to complete some 
preliminary investigations on abnormal lysosomal accumulation and catabolic 
changes in the airway epithelium of COPD patients and related these to indices 
of airway remodeling. 
Methodology: I evaluated both large airway endobronchial biopsies (ebb) and 
small airway lung resected tissues (RT) from COPD-CS and ES, NLFS and NC. 
I immune-stained with human anti-CD68+ for macrophages, neutrophil 
elastase for neutrophils, mast cell tryptase for mast cells, CD4+ and CD8+ for 
T cell populations. I conducted total cell counts as well as differential counts in 
the airway wall lamina propria (LP), epithelium and reticular basement 
membrane. For the large airways, I standardized cell counts in the LP by taking 
the depth of 150 for LA and up to 100 microns deep SA while excluding smooth 
muscle layers. Further, subpopulations of macrophages were evaluated in the 
SA wall (epithelium and LP) and BAL samples from the same cohort of patients 
and were stained with CD163 and Arginase-1 antibodies for detection of M2 
macrophages and dual stained with anti-CD68+ and anti-iNOS antibodies for 
M1 populations (CD68+ only cells were designated M0). Cells were quantified 
and normalized as per mm2 of SA wall and as per mm of length for the 
epithelium, respectively. Bronchoalveolar lavage (BAL) cytospin macrophages 
were similarly stained and enumerated by randomly selecting 12 fields and 
quantified as per ml of original BAL fluid extracted. BAL cytokines to profile for 
both M1/Th1 and M2/Th2 cytokines used FACS multiplexing strategies.  
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The degranulation capacity of mast cells and total degranulating cells in the 
small airway wall were measured by dual staining mast cells with anti-mast cell 
tryptase and LAMP-1. Epithelial and sub-epithelial LAMP-1 were assessed per 
area and represented as percent degranulation. I measured the total airway 
wall thickness of SA and divided it into the epithelium, reticular basement 
membrane (Rbm) LP, smooth muscle layer, and sub-mucosal adventitia, which 
meets the alveolar tissue. Further, I quantitated the α-SMA+ cells present in the 
SA lamina propria and adventitia, while the ECM markers (collagen-1 and 
fibronectin) were quantitated as a percentage of area staining in the same 
areas.    
Results: I confirmed hypo-cellularity in the airway wall in both large and small 
airways in smokers and in COPD; with LA wall cellularity least in the COPD-
current smoker (CS), while SA cellularity was similar across smoker/COPD 
groups. LA neutrophils were decreased in COPD-CS, while SA neutrophil 
counts were unchanged. In contrast, a small but significant increase was 
observed in SA CD8+ cells in both normal smokers and COPD-CS but not in 
LA. Ratiometric analysis of CD4+ and CD8+ T cells showed a dominance of 
the CD8+ phenotype in the LP area of LA, but not SA.  Compared to controls, 
LA macrophage numbers in COPD were significantly lower, with SA 
macrophage numbers unchanged. Further evaluation of the SA macrophage 
subpopulations showed a significant increase in pro-inflammatory M1s in the 
small airway walls of NLFS and COPD compared to controls with a reciprocal 
decrease in M2 macrophages, which remained unchanged among pathological 
groups. However, luminal macrophages went the other way, with a dominant 
M2 phenotype in both NLFS and COPD subjects. BAL cytokine profiles were 
skewed towards M2 with an increase in CCL22, IL-4, IL-13, and IL-10 in both 
NLFS and COPD.  
A decrease in degranulating mast cell and total degranulating cells was 
observed in the SA wall via monitoring intracellular LAMP-1 expression. 
Further, and unexpectedly, this lysosomal LAMP-1 expression was also found 
to be markedly increased in the epithelium of small airways in COPD. This 
increase in LAMP-1+ lysosomes significantly correlated with a decrease in lung 
function increased airway obstruction and increased in airway thickness. 
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Among the non-inflammatory cell populations characterized, I found a 
significant and marked increase in αSMA+ myofibroblast numbers in the small 
airway tissue in both smokers and COPD compared to normal controls, which 
directly correlated with decreased airway caliber measures in COPD patients. 
A significant increase was observed in the ECM proteins collagen-1 and 
fibronectin in the small airway wall of smoker and COPD groups. The 
proliferation of myofibroblast directly co-related to this increased collagen and 
fibronectin deposition and airway wall thickening, which suggested an active 
role in airway remodeling. The increase in the myofibroblast population also 
correlated with increases in expression of the EMT markers S100A4 and 
vimentin and lung function. 
Conclusions: These current studies confirmed our group`s novel finding of 
hypocellularity in the airway wall of COPD patients, both in large and small 
airways. Analysis of the literature suggests that this has hardly been looked 
previously and probably not as rigorously as this investigation.  These changes 
corresponded to decreases in most airway inflammatory and immune cells. 
Overall, the contribution of inflammatory/immune cells to total airway wall cells 
was small, again something else never previously documented, with the 
majority likely to be stromal cells. Macrophage subpopulation showed abnormal 
differential switching in both the airway wall and lumen, though in different 
directions. Lack of degranulation activity in the cells of the airway wall in COPD 
indicated dysfunctionality, which could be crucial in viral and bacterial infections 
known to be essential disease exacerbations in particular. A proliferation of 
myofibroblast was present in small airways and strongly associated with both 
remodelling, active EMT and loss of airflow in COPD. 
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 COPD: An introduction 
 
 Respiratory Tract:  Normal anatomy and histology  
 
The respiratory system does the critical function of acting as a portal for 
oxygen in the air and exporter of carbon dioxide, so facilitating the trillions of 
cells in the human body to carry out the fundamentally vital function of 
respiration. It consists of conducting airways, which extend from the nose to 
lung parenchymal alveoli. Thus, the nose, pharynx, larynx, trachea, bronchi, 
and bronchioles in series functionally connect the external environment with the 
internal extensive thin and delicate alveolar surface. The whole neuro-
respiratory system coordinates four vital processes: pulmonary ventilation 
(breathing), gas exchange in the alveoli requiring optimal ventilation/circulatory 
matching, blood transport of respiratory gases (lung to tissue/cells and back), 
and finally internal cellular respiration at a mitochondrial level (Scanlon and 
Sanders, 2007). The intricate details of all these processes and their control 
and integration are beyond the scope of this review, and I will focus initially 
mainly on the structure of the respiratory system as it relates to function. 
 
A respiratory system is functionally a single unit that can be divided into 
upper and lower respiratory tracts. As outlined above, the gas-conducting upper 
respiratory tract consists of parts outside the chest cavity - nasal air passages, 
nasal cavities, pharynx, larynx, and upper trachea, while the lower respiratory 
tract consists of lower trachea, approx 23 generations of branching bronchial 
tree (large airways defined as >2mm in diameter, and small airways <2 mm in 
diameter). The final bronchioles being tiny airways gradually merge with the 
gas-exchanging clusters (acini) of the alveoli (Kerr, 2010).  
 
Histologically, the mucosa of the upper respiratory tract consists of, from 
the outside to inside, a luminal/superficial ciliated epithelium lining in contact 
with the atmosphere  and attached to a basement membrane deeply, a denser 
connective tissue reticular basement membrane beneath that which fuses into 
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a less dense connective tissue lamina propria, then a circumferential smooth 
muscle bundle layer, and below this the adventitia of looser connective tissue 
containing supporting cartilage structures, and mucous glands containing 
mucus secretory cells which empty into ducts which join to find their way out to 
the lumen through the other more superficial structures. The adventitia itself in 
the lower airways gradually fuses with the lung parenchyma and provides basic 
anchoring points for the alveoli, which provide elastic and supporting 
interactions between the parenchyma and airways for optimal airflow.   
  
The structural details of the airways change as they transition into the 
smaller airways - cartilage, goblet cells, smooth muscles and connective tissue 
gradually diminish, and are completely absent in the terminal gas-exchanging 
respiratory bronchioles and alveoli (Figure 1.1).  
 
Ciliated epithelial cells persist as far down the bronchial tree as the 
bronchioles, while goblet cells are replaced by  non-ciliated dome-shaped club 
cells, present intermittently along the bronchiole epithelial lining. The club cell 
carries out the vital function of secreting surfactant proteins (Kerr, 2010). 
 
The connective tissue across the airway wall have large numbers of 
resident interstitial stromal cells, mainly comprised of fibroblasts. Fibroblasts 
produce extracellular matrix protein (ECM) such as collagen, fibronectin and 
various varieties of proteoglycans which includes versican, desmin among 
other, which are vital to maintaining airway stiffness/ elasticity for their 
mechanical function (Burgess et al., 2016). Thus, there lies a huge potential for 
variability in all these structural and cellular composition across the airways 
(and lung parenchyma) that has enormous implications for disease states, 
which underlies the core interest of my thesis work. For instance, thickening of 
reticular basement membrane – one of the two structural layers of the bronchial 
epithelial basement membrane – is usually observed in asthma 
characteristically though our research group has also shown significant 
changes in COPD (Figure 1.1). 
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Figure 1.1 Pictorial illustrations of the central compartment and their sub- 
divisions of the human lung.  
 
Figure 1.2 Schematic adapted and modified from Sun et al. Nat Rev Cancer 2007 
titled ‘Lung cancer in never smokers: a different disease’ shows the central 
compartment (top left), and structure of large bronchus (top right) and respiratory 
bronchioles (bottom left). Histological representation of thin-walled small airways (SA) 
(A and C) from a normal non-smoker, thickened in COPD (B and D) (bottom right). A, 
B at 50X, and C, D. is at 200X magnification. 
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 Characteristics of COPD 
 Clinical  
 
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) has defined 
COPD as a disease state characterized by airflow limitation (obstruction) that 
is not entirely reversible. The airflow limitation is usually both progressive and 
associated with an abnormal inflammatory response of the `lungs` to noxious 
particles or gases” (GOLD 2015) (Vestbo et al., 2013), by far the most common 
of these in Western countries being cigarette smoke. This “abnormal 
inflammatory response” is instead an ambiguous and vague term, which in fact 
is a matter that I have dealt with in depth in this thesis, at least as far as the 
airway wall is concerned.  
 
Common signs and symptoms of COPD include especially progressive 
shortness of breath, but also commonly chronic cough and mucus 
hypersecretion. The major pathologic changes of COPD are observed in the 
airways, at least in its early stages in most cases. Lung parenchyma and 
pulmonary vasculature also go on to show significant pathological 
manifestations in many patients at a later stage in COPD natural history 
(Thurlbeck et al., 1968). 
 
The landmark study by James Hogg, working as a young researcher in Peter 
Macklem`s lab in Montreal, from the late 1960s, suggested that the earliest 
pulmonary changes relating to airflow obstruction in smoking-related COPD 
occur mainly at the level of the small conducting airways (Hogg, Macklem & 
Thurlbeck 1968). Briefly, what have been again somewhat vaguely termed 
“various cellular and biochemical processes” result in progressive fibrosis and 
thickening of the airway wall in the small airway with luminal narrowing, 
progressing to small airway obliteration (~50% gone before conventional lung 
function deteriorates) (Belperio et al. 2003; Hogg et al. 2004; Hogg, 
McDonough & Suzuki 2013). These changes gradually increase airway 
resistance and eventually show up as classic airflow obstruction. Subsequent 
experimental measurements suggested that as high as 30-40% of airway 
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resistance could be attributed to small airways (Takishima, Yanai & Sasaki 
1991), which is considerably higher than what had been estimated earlier 
(~20%) (Hogg, Macklem & Thurlbeck 1968).  
 
More generalized throughout the airway wall in COPD, but also in smokers 
without COPD, is remodelling in the form of epithelial goblet cell hyperplasia 
(“bronchitis”), epithelial squamous metaplasia and submucosal gland 
hyperplasia in a majority of patients. This aspect of COPD was very much the 
focus of clinical and epidemiology research in the 1950s and 1960s with some 
excellent researchers such as Prof Lynne Reid in London, but it took some time 
to realize that these changes are not central to functional abnormalities on 
spirometry, although they may have a symptomatic impact.   
 
Emphysema is the destruction of the lung parenchyma, i.e., the alveolar lung 
compartment, leading to loss of elastic recoil forces and so airway tractional 
support and luminal pressure during expiration, so adding to airflow obstruction 
due to pre-existing intrinsic airway fibrosis and luminal narrowing. This 
develops only in a subset of individuals, usually as a secondary phenomenon. 
Thus, the dilatation and destruction of the gas-exchanging tissue beyond the 
terminal bronchioles are termed “emphysema” (McDonough  et al., 2011). 
Emphysema is defined in pathologic terms as "alveolar wall destruction with 
irreversible enlargement of the air spaces distal to the terminal bronchioles and 
without evidence of fibrosis” (Snider et al., 1985), and in general, occurs a 
decade later than airway narrowing (Dunnill et al., 1969). Morphologically, there 
are two main subtypes of emphysema (Kim et al., 1991). The centrilobular (or 
centriacinar) emphysema is more closely associated with cigarette smoking, is 
usually most marked in upper lobes. The emphysema subtype causes more 
severe small airways obstruction, because of loss of alveolar-airway support 
points. Panlobular (or panacinar) emphysema is mainly associated with α1-
antitrypsin deficiency, resulting in an even dilatation and destruction of the 
entire acinus, and especially in the lower lobes (Litmanovich et al., 2009), which 
leads especially to early loss of lung gas diffusion capacity and 
ventilation/perfusion mismatching with exercise-related breathlessness being 
the primary symptom as a result. 
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Changes in the pulmonary vasculature include intimal hyperplasia and smooth 
muscle hypertrophy/hyperplasia, likely attributed to be chronic hypoxic 
vasoconstriction of the small pulmonary arteries (Harkness et al., 2014), 
although this is likely  an over-simplification with loss of pulmonary capillary 
capacity and also endothelial activation occurring. Thus, emphysema 
especially can lead to loss of the associated areas of the pulmonary capillary 
bed, and some have said that this is a primary pathology in causing 
emphysema. 
 
 
 
 
 
Figure 1.2 Clinical characteristics of COPD. 
 
In summary, the primary pathophysiology in smoking-related COPD, including 
fibrosis and obliteration of small airways, associated temporally with other 
airway remodelling changes such as squamous metaplasia, mucus 
hypersecretion and goblet cell hyperplasia in large airways. Basal cells in the 
airway epithelium are increasingly regarded as extremely important in all of 
these aspects of airway remodelling, one manifestation of which is a feature 
that our group described and had focused on, namely epithelial-mesenchymal 
transition (EMT), type II or III, categorized on the basis of presence (type III) or 
absence (type II) of angiogenesis. We feel that this is a fundamental process in 
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airway fibrosis and obstruction and I will overview the literature on this later, 
and come back to it repeatedly in the experimental sections of my thesis.  
 
I have already mentioned that there is a dogma reflected in international 
position papers and initiatives, e.g., GOLD definitions, that airway 
“inflammation” is a core feature of COPD. I will be dealing with this aspect also 
in great detail later, but Fig 1.2 summarises what my research group felt was 
the provisional truth about inflammation and airway pathology in general when 
I began my work, and it has been a model that I have been much guided by. It 
emphasizes that innate inflammatory activation is really a proven feature only 
of the airway lumen in COPD, with marked increases in macrophages and to a 
lesser extent neutrophil (and sometimes eosinophils) in this compartment, 
perhaps driven by oxidant stimulation and chronic infection. The high 
vulnerability of the airways to infection and chronicity of infection with particular 
viral and bacterial organisms have been the subject of the thesis and published 
papers from a co-PhD student, Dr. Shakti Shukla, within the CRE (Shukla et 
al., 2015). I am not going to deal with this further, except to say that these 
infective manifestations of COPD, and the significant associated exacerbations 
of COPD clinically which tend to occur increasingly frequently as the disease 
progresses. All these manifestations are the consequence of abnormally 
activated epithelium that induces infection and inflammation in the epithelial 
and luminal airways, thus forming a major feature of this complex disease. 
However, my work has dealt with the nature of cellularity in the airway wall itself, 
rather than the airway lumen, and this will remain the almost exclusive focus of 
my discussions. 
 Historical developments in understanding COPD 
 
Some early clinical finding relating to COPD were reviewed by Thomas 
PL Petty in 2006. The most prominent observations were: Badham C in 1814 
was the first to provide a clinical description on “chronic bronchitis,” a major 
symptomatic component in COPD patients. He described the presence of 
“bronchiolitis” as well as chronic bronchitis as disabling disorders (Badham, 
1814, Petty, 2006). Laënnec (1821) in his book titled “Treatise on the diseases 
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of the chest” was the first to describe the emphysematous lung along with the 
presence of chronic bronchitis (Laënnec, 1821). The Spirometer as the key 
instrument in the physiological diagnosis and management of COPD was first 
invented by John Hutchinson in 1846 and further developed a hundred years 
later by Tiffeneau in 1947 (Tiffeneau,1947). Although there were considerable 
clinical advances in the late 19th and early 20th century, it was not until the mid-
20th century that COPD was more clearly defined in modern terms  
Two symposia played a critical role in defining the disease, the CIBA 
Guest Symposium in 1959 (Donald, 1971) and the American Thoracic Society 
(ATS) meeting on diagnostic standards in 1962. While the former delved into 
defining and classifying emphysema, the latter provided a key understanding 
of the components of COPD with “chronic bronchitis” defined in clinical terms 
as a persistent cough that last for three months for a two-year duration, and 
emphysema in anatomic terms, as enlarged alveolar and the loss of alveolar 
walls. Though there were no physiological parameters considered, these 
statements have provided strong foundations in how we now define the disease 
today, as I did earlier. William Briscoe first coined the term COPD (Chronic 
Obstructive Pulmonary Disease) itself in 1965 in a presentation at the 9th 
Aspen Emphysema Conference (Briscoe and Nash, 1965), although other 
variants such as Chronic Obstructive Airway or Lung Disease (COAD/COLD) 
have been in vogue at different times. The term COPD has the advantage of 
being deliberately open about where the obstruction is anatomically and how 
caused, i.e., instead presumes a mix of airway fibrotic obstruction and 
emphysema, but also suffers from not emphasizing the core airway component.   
Lynne Reid in 1960 was the first to provide pathology measurement 
criteria for COPD called the Reid Index (Reid, 1960), which was a ratio of the 
mucous glands to the thickness of the bronchial wall. Later on, in a book 
authored by her, titled “The pathology of Emphysema” she makes a clear 
distinction between airway bronchitis and anatomic emphysema (Reid, 1966). 
However, she missed the central role of small airway narrowing/fibrosis rather 
than the cause of symptoms in her emphasis on mucus production. 
Dunhill,1969 further developed the field by emphasizing with the pan airway 
nature of the disease and its mixed pathology and suggested studying both 
airway and lung components to establish the pathogenesis of the disease 
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(Dunhill, 1969). Macklem and Mead were first to define the role of small airway 
pathology in COPD, and their study was based on a novel method developed 
using a specialized catheter to provide direct measurements of the resistance 
in peripheral airways with less than <2 mm in diameter (Macklem and Mead, 
1967). 
 Since the 1960’s research into COPD substantially lost out to interest in 
asthma, at least for 3-4 decades as the key airway disease. However the last 
decade (partly due to the increased smoking-related disease and co-
morbidities) has seen a surge in focused research around COPD.  
 
 Clinical classification of COPD 
 
 Measurement of Lung Function 
 
The symptoms of COPD are a cough, sputum production and chronic 
progressive dyspnoea as guided by the GOLD standards. Hyatt and Black 
introduced the obstructive index ratio also called forced expiratory ratio (FER), 
which essentially is described as the ratio of forced expiratory volume in 1 
second (FEV1) to the forced expiratory vital capacity (FVC) (Hyatt and Black, 
1973a, Hyatt and Black, 1973b). Spirometry has been successfully used for the 
physiological assessment for determining lung function, and it is a safe, non-
invasive, reproducible breathing test. Spirometry is an essential pulmonary 
function test (PFT) and can be performed to assess bronchodilators responses 
before and after their administration. The test can thus be used to confirm 
whether airflow limitation is wholly or partially reversible.  An FER of <0.7 
confirms the presence of airway obstruction, while FEV1percentage predicted 
is used to classify COPD severity (mild ≥80 percentage, moderate 50-80%, 
severe 30-49%, very severe <30%) (Table 1).  
Aging also affects FEV1 and FER, which remains underdiagnosed using a fixed 
ratio method in COPD patients (Ito & Barnes, 2009). For smokers who are 
having more than ten pack-years the decline in FER is much more rapid and 
twice higher than for healthy non-smokers (Rennard, 1998). Further, in healthy 
people, the lower limit of normal (LLN) for FER is dependent on the age and 
thus requires to be accounted in COPD patients (Hankinson et al., 1999). 
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One other disadvantage of the traditional PFTs is that evaluation of patients are 
usually done at rest, and at best provide only baseline pulmonary performance. 
A more modern cardiopulmonary exercise testing (CPET) is a potentially 
alternative for PFT as the preferred predictor of actual lung function. CPET is 
primarily employed in sports physiology to analyze endurance capacity in elite 
athletes; they are sophisticated physiologic testing technique capable of 
measuring multiple physiological parameters in an exercise environment. The 
instruments measure maximal or peak oxygen consumption (VO2max), 
Respiratory exchange ratio (RER), minute ventilation (VE) and Anaerobic 
Threshold (AT) which is calculated from data collected from CPET gas analysis 
(Suji Eapen et al., 2016). These sophisticated instruments are highly priced and 
are less likely affordable in every hospital facility.  
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Table 1. Staging of disease severity in COPD patients 
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 Measurement of Airway obstruction 
 
Although FER remains the standard measurement for measuring lung flow 
capacity, there has been increasing recognition that small airway represents a 
quiet zone in the normal lung where the disease can persist. This would 
possibly help predict early detection of the disease before symptoms are 
noticed and when routine test is abnormal. Currently, the measure of small 
airway dysfunction by spirometry is determined by measuring the average 
forced expiratory flow over the middle half (50%) of the FVC (FEF25-75%) and 
forced expiratory flow at 75% of the FVC (FEF75%) (McFadden and Linden, 
1972). However, the clinical relevance of these measures has been debated 
recently by Quanjer et al., (2012) who found no difference in the convention 
indices to that of FEF25-75% measurements. Recently, however, a new method 
for accurately analysing the concavity in the descending expiratory limb of the 
routinely used flow-volume curve. Such concavity is a hallmark of small airway 
obstruction, and this new analytical technique has been reported to improve the  
detection of fixed small airway obstruction by 25%  in community-based 
samples (Figure 1.3) (Johns et al., 2014). Other recent technology 
developments have used forced oscillations of air at the mouth into the 
respiratory tract as a convenient way to detect small airway abnormalities. This 
method uses air pressure-wave impedance oscillometry , and includes a forced 
oscillation during tidal breathind and impulse oscillometry which are both now 
entering clinical practice (Hogg et al., 2017).  
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Figure 1.3. Variables used to quantify global and peripheral concavity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A novel way of interpreting the expiratory limb of the F-V curve. Measured FEF50% and 
measured FEF75% are the forced expired flows when 50% and 75% of the FVC has 
been expired. Reference FEF50% and Reference FEF75% are the references flows that 
would be obtained if the flow-volume curve had zero curvature, i.e., a linear 
descending limb (dotted line). The variable, y, is the volume of peak expiratory flow 
(PEF); a value of 0.6 L can be assumed for this. In this example, the global concavity 
is approximately 50 Units, and the peripheral concavity is approximately 65 Units. Such 
an analysis may markedly improve the detection of early COPD (by perhaps 25%).  
The graph and the legends are reproduced from Johns, Walters, and Walters 
(Johns et al., 2014).  
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 Epidemiology of COPD 
 Burden of COPD (Global) 
 
 COPD, which was ranked the sixth leading primary cause of death in the 
1990s,  increased rapidly in prevalence to gain the fourth position by 2000 and 
is now being estimated to rise to be in third place by 2020 (Mathers et al., 2006, 
Lopez et al., 2006).  
 
The Burden of Obstructive Lung Disease (BOLD) initiative was designed to 
develop standardized, objective methods for estimating COPD prevalence 
worldwide that would be practical for use in countries with different economic 
development profiles, and also to then estimate the economic burden of COPD 
(Buist et al., 2005). This showed that the prevalence of COPD increased with 
age and pack-years of smoking (multiples of 20 cigarettes per day for 1 year, 
which is one pack-year), although other risk factors, such as use for biofuels for 
internal home heating and/or cooking, occupational and environmental 
dust/fume/gas exposures and airway infections, could also contribute 
significantly to COPD in a location-specific way (Buist et al., 2007).  Halbert et 
al., (2006) conducted a systematic review with random effects of meta-analysis 
to quantify the global prevalence of COPD. The overall prevalence of 
physiologically-defined COPD by GOLD criteria in adult’s ≥40 year of age was 
again approximately 9–10%. The authors also reported the prevalence of 
chronic bronchitis, i.e., a chronic cough and sputum production alone as 6.4% 
from 38 studies and for emphysema alone as 1.8% from eight studies.  
 
From all these studies, COPD prevalence has been found to range from 0.2% 
in Japan to 37% in the USA, but varied widely across the populations reported, 
with variations dependent on diagnostic methods and groups reported. The 
burden of COPD was more commonly reported in older populations, socially 
with median population age greater than 75 years. Although, the prevalence of 
COPD has increased over time, this rate of increase has declined in recent 
years, particularly among male populations. Globally, COPD affects 
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approximately 329 million people, which accounted for nearly 5 percent of the 
total world population at the time assessed (Vos et al. 2010) 
 
Respiratory diseases, which includes airway diseases such as asthma and 
COPD, are the third most lethal non-communicable diseases (NCDs) causing 
4.2 million deaths globally in 2008 and are expected to become even more so 
in the quite near future (WHO 2014). COPD alone resulted in 2.9 million deaths 
in 2013, which increased from 2.4 million deaths in 1990, in data published as 
an international collaborative global burden of disease project ('Global, 
regional, and national age-sex specific all-cause and cause-specific mortality 
for 240 causes of death, 1990-2013: a systematic analysis for the Global 
Burden of Disease Study 2013'  2015). Also, these figures do not take into 
account the death burden from lung cancer, which is the most lethal malignancy 
now in both men and women (5-year survival only about 15%), and increasingly 
understood as closely associated with COPD rather than just smoking as such. 
 National burden of COPD (Australia) 
 
Interestingly in Australia, the death rate due to COPD has approximately halved 
between 1979 and 2011 among males, although it was increasing among 
females before now starting to decline (Figure 1.4). Furthermore, an increase 
in death rates, almost 2.5 folds higher are observed among the indigenous 
community with COPD compared to that of the non-indigenous population 
according to AIHW 2012, while this is more prevalent in the rural areas where 
poor socio-economic factors could be the reason.  
 
Although there is a declining trend in COPD (mainly due to ongoing 
governmental and non-governmental initiative using various other social 
awareness programmes), up until 2013, it is still one of the leading cause of 
death and disease burden after heart disease, stroke, and cancer. Again, 
remembering that much of cancer mortality is related to COPD, though not 
currently considered in the national statistics. Lung cancer and chronic 
obstructive pulmonary disease (COPD) coexist in smokers, and the prevalence 
of COPD increases the risk of developing lung cancer by 4-5 folds, even after 
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smoking history is controlled (Eapen et al., 2016). The major risk factor for 
COPD in Australia is cigarette smoking, as for like other developed and now 
increasingly for under-developed countries, COPD as of 2014 is the fifth leading 
cause of mortality and caused 7,025 in this year alone which was 4.9 percent 
of the total deaths in Australia (AIHW, 2014). An estimated 750,000 Australians 
have COPD, which has progressed to a stage, such as breathlessness may 
already be, affecting their daily lives (Toelle et al., 2011).  While half of these 
people do not have a doctor’s diagnosis of COPD and are therefore not taking 
the essential steps to slow down the progression of the disease. 
 
The median age of death from COPD was reported to be 81 years in 2007–
2011, which suggests that perhaps there is not too much to worry about. 
However, more recently convincing data from the Sax Institute’s 45 and up 
study found that two-thirds of the deaths in existing smokers could be directly 
attributed to smoking, which is higher than the previous international estimates 
of 50%, and in addition, current smokers are estimated to die an average of 10 
years earlier than non-smokers (Banks et al., 2015). The age of 45 seems to 
be something of a watershed, such that if a smoker stops smoking before then, 
they come out mostly unscathed, but beyond that, the real trouble starts. This 
study also emphasized the substantial morbidity in the 20-40-year group from 
smoking-related anxiety and depression. 
 
The Australian limb of the BOLD study estimated that approximately 14.5% 
(one in seven) of Australians >40 years have airflow limitation/obstruction, 
which increased to 29.2% in the >75 years. Moreover, around 7.5% of 
Australians >40 years have subjective COPD-type symptoms, and it was 
estimated that about half of COPD was not diagnosed (Toelle et al., 2013).  
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Figure 1.4 COPD death rates in Australia related to smoking rates. The data is 
presented on 3-year moving averages. Smoking rates and death rates are obviously 
closely linked, albeit with about a 20-year lag. Source: (AIHW 2012).  
 
COPD is more expensive per case than cardiovascular disease (CVD) and 
exerts substantial economic burden on Australia. In fact, COPD ranks second 
in the most number of inpatients being hospitalized (Glover J, 2007). However, 
the major financial costs in COPD which are estimated to $8.8 billion, is due to 
the loss of productivity due to COPD lower employment, absenteeism and the 
workplace impact of the premature death of Australians with COPD. The direct 
cost to the Australian health care system is estimated to be $900 million. In 
addition to the above costs on the public and private sector purse, there are the 
costs that are harder to quantify – those of lost wellbeing because of COPD.   
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 Risk Factors associated with COPD 
 
There are several risk factors associated with COPD patients which can thus 
be broadly classified as external exposures and host-related (Figure 1.5). 
Exposures include those from cigarette smoking, biomass exposure, air 
pollution and occupational hazards among others. However, host-related such 
as (genetic) factors predisposing to lung pathology and other factors mentioned 
in the figure below are extremely difficult to control. These factors are briefly 
summarized here, with a significant focus on cigarette smoke exposure.  
 
Figure 1.5 Known risk factors for COPD. 
  
 
 
The pulmonary function (FEV1), which that increases during childhood and 
adolescence up to the age of 18–22 years, then plateau before declining during 
a normal ageing process (Eisner et al., 2010). Various factors that affect the 
average lung growth phase lead to decreased maximal lung function and this 
is an area under active current investigation, e.g., by the Tasmanian 
Longitudinal (Respiratory) Health Study (TAHS) which is closely aligned with 
our group. Of importance, both in the TAHS and elsewhere it has become 
increasingly recognized that reduced lung function in children leads to poorer 
maximal lung function and is a significant contributor to diminishing lung 
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function in adults (Bui et al., 2017). In this section, I will focus more on factors 
that cause more rapid subsequent decline from whatever the maximal attained.  
 Cigarette Smoking 
 
Currently, World Health Organisation (WHO) has estimated that on an average 
there are about six million annual deaths due to tobacco use (both smoking and 
smokeless). According to the projection by Bilano et al., globally there are 
approximately 1.1 billion daily smokers, which are estimated to increase to 1.6 
billion daily smokers by 2025 (Bilano et al., 2015). The authors further observed 
that there were huge disparities among the countries in tobacco consumption 
rates and many were not on track to achieve tobacco control targets and further 
in low-income and middle-income countries, there is an increased risk of 
worsening tobacco epidemics. Similar projections by earlier by Mathers and 
Loncar, (2006) -also attributed tobacco-related deaths per year to increase at 
an alarming rate from 5.4 million in 2005 to 6.4 million in 2015, which could 
further rise to 8.3 million by 2030. However, as mentioned, the picture among 
countries remains mixed, with tobacco-related deaths in more developed 
nations projected to decline by estimated 9% between in 2030 , while at the 
same time will double from 3.4 million to 6.8 million in low- and middle-income 
countries (Mathers and Loncar, 2006). The difference can be attributed to the 
lack of education, poor awareness of the risk of smoking and an ineffective 
government tobacco control policy in place in these nations. Direct or indirect 
exposure to cigarette smoking is by far the main casual factor for COPDs; Forey 
et al., (2011) in a  systematic meta-analysis review of 218 studies found that 
smoking history had a direct impact on all three symptomatic outcomes COPD, 
chronic bronchitis and emphysema. Interestingly, the decline in lung function 
and mortality rate did not mitigate even after COPD subjects quit smoking,  
 
The indirect effects of smoking are significant, especially for children. A recent 
study evaluating participants from the Tasmanian Longitudinal Health Study 
cohort (TAHS) concluded that children exposed to extensive maternal smoking  
(smoking history greater than twenty pack per year) during their childhood 
increased the prevalence of post-bronchodilator (BD) fixed airflow obstruction 
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in their middle-age. (Perret et al., 2016). The effects of parental smoking  on 
children are multiple: these children themselves are more likely to become long-
term adult smokers; they have lower childhood and so lower maximal early 
adult lung function, and on both counts they are likely to have accelerated loss 
of lung function in middle age (Perret 2016, plus more recent unpublished 
TAHS data)  
 
The death rate among current smokers was found to be two to three times 
higher than that of non-smokers but taking into account other deaths caused 
by disease associated with current smokers involving heart, kidney, liver, 
intestine, infection and various cancers, the increase is further substantial. 
However, among former smokers, the relative risk for mortality had reduced as 
the number of years since quitting increased (Carter  et al., 2015). Moreover, 
compared to the smokers and ex-smokers the decline in lung function (FEV1) 
in current smokers remained persistent over time as demonstrated a (figure 
1.5). This thus emphasizes the need for early smoking cessation for patients 
with chronic conditions such as COPD (Vestbo et al., 1996).  
 
 
 
 
 35 
 
Figure 1.6 Decrease in forced expiratory volume in 1 second, according to 
smoking status (Reproduced from Fletcher & Peto (1977).  
The strategies for smoking cessation at a personal and community level are 
beyond the scope of this account, but a combination of limiting access to 
tobacco (e.g., price), public media campaigns, quit facilities including 
reasonable access to nicotine replacement therapy and other pharmacological 
aids, and potentially limiting supply (e.g., Tobacco Free Generation legislation 
in Tasmania) are all critical (Walters et al., 2015). 
 Environmental exposure to particulate matters (air pollution) 
 
Particulate matter (PM) can be characterized by the size of the particulates. 
The PM mass suspended in the atmosphere which is on average 10 microns 
or less in diameter (PM10) generated from plants, tree pollens, road dust, 
agricultural outputs, and industrial processes that generate smoke and dust. 
Smaller particles that are on average 2.5 microns in size are generated by 
vehicular pollution, industrial pollution, natural burning of biomass fuels and 
forest fires; these particles especially remain suspended in the atmosphere for 
a long period and can be carried by the winds for long distances (Hogg et al., 
2017).  
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The PM deposition into the surface of the lung is also mainly dependent on 
particle size. Thus, larger particles of PM10 tend to settle more towards the 
central areas of the lungs while particulate matter with an average diameter of 
2.5 penetrate deeper into the airways and can initiate deleterious effects on the 
small airways, including increased oxidative stress and inducing pro-
inflammatory cytokines. They may also impair the phagocytic capacity of 
macrophages (Donaldson et al., 2002).  
 
Further, it has been observed that in COPD patients when exposed long-term 
to the airborne particulate matter had an increased risk of premature deaths 
and acute care hospitalization ( Zanobetti, Bind & Schwartz 2008; Sunyer 
2001). The mechanisms of airway obstruction due to air pollution are likely to 
be the similar to those due to cigarette smoking, but there is limited mechanistic 
evidence for this.  
 Occupational exposure   
 Occupational exposures are most thought about regarding interstitial lung 
disease (the Pneumoconioses) or asthma development. However, several 
longitudinal studies show an association between occupationally generated 
dust exposures and COPD. For example, a Swedish cohort of construction 
worker exposed to dust had increased mortality rates than those unexposed; 
cigarette smoking and aging were found to further enhance these effects (Toren 
and Jarvholm, 2014). A population-based study found positive associations 
between several occupational exposure measures (mineral dust, metal dust 
and fumes, organic dust, irritant gases or vapors, sensitizers, organic solvents, 
diesel exhaust, and environmental tobacco smoke) with COPD, among both 
ever-smokers and never-smokers (Weinmann et al., 2008).  
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 Biomass smoke inhalation 
 
Various form of biomass fuel that is used as energy source in third world 
countries. This includes traditional combustible material such as wood, coal, 
dried animal dung, and crop residues. One-third of the world rely on biomass 
fuel for cooking, heating, and lighting. The combustion of these materials is 
associated with high levels of indoor air pollution and increases the incidence 
of respiratory infections, including pneumonia, tuberculosis and chronic 
obstructive pulmonary disease, both in adults and children. (Fullerton et al., 
2008). Depending on the fuel type, the combustion of biomass fuel generates 
significant amount of smoke and adds significantly to indoor and local air 
pollution (Naeher et al. 2007). The indoor biomass pollution has also been 
observed to affect women more than men, mainly due to their extended 
exposure to cooking related activities. Further, the exposure to biomass fuel 
combustion in these women may trigger their development of COPD and show 
similar clinical characteristics and, increased mortality rate to those of tobacco 
smokers (Ramirez-Venegas et al., 2006). Further, repeated and sustained 
exposures to acrid to low-efficiency biomass smoke  while cooking or heating 
with poorly or non-ventilated houses has again been related to increased 
mortality worldwide (de Koning et al., 1985). Given the conditions of use, 
women and children are especially exposed. When compared to the third world 
nation, the majority of industrialized countries, biomass fuel use is below <5% 
(Rehfuess et al., 2006).  
 
 
 
 
 
 
 
 
 
 
 
 38 
  
Current published evidence of cellular and inflammatory changes in 
the airways of COPD patients 
 
Note: This chapter is published with ‘Expert Review of Respiratory Medicine’ 
and is explained in with the overall textual context. 
Mathew Suji Eapen, Eugene Haydn Walters, Sukhwinder Singh Sohal. Airway 
Inflammation in Chronic Obstructive Pulmonary Disease (COPD) - A True 
Paradox. Expert Review in Respiratory Medicine Volume 11 Issue 10: pages 
827-839. DOI:10.1080/17476348.2017.1360769. 
 Tissue Composition and Cellularity 
The lungs can be compartmentalized into airways and lung (alveolar) 
parenchyma, and air-containing lumen and actual tissue in both areas. The 
airway walls (tissue) consists of epithelium, sitting on its basement membrane 
and reticular basement membrane (RBM), and then the underlying layers of 
lamina propria), smooth muscle and the outer sub-mucosal adventitia, 
respectively. The adventitia abuts and anchors the alveolae. Much of the airway 
wall is composed of a complex glycoprotein extracellular matrix (ECM), and 
changes in composition and quantity of this are intimately related to wall 
thickening. 
An increase in luminal cellularity could be attributed to cellular infiltration via 
systemic migration of cells at the site of infection and damage/injury. In COPD, 
the literature, especially in the sampling of cells from induced sputum and in 
the BAL, suggests an increase in the total cell counts, especially of 
macrophages and to lesser extent neutrophils, compared to healthy non-
smokers; it occurs early and overlaps with a smoking-only effect. (Lacoste et 
al., 1993a, Traves et al., 2002, Leckie et al., 2003, Profita et al., 2010). 
However, no difference in sputum total cell counts was observed between 
exacerbating and non-exacerbating stable COPD patients (Bhowmik et al., 
2000). Sputum, which mainly consists of cells from the more proximal end of 
the airways were found to be relatively more neutrophilic, while BAL fluid, which 
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more represents the cells from the distal end of the respiratory tract, had a more 
macrophage profile (Traves et al., 2002).   
The cellularity in the airway wall, including the proximal large airways and distal 
small airways, is more heterogeneous, with variable cellular composition. The 
epithelial layer is classified as “pseudostratified columnar”, with a basal “stem” 
cell population and then more mature and differentiated cells, but all component 
cell directly attached to the basement membrane. Differentiated epithelial cell 
types include the majority of columnar ciliated cells, non-ciliated secretory 
goblet cells, and in the small airway club cells which secrete surfactant-like 
molecules (Mercer et al., 2006).  Unlike the epithelium, the lamina propria is 
highly heterogeneous, with varied cell types, mainly stromal, vessel, smooth 
muscle and inflammatory cells of various sorts. Until recently there have been 
few attempts to describe the cellularity of the airway wall in any comprehensive 
detail. Sohal et al., (2013)  were the first to report a decrease in total lamina 
propria cellularity in COPD patients in the large airways and also observed that 
these patients had a prominent cleft formation in the RBM with cells within these 
clefts, features notably absent in normal non-smokers.  
 
 Inflammatory changes in COPD 
 Neutrophils 
Neutrophils are the first innate immune cell to migrate rapidly from residing lung 
tissue to a site of infection or injury with further recruitment from the blood. They 
are also implicated in mucous metaplasia in chronic bronchitis and play a vital 
role in peripheral lung tissue damage in emphysema. Neutrophil infiltration is a 
consequence of the release of chemoattractants such as IL8 from activated 
epithelial cells and alveolar macrophages.  
 
Neutrophils phagocytose bacteria, inactivate pathogens directly and indirectly, 
and cause local tissue damage through secretion of neutrophil elastase, 
metalloproteases, and oxidative reaction species (Shaykhiev and Crystal, 
2013).  In COPD, neutrophils are observed to be increased in the central and 
peripheral airway lumen of COPD patients as found in sputum and BAL fluid 
(Pesci et al., 1998, Brusselle et al., 2011, Di Stefano et al., 1998, Stanescu et 
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al., 1996, O'Donnell et al., 2004). The increase in neutrophils correlates with 
the severity of disease (Di Stefano et al., 1998b, Keatings et al., 1996).  
However, in airway wall tissue, there have been conflicting results. . Lacoste et 
al., (1993) showed a decrease in neutrophils in the large airway wall in patients 
with both chronic bronchitis and COPD, while others found no change in their 
numbers (Saetta et al., 1993, O'Shaughnessy et al., 1997).  In contrast, 
DiStefano et al., (1998) showed a significant increase in the large airways 
neutrophils of COPD patients when compared to smokers without airflow 
obstruction but lacked normal controls for comparisons. In the small airways 
Hogg  et al., (2004) provided evidence of an increase in percent neutrophils in 
severe COPD phenotypes (GOLD stage III and IV), However, interestingly they 
were lower in the mild COPD when compared with healthy smokers. Further, 
Lams et al., (1998) found no change in the number of neutrophils in the small 
airways of smoker and non-smokers which significantly decreased in life-long 
smokers. In contrast, studies by Isajevs et al., (2011) showed an overall 
increase in neutrophils in both large and small airways resected tissue in the 
airway mucosa, while specific area remained undefined. The inconsistencies in 
findings in the airway wall of COPD may be partly due to the variability in the 
measurement strategy employed by different groups, though a shorter half-life 
of neutrophils in the tissue or dysfunctionality in neutrophils could be a 
significant factor.  
Neutrophil counts in peripheral blood of stable COPD patients are slightly but 
significantly, higher than those of healthy controls, and during acute 
exacerbation of the disease, there is an even more significant peripheral blood 
neutrophilia (Gunay et al., 2014). This may be a response to infection or even 
treatment (e.g., corticosteroids). In moderate to severe COPD patients (GOLD 
Stage II-IV), but not in milder COPD, peripheral blood neutrophils showed 
reduced levels of spontaneous migration and chemotaxis to the chemotactic 
peptide fMLP and also IL-8. This suggests that long-term smoking or more 
severe disease (perhaps mediated by chronic infection) may induce post-
stimulation exhaustion in the cells (Yoshikawa et al., 2007). Further, studies by 
Sapey et al., (2011) demonstrated that systemic neutrophils from COPD 
patients showed aberrant migratory patterns in the presence of 
chemoattractant such as GROα, IL-8 which strongly resembled neutrophils 
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from patients with alpha1 trypsin deficiency. Further, neutrophils from COPD 
patients were also shown to be deficient of pseudopodia formation, a vital 
feature for phagocytosis and bacterial clearance 
In summary, there is a considerable literature that suggests an increase in 
blood, BAL, and sputum (i.e., luminal) neutrophils, but the overall picture in the 
airway wall is not yet definite. 
 Macrophages 
 
Two distinct populations of macrophages have been identified in the lung, one 
that resides in the airway sub-epithelial layer of the mucosa, and the other being 
the mature alveolar macrophages, which reside within the alveoli. Both cell 
types are strategically located to play a significant role in maintaining tissue 
homeostasis (Nicod, 1999). Activated alveolar and tissue macrophages belong 
to the innate immune system (Ambarus et al., 2012), but whether the presence 
of such a limited set of cells should be called “inflammation” in the broad sense, 
may be debatable.  
 
An increase in the total numbers of macrophages in the airway lumen has 
previously been observed in smokers and is accepted as the firmest 
inflammatory cellular change in the airways and lung parenchyma in COPD 
patients (Kaku et al., 2014, Kuschner et al., 1996). In the sub-epithelium, the 
literature suggests variable outcomes with macrophages. Rutgers et al. showed 
an increase in the number of macrophages in the large airway lamina propria 
of COPD patients with severe chronic bronchitis (Rutgers et al., 2000). . Saetta 
et al., (1993) showed an increase in macrophages in a mixed population of 
chronic bronchitis patients which included smokers with and without COPD, but 
this lack of rigorous phenotyping challenges the validity of these findings. 
Notably, Di Stephano et al., (1998) found significantly increased macrophage 
numbers in severe but not in mild-moderate COPD subjects, suggesting it was 
not a fundamental pathogenic issue.  Lams et al., (2000) found no change in 
the numbers of macrophages in the large airway lamina propria in COPD in 
comparison to smoker and non-smoker healthy controls.  
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There are fewer reports on macrophage numbers in the small airways. While 
one study suggested an increase in macrophage numbers (Utokaparch et al., 
2014) in the COPD group, another reported the opposite (Lams et al., 1998).  
Our group recently found that macrophage numbers are unchanged in both 
smoking and COPD groups in both the large and small airways, though even 
in healthy non-smoking individuals, a higher number of macrophages reside in 
the small airway wall than in the large airways (Sohal et al., 2015).  
 
Macrophages with their increased activation of Nuclear Factor-kappaB (NF-kB) 
have been suggested to have a substantially longer survival time than 
neutrophils, and this may be true in the alveolar macrophages in lungs of 
smokers and patients with COPD, (Caramori et al., 2003, Park et al., 2005). 
Elastolytic enzymes such as matrix metallopeptidase-9 (MMP-9), neutrophil 
elastase and cathepsins are secreted by alveolar macrophages in COPD 
(Russell et al., 2002), and these may be significant players in the progression 
to emphysema.  
 
Efferocytosis, the removal of cellular debris by active macrophage 
phagocytosis, has been shown to be decreased in BAL macrophages of COPD 
patients, and this could lead to increase in neutrophilic inflammations, but the 
reason and consequences remain unclear (Mukaro and Hodge, 2011). Since 
there is an increase in total macrophages in BAL in smokers/COPD, the overall 
efferocytosis function should not be decreased but indeed be markedly 
improved. However, understanding the complexities of macrophage 
phenotypes, and phenotype switching that may occur, and consequent 
alterations in functions have not been done for COPD as it has in other disease 
processes, and would offer new insight into the role of these innate immune 
cells in COPD. Until I have such a full picture, it is hard to judge the current 
empiric observation about any alterations in airway macrophage function. 
 
The concept of differentiation of macrophages into the M1/M2 classification 
(Mantovani et al., 2004) follows on from the similarly structured Th1/Th2 
paradigm for lymphocytes (Mosmann et al., 1986). M1 macrophages are 
defined as classically activated macrophages with pro-inflammatory properties. 
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They are thought to be involved in the eradication of intracellular pathogens 
and to secrete pro-inflammatory cytokines. They have a robust antigen-
presenting capacity and promote Th1 immunity (Martinez and Gordon, 2014). 
M2 macrophages are defined as “alternatively activated” macrophages with 
anti-inflammatory and more pro-fibrotic properties, linked to tissue repair and 
secretion of anti-inflammatory mediators; they display poor antigen-presenting 
capacity and promote T cell (Treg) development (Martinez and Gordon, 2014). 
Alternative pathways of L-arginine substrate catabolism have been identified 
as functional markers for M1 and M2 macrophages. iNOS (inducible nitric oxide 
synthase)-produced NO (nitric oxide) expresses M1 cytotoxic properties and 
Arg1 (arginase)-produced L-ornithine promotes M2-mediated collagen 
synthesis, cell division, and growth (Benson et al., 2011).  
M2 alveolar macrophages (over-expressing CD163, CD204, and CD206) have 
been shown to be upregulated in the alveolar lumen in severe COPD (Kaku et 
al., 2014). Further, CD204 overexpression induced by the presence of MSR1 
gene SNP is associated with high susceptibility to COPD (Ohar et al., 2010). 
Further, transcriptional profiling of BAL alveolar macrophages in smokers and 
COPD showed significant deactivation of M1-related genes and induction of 
genes related to the polarization of macrophages towards the M2 phenotype. 
(Shaykhiev et al., 2009)  However, in contradiction to this, higher levels of iNOS 
have been described in macrophages within induced sputum of COPD patients 
than in normal controls (Ichinose et al., 2000). Tissue macrophages in the 
airway walls are yet to be investigated and classified into M1 and M2 
phenotypes. However, further M1/M2 macrophage identification may offer a 
significant step in better understanding the pathology in airway and lung 
compartments of COPD and the relative involvement of macrophages to 
inflammation versus fibrosis in the disease. 
 
 Eosinophils 
 
The presence of eosinophilic inflammation has been associated traditionally 
with allergic asthma rather than COPD. Thus, previous studies by Lacoste et 
al., (1993) compared eosinophil numbers in bronchial biopsies and BAL 
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samples of asthma and COPD subjects and found that while asthmatics had 
eosinophilic inflammation, in COPD and chronic bronchitis (CB) patients, 
eosinophil numbers were similar to normal non-smokers. However, in contrast, 
Rutgers et al., (2000) suggested a significant increase in eosinophils in COPD 
subjects in the large airway lamina propria and induced sputum in COPD over 
healthy non-smoker controls. The increase in eosinophils was further 
corroborated by the presence of an increase in eosinophil cationic protein 
(ECP) which was also found to be increased in sputum of stable COPD 
although much less than in asthma patients (Balzano et al., 1999). These 
paradoxes may be related to recent evidence that eosinophilia is present in 
some (approx. 30%) of COPD subjects in induced sputum and blood, but not 
in the majority of COPD cases, and defines their corticosteroid responsiveness 
(Singh et al., 2014, Prajakta et al., 2015, Bafadhel et al., 2011).  
 Mast cells 
Mast cells play a critical innate immune function role in mounting responses 
after recognizing possible pathogens. However, mast cells are also 
“accidentally” stimulated by allergens reacting with cell surface IgE, causing the 
cells to degranulate and release mediators such as histamine and bradykinin 
which cause smooth muscle constriction and vasodilation. 
 
 In COPD, there have also been reports of an increase in the number of mast 
cells in both large and small airways. Grashoff et al., (1997) showed a 
significant rise in these cells in the small airway epithelium, though no change 
was noticed in the rest of the small airway wall. In the large airway wall, our 
group showed a significant increase of mast cells both in the epithelium and 
lamina propria of asymptomatic smokers (Ekberg-Jansson et al., 2005) and the 
lamina propria of COPD current and ex-smokers (Soltani et al., 2012). In 
contrast are the observations of Andersson et al., (2010) who reported a 
significant decrease in mast cell numbers in the sub-epithelial region of the 
small airway mucosa of COPD patients across GOLD stage I-IV subjects, with 
the decrease correlating with the severity of the disease. A similar reduction in 
tissue mast cells was also found by Gosman et al., (2008) in COPD subjects 
when compared to control. It is hard to reconcile these difference between 
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findings of different groups, although where exactly in the airways was this 
being assessed in the airway is essential as Soltani et al. (2012) demonstrated; 
they found that most of the increase in mast cells in COPD was specifically 
around blood vessels (Soltani et al., 2012). Further, Gosman et al., (2008) also 
showed that the increase in mast cells they found was far more in the peripheral 
small airways than in the central airway in both COPD and control groups. 
Interestingly, this group, though only using morphological analysis based on 
cellular conformation, observed no change in the percent of degranulated mast 
cells in COPD compared to their control group, which suggests that the mast 
cells were recruited to but not activated in the airway wall, perhaps  in response 
to local chemo-attractants or bacterial infection rather than to allergens, as in 
the classic allergic model of inflammation (Gosman et al., 2008). This finding,  
however, actually requires further validation using a more specific 
degranulation marker such as lysosome-associated membrane protein-1/2 
(LAMP-1/2); a decrease in this marker was recently shown to be related to 
cellular dysfunction in CD8 cellular degranulation in COPD when ex-vivo 
exposed to influenza virus (McKendry et al., 2016).   
 
 Dendritic cells 
 
Dendritic cells (DCs) are part of the adaptive immune system, including in the 
airway. They are monocyte-derived and play a crucial role in recognition, 
uptake, and presentation of antigen to lymphocytes, and are on par with 
macrophages as an antigen presenting cells. However, although fewer in 
numbers in comparison to macrophages and neutrophils, the airway DCs are 
present in the airway epithelium and subepithelium, the lung interstitium and 
the pleura, at least in immature forms. In the airways, mature and active DCs 
are especially closely associated with epithelial cells, and their extended 
cytoplasmic protrusions are thought to sample luminal antigens and 
environmental signals (Shaykhiev and Crystal, 2013).  
However, studies of DC specifically in COPD in human tissues have been few. 
A study by Tsoumakidou et al., (2009) demonstrated a decrease in mature 
CD83+ DC in the small airways and alveoli of COPD subjects in comparison to 
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normal controls. They also showed that DC numbers did not change between 
COPD current and ex-smokers or between steroid-treated and steroid-naïve 
patients. A similar decrease in sputum mature CD83+ DCs was observed in 
COPD current smokers when compared to non-smokers (Tsoumakidou et al., 
2009). Again, there are contrasting papers, with Vassallo et al., (2010) finding 
an increase in mature CD83+ DC and CD1a Langerhans cell mRNA in lung 
tissue in COPD compared to normal. Specifically, the increase in Langheran-
207+ cells was found to be pronounced in the small airway epithelium while 
remaining unchanged in the subepithelium (Demedts et al., 2007, Van 
Pottelberge et al., 2010). Paradoxically, though, other dendritic cell markers 
such as DC-SIGN and BDCA-1 showed no change in the small airway wall of 
COPD patients (Van Pottelberge et al., 2010). Sohal et al., (2011) reported the 
presence of CD11c dendritic cells closely associated with basal epithelial cells 
and in the RBM of the large airway of COPD patients, but they were few. 
Utokaparch et al., (2014) recently reported no change in CD1a dendritic cells 
in the small airway wall of COPD subjects. The variability in dendritic cell types 
and the lack of more specific marker have contributed to inconsistent reports in 
COPD research and will warrant further investigation, especially since in an 
animal model DCs were suggested to be central to COPD development 
(Hashimoto et al., 2015). 
 CD8 and CD4 T cells 
The role of CD8+ and CD4+ T cells as powerful components of cell-mediated 
adaptive immune response, in general, is well established. Both CD8s and 
CD4s are also thought to play a crucial role in the pathology of COPD especially 
in progression to or in the presence of severe disease. However, once again 
the true picture in earlier disease especially is quite unclear. O'Shaughnessy et 
al., (1997) observed both CD4+ and CD8+ T cell numbers to be increased in 
the large airways of COPD subjects with chronic bronchitis. In contrast, Di 
Stefano et al., (2001) found a decrease in large airway lamina propria CD8+ T 
cells, and progressively so with increasing severity of the disease. Our recent 
reassessment of the airway wall concluded that there is a decline in both CD4+ 
and CD8+ T cell numbers in the large airway lamina propria area of mild to 
moderate COPD in comparison to normal controls (Sohal et al., (2015). 
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However, they did find a small increase in CD8+ T cells in the lamina propria of 
the small airway, though this is in contrast to findings of Utokaparch, S., et al., 
(2014)  who showed no significant change in this population of small airway 
cells between their COPD subject and controls.  
 
The increased dominance of CD8+ lymphocytes may be due to the 
susceptibility in COPD to viral infection and especially with influenza A 
(Utokaparch et al., 2014) or a consequence of chemotaxis associated with 
smoking-induced tissue damage. CD8+ T cells are known for their potent 
cytotoxic activity, and so may be involved in tissue damage in the lamina propria 
by their secretion perforins and granzyme B in particular (Mikko et al., 2013). A 
decrease in CD4+ T cell in COPD may well be attributable to the presence of 
suppressor CD8+ T cells coexpressing CD103, which are known to reduce the 
proliferation of CD4+ T cells (71) actively, but this has not yet been studied in 
the airways. The heterogeneity of findings in this T-lymphocyte area is 
summarized in Table 2. 
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Table 2 Comprehensive summary of lymphocyte changes in COPD 
patients- 
 
Reference Cell type Tissue 
type/ 
Technique 
used 
 
Controls 
 
COPD Findings 
   NC NLFS CS ES  
(Freeman 
et al., 
2014b) 
CD8, CD4, 
NK cells 
Resected 
tissue large 
and small 
Flow 
Cytometry 
UA 16 Mild 
14 
Severe 
15 
 
 
UA Found 
decrease in 
CD8+/CD4+ 
cells co-
expressing 
CD56 in mild 
and severe 
COPD 
patients. Also, 
no change in 
NK cells was 
observed 
(Freeman 
et al., 
2014a) 
CD4 T cells Resected 
tissue 
Flow 
cytometry 
and gene 
expression 
studies 
UA 16 37 UA Reduced 
expression of 
CD4+ cells 
was found in 
COPD patients 
over smokers 
with normal 
lung function 
(Forsslund 
et al., 
2014) 
CD4 and 
CD8 T cells 
BAL 
Flow 
cytometry 
40 45 27 
(Stage 1 
and 2) 
11 Increased in 
CD8+/NKT 
cells like cells  
and a 
decrease in 
CD4 cells 
were found in 
BAL of COPD 
patients over 
healthy  
controls 
(Urboniene 
et al., 
2013) 
CD8, CD4, 
and gamma 
delta T cells 
subsets 
Used BAL, 
IS and PB 
Flow 
cytometry 
14 UA 20 UA Found an 
increase in 
CD4+ cells in 
BAL and IS 
but decrease 
in PB. CD4 
and gamma 
delta T cells 
were found to 
reduction in all 
fluids 
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(Chang et 
al., 2011) 
 
CD4 and 
CD8 T cells 
Epithelium 
and LP 
IHC in 
large 
airways 
 
15 UA 16 UA Co-expression 
of IL17A and 
IL17F was 
carried out 
along with the 
expression of 
CD8+ T cells. 
Increased 
expression of 
CD4 and CD8 
cells 
expressing 
IL17 cytokines 
was observed 
(Mikko et 
al., 2013) 
CD4 and 
CD8 cells 
expressing 
CD103 
BAL and 
PB 
Flow 
cytometry 
40 40 38 UA Increase in 
CD8 and 
decrease in 
CD4 co-
expressing 
CD103 in BAL 
while there is 
no change in 
both cell type 
over normal in 
PB 
(Mathai 
and Bhat, 
2013) 
CD4 and 
CD8 in 
peripheral 
blood 
PB 
Flow 
cytometry 
20 19 21 UA Decrease in 
CD8 and CD4 
in peripheral 
blood 
(Grundy et 
al., 2013) 
CD8+ cells 
and TCR 
zeta CD247 
co-
expression 
BAL and 
PB 
Flow 
cytometry 
UA 6 6 UA Found 
decreased 
expression of 
genes 
associated 
with active 
CD8 cells in 
smokers over 
COPD in 
pulmonary 
region when 
compared to 
the peripheral 
blood of the 
same patient 
(Freeman 
et al., 
2013) 
CD8+ and 
CD4+ co-
expressing 
TLR 
receptor 
lung 
resected 
tissue 
Flow 
cytometry 
UA 14 20 UA Found 
increase in 
CD8+ and 
CD4+ cells 
expressing 
TLR receptor 
in COPD over 
NLFS 
(Hodge et 
al., 2012) 
CD8 and 
CD4 cells 
Epithelial 
brushings 
of trachea 
left and 
right 
bronchi 
Flow 
cytometry 
11 8 16 mild 
to 
moderate 
and 
Ten 
moderate 
to severe 
UA No change in 
CD4 or CD8 
expressing 
cells 
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(Isajevs et 
al., 2011) 
CD8 
macrophage
s and 
neutrophils 
Lung 
resected 
tissue in 
small and 
large 
airway 
IHC 
19 20 20 UA Significant 
increase in 
CD8, 
macrophage, 
and neutrophil 
in large and 
small airway of 
the lung 
(Hodge et 
al., 2011) 
CD8 cells PB 
Flow 
cytometry 
 
34 15 30 18 No significant 
change in CD8 
cells observed 
in percent CD8 
of CD3 cells 
(Roos-
Engstrand 
et al., 
2010) 
CD8 cells Large 
airway 
epithelium 
IHC 
21 16 16 19 A significant 
increase in 
CD8 cells 
found in 
normal 
controls and 
smokers. 
Decrease in 
CD8 cells in 
ex-smokers 
(Olloquequ
i et al., 
2010) 
CD4 and 
CD8 T cells 
and B cells 
Lung 
resected 
tissue- 
IHC 
9 8 16 mild 
and 16 
severe 
COPD 
 Significant 
change 
(p<0.05) 
observed in 
COPD over 
normal control 
in epithelium 
but no 
significance in 
connective 
tissue area of 
small airway. 
Also high 
increase in B 
cells found in 
small airway of 
severe 
patients 
(Freeman 
et al., 
2010) 
 
CD8 cell 
that co-
express 
CD69 cells 
Resected 
Lung 
Tissues 
Flow 
cytometry 
 
3 and 6 cohort
s 
11/8/2
5 
Various 
cohorts 
GOLD 
Stage I II 
III and IV 
UA Increase in 
CD8 co-
expressing 
CD69 cells 
(Lofdahl et 
al., 2008) 
CD8 Bronchial 
biopsies 
Large 
airway 
IHC 
15 14 22  Significant 
increase in 
both CD4 and 
CD8 cells in 
COPD over 
normal 
controls 
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(Glader et 
al., 2006) 
CD4 and 
CD8 
PB 
Flow 
cytometry 
6 8 17  No significant 
difference 
found in CD8 
and CD4 cells 
found in PB. 
An increase in 
CD4 cells 
expressing 
CD69 was 
found 
 
UA- Unavailable, IHC- Immunohistochemistry, PB- Peripheral Blood, NC- Normal 
Control, NLFS- Normal Lung Function Smokers, CS- Current Smokers, ES- Ex-
Smokers 
 
 
2.2.7 B cells  
B cells are essential adaptive immune cells whose interactions with antigen 
presenting cells (macrophages and dendritic cells) and T cells are of paramount 
importance in evoking short-term and long-term (memory) responses with the 
generation of antibodies primarily targeting microbial infections and ‘self’ 
antigens in autoimmune diseases.  
 
In large airways mucosa of COPD (GOLD stage II and III), Gosman et al., 
(2006) showed an increase in CD20+ B cells in COPD current smoker 
compared to smoker controls while ex-smoker tended to have more of them 
suggesting that persistent B cell accumulation occurred even after smoking 
cessation. In contrast, O'Shaugnessy et al., (1997)  observed no change in B 
cell numbers in the airways of mild-moderate COPD compared to normal 
controls, though notably, this study had fewer subjects in their analysis. In small 
airways, Hogg et al., (2004) observed an increase in the number of both B cells 
and lymphoid follicles (LF) in more severe COPD patients compared to healthy 
smokers and mild COPD patients. Furthermore, the changes in B cell and LF 
numbers directly correlated with a decrease in lung function in this COPD 
group. More recent studies by Polverino et al., (2015) reported a similar 
increase in LF in both number and size in more severe COPD patients (GOLD 
stage IV) compared to mild COPDs and smoker controls. The authors 
importantly describe the presence of two types of LF, the first was smaller in 
size and were observed mainly in mild-moderate COPD patients. The B cells 
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in this group of COPDs LFs were highly apoptotic and expressed less of the B 
cell-activating factor of tumor necrosis factor (BAFF), an essential mediator in 
B cell maturation, while, in more severe COPD there were larger LFs that 
contained highly active B cells with higher expression of BAFF. These are 
significant observation, which suggests that smoking actively suppress immune 
function in early disease, leading to more susceptibility to infection in more 
severe COPD group. Thus, the increase in B cells and LF in the latter group 
points to a more conservative response to acute infections and perhaps related 
to exacerbation in severe patients. In a separate study, the transcriptomic 
analysis further confirmed upregulation in gene expression of BAFF and its 
receptor B cells maturation antigen (BCMF) in airways of COPD patients with 
emphysema while were absent in patients with bronchiolitis (Faner et al., 2016, 
Lee et al., 2016). Again, the distinct signature observed in COPD corroborates 
the heterogeneity in the disease phenotype and warrants selective therapeutic 
interventions. 
 
2.2.8 TH17 and T regulatory cells 
Both Th17 and Tregs are subsets of T cell population are known to have 
considerable influence in modulating various inflammatory disease conditions. 
Both cell types play a critical role in autoimmune disease (Cazzola and Matera, 
2012). While TH17 cells are considered as pro-inflammatory, with the secretion 
of IL-17, IL-22, and IL-21, the Tregs produce anti-inflammatory mediators such 
as IL-10 and TGFβ. Tregs essentially plays an essential role in modulating IL-
2, an essential cytokine for T cell expansion. 
 
In both COPD patients (mild-moderate and severe) and smokers, Di Stefano et 
al. (Di Stefano et al., 2009) demonstrated significant changes in TH17 cellular 
mediators such as IL-17A, IL-21, and IL-22, with increased expression 
observed mainly in the bronchial mucosa. A similar increase in these mediators 
was also reported in the serum and sputum of COPD patients and correlated 
with decrease in lung function and increase in a number of neutrophils and C-
reactive proteins (Zhang et al., 2013). Further, TH17 cells also seemed to be 
the dominant T cell phenotype peripheral blood of mild-moderate COPD 
patients, and this increase was attributed to increased Tregs suppressive 
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activity on  CD4+ and CD8+ T cells while being ineffective against TH17 cells 
(Vargas-Rojas et al., 2011). In contrast, observations that are more recent 
showed an imbalance in Th17 and Treg cells and associated mediators, both 
sputum and serum of moderate to severe COPD patients. Furthermore, Th17 
to Tregs ratio also showed negative physiological consequences in moderate 
COPD patients (Wang et al., 2015, Li et al., 2015). Role of Tregs in naïve T 
cells suppression are well known, though, literature evidence for their presence 
and activity in human airways are few. Barceló et al., (2008) reported an 
increase in Tregs in BALF of smokers had more of them than in mild-moderate 
COPD and normal controls, though unlike previous observation mentioned 
here, they found no change in peripheral blood population between the groups, 
suggesting  their  suppressive activity occurs more in the airway milieu (Roos-
Engstrand et al., 2011). Further, a recent study also demonstrated an 
imbalance among the BALF Treg subtypes (defined by levels of CD25 
expression), classified as regulatory (rTreg), activated (aTreg) and pro-
inflammatory (FrIII) Tregs. The FrIII subtype secretes IL-17/IFNγ. Interestingly, 
the ratio of rTreg and aTreg combined to FrIII was reduced in more severe 
COPDs compared to both smokers and normal controls, suggesting the 
dominance of pro-inflammatory FrIII cells (Hou et al., 2013).”  
Overall, the current literature provides contrasting evidence in the presence of 
Tregs and TH17 cells in COPD and their interplay, though their regulation 
remains a vital factor in understanding disease progression.   
 
 Role of Reactive oxygen species in inflammation in COPD 
 
Cigarette smoke contains roughly 4000 different chemicals, with most of them 
being potential oxidants. Indeed, it is estimated that tobacco smoking generates 
up to 1015 highly reactive free radicals per puff which can cause irreversible 
damage to lung tissue.  Reactive oxygen species (ROS) along with reactive 
nitrogen species (RNS) possess the ability to interact with vital cellular 
organelles such as mitochondria and endoplasmic reticulum to cause 
devastating imbalances in cellular metabolism. 
In COPD, substantial evidence points to an increase in cigarette smoke-
induced ROS activity and their functional ability to cause various disorders in 
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the cellular architecture as well as DNA damage. Their effect on inflammatory 
cells can be profound with the ability to cause dysfunctionality reducing their 
efficiency in combating bacterial infections (Zuo et al., 2014). Morlá et al., 
(2006) observed that circulating systemic lymphocytes in COPD patients have 
shorter telomere length compared to healthy subjects, thus a shorter lifespan.  
This is attributed to the action of ROS, which is known to accelerate the process 
of aging and aging-related pathologies. Similar studies by Ceylan et al., (2006) 
showed that systemic leukocytes had severely damaged DNA in circulating 
leukocytes with a considerable increase in levels of oxidative stress markers 
such as plasma malondialdehyde (MDA) and TBA-reactive substances 
(TBARS).  ROS induce cellular senescence via DNA damage arrests cellular 
growth and function. Immune cells that have senesced activates protein 
complex called senescence-associated secretory phenotype (SASP) which 
produce phlogogenic substances such as IL-1, IL-6, and IL-8 (Aoshiba et al., 
2013). The cytokine produced are potent attractors and activators of innate 
immune cells, which cause tissue damage by producing oxidizing molecules 
released mainly to destroy pathogens (Freund et al., 2010).  However, the 
sustained release of these potential harmful oxidants is directly linked to 
exhaustion of immune cells and their ability to mount an effective immune 
response. For example, recent ex-vivo human studies by McKendry et al., 
(2015) showed a significant decrease in capacity of CD8+ T cells isolated from 
COPD patient to effective ward off viral infections, and this was due to the 
reduced degranulation capacity of dysfunctional CD8s. Our recent assessment 
of the small airway wall showed overall a decrease in degranulating cells in 
COPD patients, pointing towards a possible dysfunctional cellular phenotype in 
the tissue (Mathew et al., 2017).  ROS also impair neutrophil and alveolar 
macrophage phagocytosis capacity and cause an imbalance in protease/anti-
protease activity causing bacterial colonization and excessive tissue damage 
(Zuo et al., 2014).   
The overall contribution of cigarette smoke derived ROS on dysregulated 
immune response together with increased oxidant production by the immune 
cells lead to development and progression of COPD pathology. 
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 Role of the Inflammasome in COPD 
 
The “inflammasome” is defined as a multimeric protein complex expressed 
mainly by innate cells such as macrophages, neutrophil, dendritic cells and also 
by adaptive immune cells in response to pattern recognition signals such as 
bacteria-derived so-called pathogen-associated molecular patterns (PAMPs) 
and host-derived danger-associated molecular patterns (DAMPs) (Schroder 
and Tschopp, 2010). These signals are recognized by an array of primitive 
germ-line-encoded pattern recognition receptors (PRR) such as Toll-like 
receptors (TLRs) that scan both the extracellular milieu as well as the 
endosomal compartments within the cells. The inflammasome complex, in 
innate cells, is now known to help maturation of cytokines such as IL-1β and 
IL-18 through the activation of proinflammatory caspase-1 (Schroder and 
Tschopp, 2010). There are numbers of PRRs associated with inflammation,  
with the most studied and best characterized being the NACHT, LRR and PYD 
domains-containing protein-3 (NLRP3) (Kim et al., 2015).     
There has been much interest in the role of the inflammasome in COPD since 
the disease pathology is strongly associated with both infection and tissue 
destruction.  However, studies by Di Stefano et al., (2014) found no correlation 
between expression of NLRP3, caspase-1, IL-1β and severity of the disease, 
in either the epithelial or subepithelial layer of large airway tissue in COPD. In 
contrast, the expression of inflammasome inhibitory molecules NALP7 and IL-
37 were shown to be significantly increased in COPD in comparison to healthy 
smoker controls. Also, no change in IL-1β, IL-18 or their receptors in BAL 
samples were found in this study, although other investigators have suggested 
contrasting finding from indirect observation (Kim et al., 2015a). Further, 
Franklin et al., (2014) showed an increase in inflammasome formation in the 
cellular compartment of COPD lungs via increased interaction of NLRP3 with 
adaptor protein Apoptosis-associated speck-like (protein) containing a caspase 
recruitment domain (ASC). The ASC can bind to pro-caspase-1 and convert it 
to active caspase-1. The authors also observed an increased level of ASC 
specks accumulated in the extracellular matrix of COPD subjects and mouse 
models. These excreted ASC specks were found to be stable and retained their 
ability to transform pro-IL-1β to IL-1β. The author further showed an increase 
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in ASC specks in BAL samples from COPD and a cigarette smoke-induced 
mouse model of experimental COPD indicative of potential activity in luminal 
fluids (Franklin et al., 2014). With little-published literature, this field warrants 
further mechanistic studies to characterize their potential role as pro-
inflammatory factors in COPD. 
 
 Inflammation and airway remodelling in COPD 
 
Unlike “airway (wall) inflammation,” which is an etiological concept that is now 
a dogma in COPD though not truly evidence-based, well confirmed structural 
changes have been observed in all compartments in the airway wall in COPD 
patients, including the epithelium, RBM and lamina propria in both the large and 
small airways.  
 Epithelial Remodelling 
Epithelium forms the “skin” that is the frontline of the airway in dealing with 
exposure to the outside world. It is the primary barrier in the innate defense 
mechanisms against microorganisms and toxic chemical entities such as 
smoke, through mechanical mucus production and ciliary clearance; 
biochemical antibacterial, antioxidant, and anti-protease functions; and 
intercellular epithelial tight junctions to prevent penetration of agent s into 
deeper tissues (Puchelle et al., 2006). Changes are seen in the normal 
architecture of the epithelium in smokers with COPD, with squamous 
metaplasia of the normal pseudostratified columnar tissue organization, mucus 
hyperplasia with an increase in goblet cells and mucous glands, and basal cell 
hyperplasia and decreased integrity in tight epithelial junctions (Shaykhiev and 
Crystal, 2014, Shaykhiev et al., 2011, Peters et al., 1993).  
 
It is believed that the fundamental alteration leading to such well-established 
epithelial changes is a crucial process of basal epithelial (stem) cell 
reprogramming (Crystal, 2014). Further, there is no evidence that this also may 
underlie airway wall remodeling through induction of epithelial-mesenchymal 
transition (EMT) which, as previously observed in smoking-related idiopathic 
pulmonary fibrosis (IPF), is now considered a core pathophysiological factor in 
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COPD development (Milara et al., 2013, Sohal et al., 2010, Sohal, Mahmood 
et al., 2015). The increased expression of mesenchymal markers such as 
S100A4 and vimentin especially in the basal cells has been observed both in 
the large and small airway in COPD along with characteristic EMT-related Rbm 
fragmentation and also increased epithelial growth factor receptor (EGFR) 
activity (Mahmood et al., 2015, Sohal et al., 2010). There is a strong relationship 
between markers of EMT activity such as S100A4 and vimentin with decreased 
lung function and airway obstruction (Mahmood et al., 2015). EMT in COPD 
potentially driven by the canonical pathways via TGFβ that induces nuclear 
transcription factor such as pSMAD2/3 while reducing the inhibitory SMAD7 
(Mahmood et al., 2017). Further, this increased expression of pSMAD2/3 
showed a high correlation to decrease lung function parameters and airway 
obstruction. I have also reported that has the potential to ameliorate EMT in 
COPD patients (Sohal et al., 2014).  Further, epidemiological studies reveal 
that the use of ICS is associated with a decrease in lung cancer risk in COPD; 
I suggest that this might be through anti-EMT effects of ICS. There have been 
few direct reports that evaluate the influence of luminal cytokines, chemokines 
and growth factors on EMT-related changes. However, Milara et al., (2013) 
showed that cigarette smoke extract (CSE) induced EMT activity in normal 
small airway primary bronchial epithelial cells (pHBECs) via ROS production, 
increased TGFβ1 expression and decreased cAMP levels. Further, they 
demonstrated that the epithelial transition could be abrogated by elevating 
cAMP levels using a PDE4 inhibitor (Milara et al., 2014). Further, inhibiting 
TGF-β1, via targeted monoclonal antibodies, during in vitro differentiation of 
pHBECs prevented mesenchymal vimentin expression and fibronectin release 
(Gohy et al., 2015). Similar findings of increased expression of mesenchymal 
markers such as N-cadherin and α-smooth muscle actin (αSMA) with a 
concomitant decrease in E-cadherin and α-catenin was observed by Wang et 
al. in small airway epithelial cells when stimulated in-vitro with CSE (Wang et 
al., 2013). They further suggested a role for urokinase plasminogen activation 
receptor (uPAR) in the modulation of EMT and exhibited a positive correlation 
between uPAR and vimentin expression in human small airways. Recent in-
vitro epithelial-fibroblast co-culture studies also pointed to the probable role of 
IL-1α in promoting EMT. The group reported an increase in IL-1α expression in 
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pHBECs derived from COPD patients when stimulated by CSE (Froidure et al., 
2016, Osei et al., 2016). These studies cited are preliminary as yet and will thus 
require further mechanistic validation to identify the role played by these 
mediators in promoting EMT; -if anything I am  now beginning to get an 
expanded understanding of the potential mechanisms on airway EMT, but it 
does seem to be a real phenomenon in the airway pathology in COPD which 
warrants urgent attention.  
 Fibroblasts, Myofibroblasts and the extracellular matrix (ECM) in 
COPD 
The primary source of airflow limitation in COPD is the result of airway wall 
especially in the small airways, tissue remodelling and scarring, i.e., 
reorganization of the extracellular matrix (ECM). These changes in the ECM 
have profound effects, the most important being the gradual obliteration of the 
small airway lumen. In contrast, the other major pathophysiological process that 
occurs in COPD subjects i.e. breakdown of the alveolar wall, is a destructive 
process leading to emphysema, that results in decrease air-blood gas 
exchange and decreased elastic recoil of the lung, with worsening airflow, is a 
later complication in only about 50% of COPD subjects. 
The cell type that is primarily involved in ECM production is the myofibroblast. 
These cells are of mesenchymal origin, have spindle-shaped morphology, and 
are highly contractile. The contractile ability of the myofibroblasts directly 
relates to the increased expression of alpha-smooth muscle actin (αSMA) 
myofilaments which form in non-muscle cells (stress fibers). Interestingly, 
isolated rat lung fibroblasts produced more αSMA and showed increased 
contractibility when compared to subcutaneous fibroblasts (Hallgren et al., 
2012, Hinz et al., 2001). 
 
Studies in COPD based on αSMA as a protein marker for myofibroblasts in 
human bronchi and bronchiolar tissue have been variable. Lofdahl et. al. in their 
histological staining of large and small airway  tissue from operative resections, 
showed an increased expression in αSMA positive cells in the lamina propria 
(LP) of the large airway in COPD patients when compared to non-smoker 
controls, although similar changes in the expression level was not observed in 
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the crucial small airway (Lofdahl et al., 2011). In contrast, findings from in-vitro 
studies with fibroblasts isolated from the distill end of the airway from COPD 
patients showed increased contractile properties associated with increased 
myofibroblasts  (Hallgren et al., 2012). These findings suggest myofibroblasts 
may be important in both the small and the large airways, but the situation 
needs to be clarified. 
 
 
 
 
Figure 2.1 
 
 
Figure 2.1 Illustrates the various possible origins of fibroblasts and their 
transformation to myofibroblast in the lung tissue. 
Myofibroblast is known to secrete a broad array of ECM proteins which includes 
fibrous proteins such as collagen and elastin, as well as glycoproteins such as 
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fibronectin, tenascin C, and proteoglycans. Fibrillar collagens type I, II, III, V, 
and XI are the most abundant matrix proteins and constitute approximately 15-
20% of the dry weight of the tissue (Pierce and Hocott, 1960). In patients with 
COPD, variability in collagen subtype deposition in both the large and small 
airways has been related to disease stage (GOLD classification). In large 
airway biopsies Harju et al., (2010) observed an increase in expression of both 
collagen I and III in stage I and II COPD in the lamina propria region, while 
stage IV COPD patients showed a decrease in expression of collagen I and an 
increase only in expression of collagen III, when compared to normal lung 
function smokers and non-smoker controls.  Small airway tissues showed an 
overall increase in both collagen subtypes in early stage COPD (stage I and II) 
but subsequently, the decline in Stage IV.  Another interesting observation was 
the co-localization of αSMA positive fibroblastic cells along with collagen III 
expressions in the small airway which was not apparently present in large 
airways (Harju et al., 2010). In contrast, again, Annoni et al., (2012) showed a 
decrease in collagen type I and no change in type III and IV in mild to moderate 
COPD patients over that of non-smokers in resected tissue in either large or 
small airway. The studies so far in this critical area have been small and 
contradictory, and again more work is required, given the importance of these 
issues. 
Recent evidence has shown that ECM glycoproteins such as tenascin C and 
fibronectin may have an immune modulation as well as tissue remodelling in 
COPD. Myofibroblasts secrete these molecules and play a critical role in the 
structural stabilization of the tissue by interacting and cross-linking with 
collagen and elastin fibers in the airway. The changes to these glycoproteins 
were investigated in COPD patients by Karvonen et al., (2013) who showed an 
increased expression of tenascin C in mild to moderate COPD patients and 
correlation with myofibroblast numbers in the lamina propria area of large 
airway biopsies. A similar increase in tenascin C was reported by Annoni et al. 
(2012) again mainly in the LP region of both large and small airways in resected 
tissue sections in mild to moderate COPD patients. For fibronectin, however, 
neither group found any change in expression in COPD patients over normal 
non-smokers either in the small or large airway and they showed no correlation 
of fibronectin to the myofibroblast population. Similarly, in-vitro studies for 
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evaluation of secretory fibronectin from fibroblasts isolated from non-smokers 
and COPD patients also showed no differences (Togo et al., 2008).  These 
findings are surprising as both glycoproteins (tenascin C v/s fibronectin) are 
known to be secreted by myofibroblasts, and the apparent differential 
expression level could be specific spatial and temporal changes that occur in 
the ECM under disease conditions. 
Proteoglycans consist of a protein core covalently attached to one or more 
glycosaminoglycan (GAG) chain. Based on the structure, function, and 
localization in the tissue, the proteoglycans are further subdivided into three 
subtypes: basement membrane proteoglycans (e.g., perlecan), small leucine-
rich proteoglycans SLRPs (e.g., decorin, biglycan, lumican) and hyalectans 
(versican, aggrecan) (Lozzo, 1998). The proteoglycans have an essential role 
in maintaining tissue homeostasis; for example, versican has a crucial role in 
determining the water content, and the viscoelasticity of the tissue, perlecan in 
wound healing, cartilage formation and angiogenesis, decorins and biglycan 
are closely involved in regulating fibrosis and tissue stiffness.  
Annoni et al. (2012) recently observed no changes in versican, decorin, 
biglycan or lumican expression in the resected large or small airway or in lung 
parenchyma among COPD patients in comparison to the non-obstructive 
smoker and non-smokers controls. In contrast, Postma et al. had earlier 
observed a decreased expression of decorin and biglycan in the peribronchiolar 
area of emphysematous lung tissues in complex COPD patients and 
associated it to decreased elastic recoil and subsequent increases in 
bronchiolar obstruction (van Straaten et al., 1999). Further, Hallgren et al. 
(2010) described variable changes in proteoglycan expression in in-vitro culture 
studies using fibroblasts isolated from both central and distal airways. Distal 
airway fibroblasts from COPD patients showed enhanced production of 
versican, which correlated with emphysema – related decreased elastic recoil. 
Lower perlecan production was observed from centrally derived cells in COPD.   
Although there is substantial report on ECM changes in other lung diseases 
such as lung parenchymal interstitial disease (ILD), including idiopathic 
pulmonary disorder (IPF), and also on the airway wall in asthma, investigations 
into changes in the ECM in COPD patients have so far been quite limited. The 
lack of differential markers to distinguish myofibroblasts from other fibroblasts 
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and other mesenchymal stromal cells have impeded this research.  New 
markers such as CD44 and CD90 (Thy1), have emerged as plausible specific 
tools that could improve sensitivity (Karvonen et al., 2013, Hagood et al., 2005).  
There has also been considerable interest in a general sense over recent 
results in the roles played by other mesenchymal cells such as pericytes and 
endothelial cells and their potential transition to myofibroblasts and also the role 
of macrophages subtypes in maintaining and disrupting the ECM homeostasis. 
(Figure 1.6) Such insights and questions also need to be detected in airway 
and lung tissue of COPD patients. 
 
 Concluding remarks for literature review, aims, and hypothesis for 
the present thesis 
 
There has arisen over the past 20 years an assumption in respiratory research 
circles that the airway wall pathology in COPD is primarily one of 
“inflammation.” This is true in the lumen, but in the airway wall, there is more 
contradictory evidence that requires further verifications. Most of the 
assumptions come from animal studies, which have not matched perfectly with 
the human situation and does not take into account the published data on 
decreased total airway wall cellularity in COPD, and, hence could be 
misleading. This hypo-cellularity needs verification in mild-moderate COPD, 
while the picture even in more severe GOLD-III and IV stages are yet to be 
confirmed. In this literature review, I have assessed the whole literature on this 
and have concluded that this prevailing inflammatory dogma may at the very 
least be over-simplistic. There is undoubtedly a great deal of fibrotic remodeling 
and obliteration especially in the small airways in COPD, which is indeed is the 
primary pathology, but what is driving and meditating this is still poorly 
understood. Our group believes that EMT is a significant contributing factor and 
I wish to take the previous studies further in relating EMT to the fibrotic process 
more directly. My provisional understanding is that EMT is causally related to 
reprogramming of the basal stem cell layer of the epithelium, which as well as 
causing dramatic changes in the structure of the epithelium, also leads to an 
active EMT in these basal cells. The EMT process directly induces changes in 
 63 
the extracellular matrix in the underlying airway wall. Importantly, small airway 
destruction occurs early in the disease even before the diagnosis of COPD.   
 
Thus, the aims of my thesis were developed to reassess in phenotypically well-
characterized population in smokers and well-characterized COPD patients, 
and are summarized below; 
 
1. To undertake a detailed and systematic analysis of critical inflammatory 
cell profiles in both the large and small airway tissue from well 
characterized normal lung function smokers (NLFS), COPD current and 
ex-smokers compared to non-smoker controls, which has been done to 
date. Our group has data to suggest that the cellular picture within the 
airway wall in smokers is not one of classic inflammatory and I wish to 
confirm or refute this.  
2. Further, I would estimate the overall dysfunctionality in inflammatory cell 
components in COPD patients via their current degranulating activity.  
3. There has been much work done in disease process on distinct M1 and 
M2 population, but this has not been done in the airways. I wish to 
assess macrophage phenotype switching in COPD in both luminal and 
wall compartments. 
4. There are very few data available on myofibroblast populations in the 
small airways which are the site of active fibrosis and obliteration in 
COPD, and I wish to explore this population to a greater extent than 
previously done and relate it to EMT activity.  
5. To evaluate the presence and changes in crucial ECM markers such as 
collagen - I and, fibronectin in smokers and COPD patients and correlate 
them to myofibroblasts, EMT activity as well as airflow obstruction and 
small airway wall thickness. 
 
Overall, I hypothesize that the airway in COPD are not inflammatory at least in 
the airway wall, but are mainly primed to undergo an alternate “journey” of 
fibrotic remodelling; that this is related to epithelial basal cell reprogramming 
and in particular EMT development and activity. 
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  Materials and Methods 
 
 Subject recruitment  
 Ethics statements 
The Tasmania Health & Medical Human Research Ethics Committee approved 
all studies (EC00337, H6532, H0013051, and H0012921). All subjects gave 
written, informed consent to use their tissue, either before volunteer 
bronchoscopy and biopsy or before lung surgery. 
 Endo-bronchial biopsies (large airways) 
Seventy-two subjects were recruited through advertisement. Bronchial biopsies 
(BB) from 20 smokers with normal lung function (NLFS), 13 current smoking 
COPD (COPD-CS) and 14 ex-smokers with COPD (COPD-ES) were compared 
with up to 25 healthy non-smokers. COPD was diagnosed according to GOLD 
criteria. Subjects with other respiratory diseases, a history of recent acute 
exacerbation of COPD and those on systemic or inhaled corticosteroids were 
excluded from the study. The diagnosis of COPD was made according to GOLD 
guidelines based on FEV1 /FVC ratio and categorized into two groups based 
on current versus ex-smoking history. For normal lung function current smokers 
the inclusion criteria were; a minimum 10 pack-year history of cigarette smoking 
with spirometry within normal limits, i.e., FEV1 >70% and no scalloping out of 
the expiratory descending limb of the flow-volume curve to suggest small 
airway dysfunction. Normal healthy volunteers had no history of respiratory 
illness or smoking and had normal lung function. 
 Bonchoscopy 
Bronchoscopy was performed using standard techniques. Briefly, subjects 
were pre-medicated with nebulized salbutamol (5 mg) 15–30 min before the 
procedure. Sedation was achieved with intravenous midazolam (3–10 mg) and 
fentanyl (25–100 µg). Lignocaine (4%) was used for topical anaesthesia above 
the vocal cords and 2% lignocaine was used to anaesthetize the airways below 
the cords, in 2 ml aliquots as required, up to a maximum of 6 ml. Subjects were 
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monitored by pulse oximetry throughout the procedure and oxygen was 
administered routinely. Eight biopsies from secondary carinae of segmental 
and sub-segmental bronchi in the right lower lobe were obtained. There were 
no complications from the procedures. Bronchial biopsies were fixed in 4% 
neutral buffered formalin for 2 hours and subsequently processed into paraffin 
through graded alcohol and xylene using a Leica ASP 200 tissue processor 
 Resected lung tissue (small airways) 
Forty patients consented for inclusion in this study. Subjects all had primary 
non-small cell lung cancer, with an approximately equal distribution of 
squamous and adenocarcinoma, and consented for their surgical tissue to be 
used for research at Royal Hobart Hospital. Twenty patients had demonstrated 
mild-moderate, Global Initiative for Obstructive Lung Disease (GOLD) stage I 
and II COPD of which nine were COPD-CS and eleven COPD-ES (>1year 
smoking cessation). Eleven individuals NLFS. Ten non-smoking tissues were 
obtained from the James Hogg Lung Registry, the University of British 
Columbia with approval from the Providence Health Care Research Ethics 
Board H00-50110, and were included as a control group (NC) for comparison. 
Subjects with other respiratory diseases, a history of recent acute exacerbation 
of COPD and those on systemic or inhaled corticosteroids were excluded from 
the study. The surgically resected material was taken well away from the 
primary tumour and contained non-cancer affected small airways).Emeritus 
Late Professor HK Muller, a professional pathologist, inspected and confirmed 
that these tissues were normal, and without the hallmarks of smoking or 
asthma. 
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Table 3. Demographic and lung function data for participants in the cross-
sectional study for endo-bronchial large airways and bronchoalveolar lavage 
fluid (BALF).  
 
Groups 
(numbers) 
 
NC 
(n=25) 
 
NLFS 
(n=20) 
COPD-CS 
(n=13) 
COPD-ES 
(n=14) 
GOLD I/GOLD II‡ N/A N/A 6/7 6/7 
Age (years) 44 (20-68) 50 (30-66) (p=0.313) 
61 (46-78) 
(p=0.001) * 
62 (53-69) 
(p=0.001) * 
Smoking 
(pack years) 0 32 (10-57) 45 (18-78) 51 (18-150) 
FEV1% predicted 
(Post BD) † 
113        
(86-140) 
99 (78-125) 
(p=0.01) * 
83 (66-102) 
(p<0.001) * 
83 (54-104) 
(p<0.001) * 
FEV1/FVC % 
(Post BD) † 
82          
(71-88) 
77 (70-96) 
(p=0.218) 
59 (46-68) 
(p<0.001) * 
57 (38-68) 
p<0.001) * 
Data expressed as median and range. 
NC- Normal control; NLFS-Normal lung function smoker; COPD-CS (current smoker); 
COPD-ES (ex-smoker) 
*Significance difference from NC  
† Post BD values after 400µg of salbutamol 
‡ Diagnosis of COPD as per GOLD guidelines (GOLD 2013). 
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Table 4. Demographic and lung function data for participants in the cross- 
sectional study for small airway resected tissue. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Study groups NC  NLFS  
 
COPD-CS 
 
COPD-ES 
n 10 11 9 10 
Age 
 (years) 
68 
 (63-75) 
70     
(52-79) 
64          
(59-78) 
68 
(56-85) 
Smoking history 
(Pack-years) 
N/A 
33     
(0.3-60) 
28.5            
(2-50) 
33           
(18-36) 
FEV1/FVC 
 (%)* 
N/A 
76      
(70-90) 
66.0        
(59.9-70) 
63.9       
(54.9-69) 
FEF25-75% L/sec 
Post BD %pred. 
N/A 
81.5   
(70-116) 
37.0         
(28-47) 
40.5       
(20-55) 
Data expressed as median and range. 
NC, Normal control; NLFS, Normal lung function smoker; COPD-CS,  
COPD current smoker; COPD-ES, COPD ex-smoker; 
 N/A, Not any. 
*Post BD values after 400µg of salbutamol 
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 BALF collection and processing 
BALF were obtained from the same cohort of patients as mentioned in section 
3.1.2 and processed as described previously (Ward et al., 2002). Briefly, 
participants were pre-medicated with nebulized salbutamol (200µg), 
intravenous atropine (0.6 mg), and sedation was achieved with intravenous 
administration of midazolam (3–10 mg) and fentanyl (25–100μg). Lignocaine 
(4%) was applied topically to the nose, pharynx, and larynx, and 2% lignocaine 
was administered below the cords. Participants were monitored by pulse 
oximetry and administered oxygen throughout the procedure. The BAL fluids 
was immediately transported to the laboratory at 4°C for processing and 
analysis 
 
BAL was performed with three aliquots, 60 mL each; of phosphate buffered 
saline (PBS) at 37° introduced by steady hand pressure into the right middle 
lobe and recovered by suction at less than -80mm Hg pressure. Total cell 
counts were determined on unfiltered BALF using a Neubauer haemocytometer 
and 1 ml of the BAL was cyto-centrifuged using CytoSpin 4 Cytocentrifuge 
(ThermoScientific) at 850 rpm for 5min producing two cytospots onto each 
glass slide. The cytospins were frozen at -80°C until use.  
 
Further, BAL fluids was filtered through a 200µm stain-less mesh and cells 
pelleted at 100Xg max for 15min at 4°C. Aliquots of the BAL supernatants were 
stored in at -80°C, for subsequent used in cytokine profiling. 
 
 Exclusion criteria  
 
1. Subjects with asthma, which included symptoms in childhood, related 
atopic disorders, significant a history of wheeze, eczema or hay fever, 
rather than progressive breathlessness and any who had previously 
used ICS (oral or inhaled) were excluded. 
2. Further, uncontrolled comorbidities such as angina or cardiac failure, 
diabetes and other associated respiratory illnesses including pulmonary 
fibrosis and bronchiectasis. 
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3. Subjects with inability to provide written informed consent were also 
excluded. 
 
 Inclusion criteria  
 
1. COPD  Current-smokers aged at  40 years and above with smoking 
history equal more than 15 pack-years and subsequently obtained BAL 
fluid had to be free of bacterial colonisation; FEV1 40% to 80% predicted, 
with FER (FEV1/FVC)≤70% post-bronchodilator with definite scalloping 
out of the descending limb of flow-volume loop on spirometry. COPD ex-
smokers with at least six months of smoking cessation were included.   
2. Normal healthy never smoking controls and current smokers with normal 
lung function recruited also underwent bronchoscopy examination and 
physiological lung function test. They were more tha eighteen year old 
and had a FEV1/FVC ratio of greater than 70% or higher and FEV1% 
predicted of 80% or higher.  
3. All never-smoking controls individuals were devoid of any respiratory 
illness or smoking history at the time of extraction.  For normal lung 
function current smokers the inclusion criteria were; a minimum 10 pack-
year history of cigarette smoking with spirometry within normal limits 
(FEV1 (forced expiratory volume) >80% of predicted, and FEV1/FVC 
(forced vital capacity) >70%) and no scalloping out of the expiratory 
descending limb of the flow-volume curve, suggesting small airway 
dysfunction. 
 
 Processing of biopsies and resected tissue 
 
Both biopsies and resected sections were cut up to 3.5 microns thick from 
individual paraffin blocks and stained with hematoxylin & eosin to assess 
morphology and damages.  
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 Hematoxylin and eosin (H&E) stain 
 
1. Slides with tissue sections were placed in Mayer’s hematoxylin for 5 
minutes to elaborate nuclei, followed by rinsing in running water.  
2. Tissue sections were placed in approximately in 400ml of water with 
eight drops of ammonia 30 seconds and rinsed well in running water. 
3. Slides were then placed in eosin solution for 2 minutes and rinsed quickly 
in running water to remove excess eosin and then placed into 95% 
ethanol for 30 seconds with agitation. 
4. Further dehydrated with three changes of 100% ethanol was carried out 
(1 minute each).  
5. Clearing of sections was done using two changes of fresh xylene (2 
minutes each).  
Sections were mounted in Depex using Dako Coverslipper (Dako, Denmark 
A/S) and dried on hotplate overnight. 
 General procedure (Tissue slide preparations for 
immunohistochemical analysis) 
 
1. Paraffin blocks (both biopsies and resected tissues) were sectioned at 
3.5 microns after cooling in –20 freezers or on ice blocks 5-10 minutes.  
2. For biopsies, two sections (approximately 3µm thick) separated by 40-
50  (approximately ten sections) were cut and placed on Dako FLEX IHC 
microscopic slides (Code K8020, Dako Denmark A/S). For resected 
tissue, only one section of tissue was used due to a greater size. 
3. Slides were either left to dry on a hotplate at 56°C for one hour or left 
overnight in a 37°C incubator. 
4. Slides were barcoded for easy identification and further marked on the 
edges with a wax pen to avoid spillage of reagents. 
5. Dewaxing of the tissue sections was carried out with lab grade Xylene 
twice for 5 minutes each in a fume hood. 
6. Hydration to water was carried out using 100% ethanol followed by 95% 
then 70% (3 minutes each) followed by rinsing the sections in running 
tap water for approximately 2 minutes. 
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Note- Unless otherwise stated, all immunohistochemical staining was done 
using Dako auto-stainer which provided a more reliable and consistent 
output.PT link (Dako), a regulated heating device, was used for antigen 
retrieval with either high pH Target Retrieval Solution, High pH (50x 
Tris/EDTA buffer, pH 9) or low pH (50x buffer, pH 6) pre-diluted antigen 
retrieval solution available from DAKO 
 
Figure 3.1 Pictorial representation of staining strategy. 
 
 
 Immunostaining for neutrophils (Neutrophil Elastase)  
1. For neutrophil elastase staining, sections were placed prior in 3% H2O2 
in distilled water for 20 minutes to block endogenous peroxidase 
activity. Note: No antigen retrieval was required as determined by prior 
optimization. 
2. Tissue sections were washed thrice with Tris HCl pH 7.5 (wash buffer) 
with two minutes intervals. 
3. Primary antibodies neutrophil elastase (Dako, clone NP57, catalog # 
M0752), was applied to the tissue at 1/500 dilution and incubated for an 
hour. Matched negative control was used: for neutrophil elastase-
isotype-matched immunoglobulin IgG1κ (X0931, Dako, Denmark A/S). 
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Lung sections from the previous biobank was used as positive controls 
for confirmation of staining. 
4. Sections were further rinsed using wash buffer (thrice, 5 minutes 
interval) before addition of anti-mouse secondary antibodies- the 
EnVision+ system-HRP labeled polymer reagent (catalog number 
K4001; Dako, Denmark A/S) for 30 minutes. 
5. After three washes, DAB+ (catalog number K3468; Dako, Denmark A/S) 
was applied to sections for further 10 minutes and rinsed in wash buffer 
(twice) followed by once with distilled water. 
6. The tissue sections were counter-stained Mayers hematoxylin to 
elaborate nuclei for approximately 5 minutes, then rinsed thoroughly in 
running water. 
7. Sections were placed in approximately 400 ml of water with 6-8 drops 
of ammonia for 30 seconds and rinsed again in running water. 
8. Dehydration was carried out in 95% ethanol, then two changes of 100% 
ethanol (2 minutes each). The clearing was done in two changes of 
xylene (2 minutes each). 
9. Sections were then mounted in Depex using Dako Coverslipper (Dako, 
Denmark A/S) and dried on hotplate overnight. 
 Immunostaining of total CD68+ cells 
1. For CD68+ staining, high pH antigen retrieval was done at 100°C for 
15min followed by treatment with 3% H2O2 in distilled water for 20 
minutes to block endogenous peroxidase activity. Tissue sections were 
washed thrice with Tris HCl pH 7.5 (wash buffer) with two minutes 
intervals. 
2. Primary antibodies mouse monoclonal CD68+ (Dako, clone KP1, 
catalog # M0814,) was applied to the tissue at 1/400 dilution and 
incubated for an hour. Matched negative control was used: for CD68+ 
isotype-matched immunoglobulin IgG1κ (X0931, Dako, Denmark A/S). 
Lung sections from the previous biobank was used as positive controls 
for confirmation of staining. 
3. Sections were further rinsed using wash buffer (thrice, 5 minutes 
interval) before addition of anti-mouse secondary antibodies- the 
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EnVision+ system-HRP labeled polymer reagent (catalog number 
K4001; Dako, Denmark A/S) for 30 minutes. 
4. After three washes, DAB+ (catalog number K3468; Dako, Denmark A/S) 
was applied to sections for further 10 minutes and rinsed in wash buffer 
(twice) followed by once with distilled water. 
5. The tissue sections were counter-stained Mayers hematoxylin to 
elaborate nuclei for approximately 5 minutes, then rinsed thoroughly in 
running water. 
6. Sections were placed in approximately 400 ml of water with 6-8 drops 
of ammonia for 30 seconds and rinsed again in running water. 
7. Dehydration was carried out in 95% ethanol, then two changes of 100% 
ethanol (2 minutes each). The clearing was done in two changes of 
xylene (2 minutes each). 
8. Sections were then mounted in Depex using Dako Coverslipper (Dako, 
Denmark A/S) and dried on hotplate overnight. 
 Immunostaining for CD4+ and CD8+ T cells 
1. For CD4+ and CD8+ cell staining, antigen retrieval was done in EDTA 
buffer (pH 8.0) at boiling temperature for three minutes followed by 
treatment with 0.3% H2O2 in methanol for three minutes. Tissue 
sections were washed thrice with Tris HCl pH 7.5 (wash buffer) with two 
minutes intervals. 
2. Primary antibodies mouse monoclonal CD4+ (Leica Novo Castra, clone 
1F6, catalog # NCL-CD4-4B11) and CD8+ (Leica Novo Castra, clone 
4B11, catalog # NCL-CD8-4B11) were applied to the tissue at 1/20 
dilution and incubated for an hour. Matched negative control was used: 
for CD4 isotype-matched immunoglobulin IgG1κ (X0931, Dako, 
Denmark A/S) and CD8 isotype-matched immunoglobulin IgG2b 
(X0944, Dako, Denmark A/S) respectively. Lung sections from the 
previous biobank was used as positive controls for confirmation of 
staining. 
3. Sections were further rinsed using wash buffer (thrice, 5 minutes 
interval) before addition of anti-mouse secondary antibodies- the 
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EnVision+ system-HRP labeled polymer reagent (catalog number 
K4001; Dako, Denmark A/S) for 30 minutes. 
4. After three washes, DAB+ (catalog number K3468; Dako, Denmark A/S) 
was applied to sections for further 10 minutes and rinsed in wash buffer 
(twice) followed by once with distilled water. 
5. The tissue sections were counter-stained Mayers hematoxylin to 
elaborate nuclei for approximately 5 minutes, then rinsed thoroughly in 
running water. 
6. Sections were placed in approximately 400 ml of water with 6-8 drops 
of ammonia for 30 seconds and rinsed again in running water. 
7. Dehydration was carried out in 95% ethanol, then two changes of 100% 
ethanol (2 minutes each). The clearing was done in two changes of 
xylene (2 minutes each). 
8. Sections were then mounted in Depex using Dako Coverslipper (Dako, 
Denmark A/S) and dried on hotplate overnight. 
 Immunostaining for mast cells, degranulating Mast cells, and 
degranulating cells  
For the enumeration of Degranulated mast cells in the small airway, dual 
staining was done by using mast cell tryptase AA1 and lysosomal-associated 
membrane protein-1 (LAMP-1). 
1. Antigen retrieval was done for the tissues in high pH buffer at boiling 
temperature for three minutes followed by treatment with 3% H2O2 in 
water for three minutes. Tissue sections were washed thrice with Tris 
HCl pH 7.5 (wash buffer) with two minutes intervals. 
2. Primary antibodies mouse anti-human mast cell tryptase (AA-1) 
monoclonal antibody (M7052; Dako; 1/1500 dilution) and a rabbit anti-
LAMP-1 antibody (Abcam; ab24170; 1/200 dilution) were sequentially 
added and further incubated for an hour. Matched negative control was 
used: isotype-matched immunoglobulin IgG1κ (X0931, Dako, Denmark 
A/S) and rabbit serum (X0903, Dako, Denmark A/S) at appropriately 
adjusted concentrations. Lung sections from the previous biobank was 
used as positive controls for confirmation of staining. 
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3. Tissue sections were washed thrice with wash buffer with two minutes 
intervals. 
4. Bound Tryptase AA-1 antibodies were elaborated using Dako REAL 
detection system (catalog number K5005; Dako) and were visualized 
with BCIP/NBT (5-bromo-4-chloro-3'-indolyphosphate and nitro-blue 
tetrazolium) in a ready-made substrate system (catalog number K0598; 
Dako). Endogenous alkaline phosphatase activity was inhibited by the 
addition of levamisole to the visualization substrate (catalog number 
X3021; Dako). 
5. Sections were further rinsed using wash buffer (thrice, 5 minutes 
interval) and bound LAMP-1 before addition of anti-mouse secondary 
antibodies- the EnVision+ system-HRP labeled polymer reagent 
(catalog number K4001; Dako, Denmark A/S) for 30 minutes. 
6. After three washes, DAB+ (catalog number K3468; Dako, Denmark A/S) 
was applied to sections for further 10 minutes and rinsed in wash buffer 
(twice) followed by once with distilled water. 
7. The tissue sections were counter-stained nuclear fast red to elaborate 
nuclei for approximately 2 minutes, then rinsed thoroughly in running 
water to remove the excess stains. 
8. Dehydration was carried out in 95% ethanol, then two changes of 100% 
ethanol (2 minutes each). The clearing was done in two changes of 
xylene (2 minutes each). 
9. Sections were then mounted in Depex using Dako Coverslipper (Dako, 
Denmark A/S) and dried on hotplate overnight. 
 Immunostaining for M1 macrophages (CD68+ and iNOS) 
1. To identify M1 macrophages, resected small airway tissues and BALF 
cytospins, were dual stained with CD68+ and iNOS. Antigen retrieval 
was done with high pH buffer at boiling temperature for three minutes 
followed by treatment with 3% H2O2 in water for three minutes. Tissue 
sections were washed thrice with Tris HCl pH 7.5 (wash buffer) with two 
minutes intervals. 
2. Primary antibodies mouse anti-CD68 monoclonal antibody (KP1, Dako, 
M0814, 1/400 dilution) and a rabbit anti-iNOS polyclonal antibody 
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(Thermo Fisher Australia, PA1-21054, 1/100 dilution) were sequentially 
added and further incubated for an hour. Matched negative control was 
used: isotype-matched immunoglobulin IgG1κ (X0931, Dako, Denmark 
A/S) and rabbit serum (X0903, Dako, Denmark A/S), Dako, Denmark 
A/S) at appropriately adjusted concentrations. Lung sections from the 
previous biobank was used as positive controls for confirmation of 
staining. 
3. Tissue sections were washed thrice with wash buffer with two minutes 
intervals. 
4. Bound CD68+ antibodies were elaborated using Dako REAL detection 
system (catalog number K5005; Dako) and were and visualized with 
BCIP/NBT (5-Bromo-4-chloro-3'-polyphosphate and nitro-blue 
tetrazolium) in a ready-made substrate system (catalog number K0598; 
Dako). Endogenous alkaline phosphatase activity was inhibited by the 
addition of Levamisole to the visualization substrate (catalog number 
X3021; Dako). 
5. Sections were further rinsed using wash buffer (thrice, 5 minutes 
interval) and the bound LAMP-1 before addition of anti-mouse 
secondary antibodies- the EnVision+ system-HRP labeled polymer 
reagent (catalog number K4001; Dako, Denmark A/S) for 30 minutes. 
6. After three washes, DAB+ (catalog number K3468; Dako, Denmark A/S) 
was applied to sections for further 10 minutes and rinsed in wash buffer 
(twice) followed by once with distilled water. 
7. The tissue sections were counter-stained nuclear fast red to elaborate 
nuclei for approximately 2 minutes, then rinsed thoroughly in running 
water to remove the excess stains. 
8. Dehydration was carried out in 95% ethanol, then two changes of 100% 
ethanol (2 minutes each). The clearing was done in two changes of 
xylene (2 minutes each). 
9. Sections were then mounted in Depex using Dako Coverslipper (Dako, 
Denmark A/S) and dried on hotplate overnight. 
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 Immunostaining for M2 macrophages 
1. To identify M2 macrophages both CD163 and Arginase-1 (Arg-1) were 
used as markers in both small airway wall and BALF cytospins samples. 
For Arg-1, a high pH antigen retrieval was done in at 97°C for 15min, 
while for CD163 no antigen retrieval was used, as determined during 
optimization. This was followed by treatment with 3% H2O2 in distilled 
water for 20 minutes to block endogenous peroxidase activity. Tissue 
sections were washed thrice with Tris HCl pH 7.5 (wash buffer) with two 
minutes intervals. 
2. Primary antibodies mouse monoclonal CD163+ mouse anti-CD163 
(EDHu-1, AbD Serotec, MCA1853, 1/100 dilution) and mouse anti-Arg1 
(BD Biosciences, 610708, 1/100 dilution) antibodies was applied to the 
tissue for 90 minutes.  Matched negative control was used: for CD163 
and Arg-1 isotype-matched immunoglobulin IgG1κ (X0931, Dako, 
Denmark A/S). Lung sections from the previous biobank was used as 
positive controls for confirmation of staining. 
3. Sections were further rinsed using wash buffer (thrice, 5 minutes 
interval) before addition of anti-mouse secondary antibodies- the 
EnVision+ system-HRP labeled polymer reagent (catalog number 
K4001; Dako, Denmark A/S) for 30 minutes. 
4. After three washes, DAB+ (catalog number K3468; Dako, Denmark A/S) 
was applied to sections for further 10 minutes and rinsed in wash buffer 
(twice) followed by once with distilled water. 
5. The tissue sections were counter-stained Mayers hematoxylin to 
elaborate nuclei for approximately 5 minutes, then rinsed thoroughly in 
running water. 
6. Sections were placed in approximately 400 ml of water with 6-8 drops 
of ammonia for 30 seconds and rinsed again in running water. 
7. Dehydration was carried out in 95% ethanol, then two changes of 100% 
ethanol (2 minutes each). The clearing was done in two changes of 
xylene (2 minutes each). 
8. Sections were then mounted in Depex using Dako Coverslipper (Dako, 
Denmark A/S) and dried on hotplate overnight. 
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 Immunostaining for αSMA+ Myofibroblast 
1. For αSMA+ staining, a high pH antigen retrieval was done in at 97°C for 
20min. This was followed by treatment with 3% H2O2 in distilled water 
for 20 minutes to block endogenous peroxidase activity. Tissue sections 
were washed thrice with Tris HCl pH 7.5 (wash buffer) with two minutes 
intervals. 
2. Primary antibodies mouse monoclonal mouse anti- αSMA (Dako, 
M0851, 1/400 dilution) antibodies was applied to the tissue for 90 
minutes.  Matched negative control was used: immunoglobulin IgG1κ 
(X0931, Dako, Denmark A/S). Lung sections from the previous biobank 
was used as positive controls for confirmation of staining. 
3. Sections were further rinsed using wash buffer (thrice, 5 minutes 
interval) before addition of anti-mouse secondary antibodies- the 
EnVision+ system-HRP labeled polymer reagent (catalog number 
K4001; Dako, Denmark A/S) for 30 minutes. 
4. After three washes, DAB+ (catalog number K3468; Dako, Denmark A/S) 
was applied to sections for further 10 minutes and rinsed in wash buffer 
(twice) followed by once with distilled water. 
5. The tissue sections were counter-stained Mayers hematoxylin to 
elaborate nuclei for approximately 5 minutes, then rinsed thoroughly in 
running water. 
6. Sections were placed in approximately 400 ml of water with 6-8 drops 
of ammonia for 30 seconds and rinsed again in running water. 
7. Dehydration was carried out in 95% ethanol, then two changes of 100% 
ethanol (2 minutes each). The clearing was done in two changes of 
xylene (2 minutes each). 
8. Sections were then mounted in Depex using Dako Coverslipper (Dako, 
Denmark A/S) and dried on hotplate overnight 
 Immunostaining for ECM proteins 
9. For collagen-1, a low pH antigen retrieval was done in at 97°C for 15min 
while for fibronectin high pH buffer was used. This was followed by 
treatment with 3% H2O2 in distilled water for 20 minutes to block 
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endogenous peroxidase activity. Tissue sections were washed thrice 
with Tris HCl pH 7.5 (wash buffer) with two minutes intervals. 
10. Primary antibodies mouse polyclonal mouse anti-collagen-1 (Abcam, 
AB34710, 1/250 dilution) and polyclonal rabbit fibronectin (Dako, 
A0245, 1/1000 dilution) antibodies was applied to the tissue for 90 
minutes.  Matched negative control was used: immunoglobulin IgG1κ 
(X0931, Dako, Denmark A/S). Lung sections from the previous biobank 
was used as positive controls for confirmation of staining. 
11. Sections were further rinsed using wash buffer (thrice, 5 minutes 
interval) before addition of anti-mouse and anti-rabbit secondary 
antibodies- the EnVision+ system-HRP labeled polymer reagent 
(catalog number K4001; Dako, Denmark A/S) for 30 minutes. 
12. After three washes, DAB+ (catalog number K3468; Dako, Denmark A/S) 
was applied to sections for further 10 minutes and rinsed in wash buffer 
(twice) followed by once with distilled water. 
13. The tissue sections were counter-stained Mayers hematoxylin to 
elaborate nuclei for approximately 5 minutes, then rinsed thoroughly in 
running water. 
14. Sections were placed in approximately 400 ml of water with 6-8 drops 
of ammonia for 30 seconds and rinsed again in running water. 
15. Dehydration was carried out in 95% ethanol, then two changes of 100% 
ethanol (2 minutes each). The clearing was done in two changes of 
xylene (2 minutes each). 
16. Sections were then mounted in Depex using Dako Coverslipper (Dako, 
Denmark A/S) and dried on hotplate overnight 
 
 Microscopic and Image analysis 
 
Computer-assisted image analysis was performed with a Leica DM 2500 
microscope (Leica Microsystems, Germany), Spot Insight-12 (Spot Imaging 
Solutions, USA) digital camera and Image Pro Plus 7.0 (Media Cybernetics, 
USA) software. Firstly, as many images as possible was taken of the tissue 
from the area of interest (for this study it was mainly epithelium, Rbm, lamina 
propria), strictly avoiding overlapping of tissue. All image analyses were done 
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using the above-described image analyzer. Randomly five selected images 
from the total number of images were used for desired measurements.  
 
Important Note- In all studies, the slides from the pathological and normal 
subject evaluated here were blinded by an independent observer and was 
revealed to me only after the data was evaluated. 
 Immune cells and Cellularity Estimation 
 
Neutrophil Elastase, CD68+ macrophage, CD4 and CD8 stained cells were 
counted in the LP up to 150 microns deep for large airways and full thickness 
airway wall (or up to 100 microns deep) in the SA wall; cells per mm2 area were 
calculated. Stained cells in the epithelium and Reticular Basement Membrane 
(Rbm) were counted and presented per mm of Rbm length. For total cell counts, 
hematoxylin stained nuclei were considered as an individual cell and measured 
with similar strategies as mentioned above. 
 Mast cell and Degranulated cell Estimation 
Full-thickness SA wall up to 100 microns deep were quantitated as cells per 
mm2 area surveyed, excluding the smooth muscle layer. Cells that stained for 
mast cells (both degranulating and non-degranulating) and degranulating cells 
in the epithelium and sub-epithelium were counted and are presented per mm 
of Rbm length for the epithelium and as per mm2 of small airway sub-epithelium.  
 M1 M2 macrophage estimation 
 
 Small Airway wall 
 
Five random fields selection of small airways less than two mm in thick (a 
minimum of two airways per subject) were chosen for comprehensive analysis 
without ad hoc area selection, although muscle bundles and glands were 
excluded from the area surveyed. Small airways sub-epithelium up to 100 
microns deep were quantitated. Stained M0, M1 and M2 cells in the sub-
epithelium and epithelium were separately counted and is presented here as 
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per mm2 of the area surveyed and per mm of reticular basement membrane 
(RBM) length respectively.  
For arginase-1 expression, a separate analysis was done for the total sub-
epithelium (excluding muscle areas) and epithelium and further, the data here 
is represented as percent of tissue expressing arginase-1 (Arg-1) expression.   
 
 BALF 
 
BAL cells counts were done using bright field microscope (Olympus BX53) 
assisted by Visiopharm newCAST™ software. An automated motorized system 
provided an unbiased uniform random area sampling for 12 fields per cytospot, 
and stained cells were manually counted for each selected field. Counts were 
normalized with BAL dilution factor and presented here as cells per ml of the 
original BAL sample. 
 
 Airway wall thickness Measurements 
All airway thickness were measured using thickness measurement analysis 
programme in the Image ProPlus version 7.0 software. I took random non-
overlapping pictures of as many images as possible (with smooth muscle layer 
captured in each picture), from a minimum of three airways per section and, 
further, eight picture were randomly selected by using an online randomiser 
programme. The tissue was divided into three sections lamina propria (the 
distance between Rbm and top of the muscle layer), smooth muscle layer and 
adventitia (the distance between the lower layers of the muscle to the airway 
septum).  For calculation of LP, thickness two lines were drawn; one at the base 
of the epithelium and the other was just above the smooth muscle wall a layer. 
Similarly, lines were drawn on top and bottom of muscle layer, and for the 
adventitia thickness, lines were drawn from below the muscle layer, outward 
into the start septal areas (Figure 3.1).  
Further, based on orientation, horizontal, vertical or curvature thickness was 
measured by the image analytic software, and average distances in microns is 
calculated. 
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Figure 3.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 Representative image of the zones used for the thickness analysis 
in the small airways.  
 
 αSmooth muscle actin (αSMA) and ECM estimation 
 
αSMA positive cells were enumerated in Rbm, lamina propria, and the 
adventitia regions of the small airway wall as illustrated in figure 3.1. αSMA 
positive cells in the Rbm were enumerated as cells per mm length of the small 
airway Rbm, while for the lamina propria and adventitia the cells were 
enumerated as per mm2 of the respective area. For collagen-1 and fibronectin, 
per object area of the lamina propria, and the adventitia was analyzed and is 
represented here as the percentage expression of the surveyed area.   
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 Cytokine Analysis 
For estimating M1/M2 cytokine profile cell-free equal volumes of BALF 
supernatants were thawed on ice and concentrated ten-folds, using 3kDa cutoff 
Amicon® Ultra-4 Centrifugal Filter Units (UFC800308 Merck Millipore) and 
centrifugation (2000g, 30 min, 4°C).  Human cytokines for M1/proinflammatory 
cytokines (IL-12, IFNγ,) and M2 (IL-4, IL-13, CCL22, IL-10, IL-6), and IL-1β 
TNFα were quantitated using multiplexing (MPHCYTOMAG60; Millipore 
Multiplex kits), and analysis was done using Luminex™ MagPix Multiplex 
technology platform according to manufacturer instructions. 
Chemokine/cytokine quantitation was derived from the standard curve and 
represented here as picograms per ml of original BAL sample. 
 
 Statistical analysis 
For all cross-sectional data, I determined the normality of the data using 
D’Agostino-Pearson omnibus normality test. Based on the distributions results 
which were skewed upwards, the analysis presented here are as medians and 
ranges; non- parametric analyses of variance were performed, Kruskal-Wallis 
Test, comparing medians across all the groups of interest and specific group 
differences and correction for the multiple comparisons was done using Dunn’s 
test.  
For correlation studies, I performed a regression analysis using Pearson or 
Spearman's rank test. Linear regression analysis for potential confounders 
were undertaken, and differences between groups in gender balance, age, and 
atopy were found to be non-contributory.  
Statistical analyses were performed either using SPSS 21.0 for Mac, 2012 (IBM 
Corporation, Armonk, NY, USA) or GraphPad Prism 7.0 (2012) for Windows, 
(GraphPad Software Inc., La Jolla, CA, USA), with a two-tailed p-value ≤0.05 
being considered statistically 
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Profiling cellular and inflammatory changes in the airway wall of mild to 
moderate COPD 
Note: This chapter is published with ‘Respirology’ and is explained in with the 
overall textual context. 
Eapen, M. S., Mcalinden, K., Tan, D., Weston, S., Ward, C., Muller, H. K., 
Walters, E. H. & Sohal, S. S. 2017. Profiling cellular and inflammatory changes 
in the airway wall of mild to moderate COPD. Respirology, 22 (10), 1125-1132. 
 Introduction 
 
COPD is a devastating global disease caused especially by cigarette smoking. 
The disease is characterized by slowly progressive fixed airway narrowing due 
to small airway fibrosis and obliteration. Up to fifty percent of COPD patients 
also go on to varying degree of emphysema (Sohal et al., 2013), and as a 
group, they are highly vulnerable to lung cancer, suggesting a common 
pathogenesis (Mahmood et al., 2015).   
 
The literature has reported convincing increases in both innate and adaptive 
cells in the airway lumen in COPD (Pesci et al., 1998, Rutgers et al., 2000). It 
has also become accepted that airway wall inflammation also plays a critical 
role in COPD, but the evidence for this is quite limited Better understanding of 
COPD pathophysiology requires more detailed information from airway wall 
tissues (Persson and Uller, 2010). 
 
There are reports of both increases and decreases in inflammatory cell profiles 
in the airway wall (Di Stefano et al., 1998a, Di Stefano et al., 2001, Saetta et 
al., 1999). Selection of patients, inadequate approaches to controls, different 
sources of tissue acquisition, have been important variables. Studies aimed at 
relatively early disease before secondary complications such as chronic 
infection and cancer would be valuable for understanding fundamental 
pathogenesis. 
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Our group has reported previously that smoking significantly decreased large 
airway (LA) lamina propria (LP) total cellularity in mild-moderate COPD 
subjects (Sohal et al., 2013). Surprisingly, few groups have examined this in 
airway tissue. Our hypo-cellularity finding in large airway biopsies questioned 
whether COPD could truly be regarded as an “airway wall” inflammatory 
disease. The limited literature evidence on cell differentials in the airway wall is 
also variable. O'Shaughnessy et al., (1997) showed that there was an increase 
in CD8+ T cells in COPD while the same cells were demonstrated to decrease 
progressively from mild-moderate to severe COPD by Di Stephano et al., and 
reports on macrophages and neutrophils have similarly varied in both directions 
(Rutgers et al., 2000, Di Stefano et al., 1998a, Lams et al., 1998, Utokaparch 
et al., 2014). This inconsistency for cell differentials in the airway wall and the 
previous finding of overall hypo-cellularity led us to believe that a new thorough, 
systematic investigation was warranted.  
 
I have also probed in more detail than previously the phenotypic specificity of 
the commonly used macrophage marker CD68 that has been used rather 
uncritically by respiratory scientists for many years. Evidence from non-
respiratory researchers suggests that this marker is not unique to macrophages 
alone but are also expressed on fibroblastic cells (Kunisch et al., 2004).  
 
 In the current study, I provide total cellularity, “inflammatory” cell differentials 
for neutrophils, CD68+ and CD8+ cells in both large and small airway tissue 
from mild-moderate, stable COPD subjects who Ire not on medication, and free 
from clinical infection. 
 
 Overview of materials and methods 
 
The subjects involved are detailed on pages 65 and 66 in the method section. 
I employed classical immunohistochemical methods to evaluate neutrophils, 
macrophages, CD4 and CD8 positive cells in both large and small airway 
epithelium, Rbm and Sub-epithelium in bronchial biopsies collected from well-
phenotyped participants (detailed in chapter 3, page 72-74). 
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 Results 
 Total cells  
 
Cell density was greater in SA and LA in normal controls (p<0.01), with cells 
per mm2 of LP compared to diseased. A decrease in overall cell numbers was 
observed in both LA LP (p<0.01) and SA wall p<0.001) in COPD when 
compared to normal non-smokers. In NLFS in LA, TC numbers were 
intermediate (p<0.01) while in ex-smokers the cell numbers were essentially 
back to NC levels though with wider variation (p=0.15). In the SA, TC numbers 
were significantly fewer compared to normal controls in all smoker/COPD 
groups with little difference between these three (Figure 4.1 A. and B.).  
 
 Neutrophils 
 
Neutrophil numbers were similar between the SA and LA in NC. Neutrophil 
numbers in the pathological groups in large airways reflected the changes in 
total cell counts, i.e. were reduced with least density observed in COPD-CS 
(p<0.01). In SA, However, neutrophil density was little different from normal in 
all groups, even if apparently (non-significantly) slightly reduced in the NLFS 
(Fig 4.1 C. and D.).  
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Figure 4.1  
 
Figure 4.1. Total number of cells per square mm of the airway wall examined: 
(A). Large Airways; (B), Small Airways. Neutrophils per square mm of the 
airway wall examined: (C), Large Airways; (D), Small Airways 
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 CD68+ cells  
 
 I observed two morphologically variable populations of CD68+ cells: round 
macrophages and spindle-shaped cells, which I will refer to as macrophages 
and fibroblast-like cells respectively (Fig 4.2 A. and B). In normal, LA these 
CD68+ fibroblast-like cells were much more numerous than macrophages, but 
in contrast, macrophages dominated the SA CD68+ profile (Figure 4.3, Figure 
4.2 C and D).  
In COPD-CS LA, compared to normal controls, I found fewer macrophages 
(p<0.05), while in contrast, macrophages in the NLFS were significantly higher 
(p<0.001) than normal. In COPD-ES subject’s macrophages numbers were 
close to normal levels. In SA, although macrophage numbers were high 
generally, I found no significant change from normal in their numbers in 
smoker/COPD groups (Figure 4.3).  
Fibroblast-like cells were slightly higher in normal LA than normal SA but not 
significantly so (p=0.09). There was a reduction in all smoker/COPD groups in 
large airways (significant only for NLFS, p<0.01) but fibroblast-like cell densities 
were unchanged in corresponding small airways (Figure 4.3).  
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Figure 4.2  
 
 
 
Figure 4.2 Illustrates the presence of two morphologically distinct populations 
of CD68+ in (A). Large Airways and (B). Small Airways (400X magnification). 
(C) and (D), represent percentages of the total CD68+ for each morphological 
phenotype. 
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Figure 4.3 
 
 
 
 
Figure 4.3 A, B, C, and D represents the data for CD68+ve round-shaped 
macrophages, and spindle-shaped fibroblast-like cell numbers per square mm 
of airway wall examined. 
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 Lymphocytes  
 
In the LA wall, the lymphocyte populations studied were dominated by the 
CD8+ phenotype. Both CD8+ and CD4+ T cells were found to be lower than 
normal in the smoker/COPD groups but with some substantial changes in their 
ratio, especially in the COPD-CS where there was an even more marked 
relative excess of CD8+ over CD4+ lymphocytes (Figure 4.4D).   
There were many fewer CD4+ T cells throughout the airways, and indeed so 
few in the small airway that I did not formally count them. In contrast in SA, 
CD8+ cells tended to be higher than normal across all clinical groups, and 
especially so in COPD-CS (p<0.01).  
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Figure 4.4 
 
 
 
Figure 4.4. Number of CD8+ve T cells per square mm of airway wall examined: 
(A), Large and (B), Small airways. (C), CD4+ve T cells in LA. (D), Ratio of CD8+ 
to CD4+ T cells in the LA LP. 
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 Inflammatory cells in airway epithelium and Rbm 
 
Overall, the inflammatory cell densities in the airway epithelium and Rbm were 
far lower in comparison to the LP. Although the absolute number was small, a 
significant increase above normal was observed for macrophages in the 
epithelium of NLFS when compared to NC (Table 5). 
Table 5. Inflammatory cells in airway epithelium and Rbm in large and small 
airways 
Epithelium 
Large 
Airways Neutrophils 
Macrophages 
(CD68+) 
Fibroblasts  
(CD68+) CD8+ CD4+ 
NC 0.4 (0-10) 0 (0-2.5) 0 (0-9.3) 3.7 (0-13) 0 (0-1.7) 
NLFS 0.5 (0-5.6)  2 **(0-6.5) 1.1 (0-4.9) 7.3(0.5-21.8) 0 (0-4.1) 
COPD-CS 0 (0-7.5) 0 #(0-3.9) 0.5 (0-9.3) 5.4 (1-23) 0 (0-0.9) 
COPD-ES 0.4 (0-2) 1.9 #(0-1.8) 0.2(0-3.15) 5 (1-25.6) 0 (0-3.2) 
Small 
Airways 
     
NC 0 (0-0.5) 2.1(0-6.4) 0.5 (0-3.2) 0.5 (0-9.1) - 
NLFS 0 (0-1.4) 3.6 (0.4-9.4) 1.0 (0-6.5) 1.3 (0-12) - 
COPD-CS 0.5 (0-2.4)  3.4(1.2-5.3) 0.5 (0-3.6) 2.6(0-11.3) - 
COPD-ES 0.2 (0-3.7) 2.3 (0.3-6.2) 1.0 (0-3.6) 0.48 (0-2.2) - 
Rbm 
Large 
Airways 
Neutrophils Macrophages 
(CD68+) 
Fibroblasts  
(CD68+) 
CD8+ CD4+ 
NC 3.0 (0-13.29) 0 (0-0.36) 0 (0-2.3)       0 (0-4) 0 (0-1.1) 
NLFS 2.5 (0.6-9.6) 0 (0-1.8)* 0 (0-3.4)   0 (0-2.7) 0 (0-0.4) 
COPD-CS 0.5 (0-10.26) 0 (0-0.33) 0 (0-2.3)   0 (0-2.1) 0 
COPD-ES 0.8 (0-7) 0 (0-0.17) 0 (0-2.3)  0(0-1.9) 0 
Small 
Airways 
     
NC 0.4 (0-4.3) 0.0 (0-1.5) 0.0 (0-1.5) 0 (0-1.2) - 
NLFS  0 (0-0.97) 0.5 (0-2.17) 0.4 (0-2.17) 0 (0-0.4) - 
COPD-CS  0 (0-1.65) 0 (0-1.0) 0.4 (0-1.0) 0 (0-0.4) - 
COPD-ES 0 (0-2.5)  0 (0-0.45) 0.3 (0-0.45) 0 (0-0.6) - 
Data are presented as medians (range). 
** and * Represents P < 0.01 and P < 0.05 compared with NC, respectively; # 
represents P < 0.05 compared with NLFS; — represents not done. 
COPD‐CS, current smoker with COPD; COPD‐ES, ex‐smoker with COPD; LA, 
large airway; NC, normal control; NLFS, normal lung function smoker; Rbm, 
reticular basement membrane; SA, small airway. 
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 Discussion 
 
 In contrast to the current belief of COPD pathology being primarily an 
inflammatory airway disease, we have found that the main finding in the COPD 
“airway wall” is a reduction in total cellularity at least in the mild-moderate 
disease. This overall decrease was accompanied by quite small fluctuations in 
specific inflammatory cell types; the most marked change was a general 
increase in macrophages in the small airway wall compared to the large 
airways, but this was in both healthy controls and the diseased as well. 
Changes in neutrophil numbers largely tracked total cell counts. In the COPD 
large airway wall, CD8+ T cells were the dominant lymphocyte phenotype over 
CD4+T cells and were the only cell type found to be significantly increased in 
COPD in the small airway wall.  
These data are unique in their comprehensive nature, although the importance 
of sampling the airway wall has been emphasized as needed to complement 
more easily obtained luminal cell counts in BAL or sputum (O'Donnell et al., 
2004). The activation of an innate neutrophil and macrophage reaction in the 
airway lumen in COPD is well established. This may be because of smoking 
itself or secondary to infection, which may have a crucial role (Pesci et al., 1998, 
Sethi et al., 2006). 
 An earlier report (Di Stefano et al., 2001) suggested a moderate increase in 
the number of neutrophils in the sub-epithelial airway wall lamina propria (LP) 
in large airway biopsies in mild to moderate COPD  in comparison to smokers, 
but typically this finding is difficult to evaluate since there was no normal control 
group. Our study suggests, in contrast, that in the airway wall the neutrophils 
are reduced in stable COPD subjects especially in the large airway LP. These 
data also suggest that the neutrophils trend back towards normal levels in ex-
smoker COPD, suggesting mainly a smoking and to a lesser extent a COPD 
effect.  
For the small airways, published neutrophil data have been both limited and 
contradictory. Studies conducted by Lams et al., (1998) suggested no change 
in smokers, which was similar to the conclusion of Hogg et al., (2004), in mild 
COPD subjects (GOLD stage I), while more recent evidence suggested a small 
increase in neutrophil numbers in mild to moderate COPD patients (Utokaparch 
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et al., 2014). My findings again showed no significant change in COPD subjects 
in comparison to either normal lung function smokers or normal controls. 
 Neutrophils are known to be frontline innate inflammatory defenders against 
infectious agents; they also play a major role in generating chemotactic factors 
for recruitment of other cells, especially macrophages. Whether functionally the 
reductions in neutrophils we described are sufficient to suppress innate 
immunity within the airway wall is not known, but it is possible. The lack of 
neutrophilia in the airway wall of smokers and COPD could be hypothesized as 
being due to active egress of neutrophils into the airway lumen, though there 
was no obvious gradient of wall neutrophils from deep to superficial 
(epithelium). Whether such a postulated but unproven trans-epithelial migration 
would have a beneficial or adverse effect on the airway wall itself needs further 
investigations (Persson and Uller, 2010, Porter, 2011). 
I demonstrated a significant decrease in the number of macrophages in the 
large airway wall in COPD. Interestingly, macrophages were increased in 
normal lung function smokers, but it seems doubtful that this reaction is related 
to COPD development. My macrophage findings are contrary to those of Di 
Stefano et al., (1998) who suggested a small increase in large airway 
macrophages in COPD, but they only had smoking controls.  
In the current study, I have shown morphological variation in cells expressing 
the CD68 epitope. Thus, I have observed two phenotypically distinct 
populations staining with CD68; one is more rounded and darkly staining and 
considered as typical macrophages phenotypically, while the others more 
lightly stained, spindly and fibroblast-like. This duality of CD68 staining has 
been previously shown in other disease tissues and in (Kunisch et al., 2004, 
Lau et al., 2004, Kunz-Schughart et al., 2003, Gottfried et al., 2008) but so far 
has received little attention in the respiratory literature.  
The small airway wall had far greater number of both “true” tissue macrophages 
and also the more fibroblast-like CD68+ cells. This would be consistent with 
small airway fibrosis, but the uniform numbers belied this across groups with 
no signal here for COPD. The macrophage phenotypes have been established 
in recent years; macrophages can exist in the pro-inflammatory, tissue-
destructive M1 phenotype and also as a phagocytic, anti-inflammatory, anti-
bacterial and pro-fibrotic M2 phenotype (Martinez and Gordon, 2014). I 
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hypothesize that the tissue milieu will determine the fate of macrophages and 
the variability of the individual population of these cells in the airway wall is 
actively investigated. Preliminary data (Sukhwinder et al., 2016) indicate that in 
the airway wall there may be phenotype shift from M2 to M1 macrophages, 
which could perhaps be the strongest signal found for a true inflammatory signal 
and has been further confirmed in the next chapter. 
The decrease in both CD8+ and CD4+ T cells in the large airway LP in COPD   
are contradictory to findings from O’ Shaughnessy et al., (1997) where both 
CD4+ and CD8+ T cell numbers were said to be increased, at least in those 
with “chronic bronchitis”. The difference in result may be a consequence of this 
phenotypic co-morbidity absent in our subjects. However, we agree with the 
one other report (Di Stefano et al., 2001).  
My observations on CD8+ to CD4+ T cell ratios did suggest that the large 
airway wall in COPD is immunologically skewed toward CD8+ T cells, perhaps 
a response to the susceptibility of COPD patients to airway viral infection 
(Utokaparch et al., 2014, Koch et al., 2008). The decrease in CD4+ T cell in 
COPD could be attributed to the presence of suppressor CD8+ T cells co-
expressing CD103, which reduce the proliferation of CD4+ T cells (Koch et al., 
2008)), and this should be studied.  CD8+ T cells were decreased in large 
airway LP with both smoking and COPD but CD4+ cells markedly more.  
The current report is limited to the more highly cited “classical” inflammatory 
cells. Also, we have previously observed an increase in mast cells in COPD 
large airways LP (Soltani et al., 2012), and are studying small airway mast cells. 
Others have looked at dendritic cells (CD83+) and found them to be few and 
variable in number and reduced essentially to zero in the airways in COPD 
(Tsoumakidou et al., 2009). In contrast, Demedts et al.  (2007) showed a slight 
increase in Langerin+ DC in small airways in mild COPD, though absolute 
numbers were very low. Our assessment of CD11c+ dendritic cells in COPD 
large airway LP found them to be too few to analyse (Sohal et al., 2011). There 
are even fewer data available on eosinophils in the airways wall of COPD 
patients, and these are variable and contradictory (Saetta et al., 1999, Lacoste 
et al., 1993), but absolute numbers were consistently very low. Thus, even if 
these cell types were added to the calculation, the total inflammatory cell 
number in the airway is a small proportion of total cellularity, with over 70% 
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being “others,” and most likely stromal cells (Fig 6). We are currently trying to 
define these more systematically.    
In conclusion, I have found that there is a marked decrease in total cellularity 
in both large and small airway walls of smokers and especially in COPD. This 
change is reflected in a decrease in the number of inflammatory cells in the 
airway wall in these clinical groups. One is left very hard-put to defend the 
currently prevalent dogma that COPD is inherently an airway (wall) 
inflammatory disease; at most the small change in CD8+ to CD4+ T cell balance 
in the large airways might fit the bill. 
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   Abnormal M1/M2 macrophage phenotype profiles in the small 
airway wall and lumen in smokers and chronic obstructive 
pulmonary disease (COPD). 
Note: This chapter is published with ‘Scientific reports’ and is explained in with 
the overall textual context. 
Eapen, M. S., Hansbro, P. M., Mcalinden, K., Kim, R. Y., Ward, C., Hackett, 
T.-L., Walters, E. H. & Sohal, S. S. 2017. Abnormal M1/M2 macrophage 
phenotype profiles in the small airway wall and lumen in smokers and chronic 
obstructive pulmonary disease (COPD). Scientific Reports, 7, 13392. 
 
 Introduction 
 
With the overall decrease in cellularity in the small airways and further 
having observed no change in the CD68+ macrophages of COPD patients in 
their small airways, it was imperative to analyze and provide a more thorough 
assessment of the role of macrophage subpopulation in driving the 
inflammatory process.  
Macrophages are known to exhibit polarized phenotypes, with, M1 and 
M2 subpopulations reflecting the paradigm of Th1 and Th2 lymphocytes (Mills, 
2012). M1 macrophages have been described as cytotoxic and pro-
inflammatory, and are characterized by secretion of the cytokines interferon 
(IFN)-γ and IL-12, and by promoting Th1-type immunity (Mills, 2015, Beckett et 
al., 2013). In contrast, M2 macrophages are considered anti-inflammatory and 
are linked to tissue repair and fibrosis, secreting pro-Th2 cytokines including 
CCL22, IL-4, IL-13 and IL-10 (Martinez and Gordon, 2014).  
Macrophages have the fundamental ability to metabolize L-arginine to 
nitric oxide (NO) or ornithine, using the mutually substrate-competitive enzymes 
inducible nitric-oxide synthase (iNOS) or arginase-I (Arg-1), respectively 
(Benson et al., 2011). Phenotypically M1 macrophages exhibit increased iNOS 
expression, while M2 macrophages are typified by an increase in Arg-1, which 
promotes collagen synthesis by making the amino acid proline available to 
fibroblasts (Benson et al., 2011, Mora et al., 2006). The competition between 
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iNOS and Arg-1 for L-arginine can drive contrasting pathologies functionally 
through opposed macrophage phenotypes (El-Gayar et al., 2003).   
 In the chapter, I have characterized the phenotypic and metabolic 
regulatory dichotomy of airway wall macrophage populations and their 
microenvironments in human lung tissue and bronchoalveolar lavage (BAL), 
and related phenotype is switching to smoking, COPD, and lung function.  
 
 Overview of materials and methods 
 
The subjects in this cross-sectional study involved have been detailed in Table 
3 and Table 4 in the method section. I again employed classical 
immunohistochemical methods including dual staining techniques for the 
identification of M1 macrophages in the airway wall as well as in the lumen 
(chapter 3 page 76, 77). The M0, M1 and M2 macrophages were enumerated 
in the small airway epithelium and sub-epithelium, and airway lumen BAL cells 
(chapter 3, page 81). Multiplexing strategies were used in estimating the BALF 
cytokines in all the four groups evaluated (Chapter 3 page 84). 
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 Results 
 M1/M2 phenotypes in small airways 
In the small airways epithelium, the dominant macrophage type in both 
in numbers and percent terms was the non-differentiated M0, especially in 
controls subjects (figure 5.1 a, c), where there were essentially very few M1 
(median 0%; range 0-5.2)  macrophages. There was a significant increase in 
M1 population in normal lung function smokers (NLFS) [median 18%; range 0-
100; (p<0.05)]  and COPD current smokers (COPD-CS) [median 21.2% range 
0.0-64.1; (p<0.01)], which slighty reverted in COPD ex smoker (COPD-ES) 
[median 10% range 0.0-42; (p<0.05)] (figure 5.1 c). Small numbers and percent  
M2 macrophages were present in the controls (median 6.4%; range 0.0-43.3) 
but were almost absent in NLFS [median 0% ; range 0.0-9.0 (p<0.05)], COPD-
CS [median 0% ; range 0.0-0.01 (p<0.01)] and COPD-ES [median 0% ; range 
0.0-10.1 (p<0.05)] (figure 5.1b, c ). 
In the subepithelium in NC, the M0 population was less dominant than 
in the epithelium, with fewer percent M1 (median 1.6% range 0.0-6.3) and more 
M2 macrophages (median 36%; range 0.0-63) (figure 5.1f). A significant rise in 
the M1 population was observed in the NLFS [median 10.1%; range 0.0-60.2 
(p<0.01)] and COPD-CS [median 9.6% range 1.6-48 (p<0.05)]. There were 
declines compared to normal in the M2 population in smokers (median 23% 
range 0.0-64.1) and  COPD, again especially significant in COPD-CS [median 
8.4%;range 0.0-19.9 (p<0.01)] (figure 5.1f). No statistical difference was 
observed between NLFS and COPD-CS. 
There was a positive correlation between smoking pack-years and 
increase in  M1 macrophages in the epithelium  (Pearsons r = 0.55, p = 0.006) 
(figure 5.3a.) while a negative correlation was observed for sub-epithelial M2 
macrophages (Pearsons r = -0.46, p = 0.02) (figure 5.3b). 
 
 
 
 
 
 
 
 
 102 
Figure 5.1 
 
 
Figure 5.1 Macrophages phenotype numbers in SA tissue. In epithelium: an 
increase in the numbers of a) M1 and a decrease in b) M2 macrophages 
observed in smokers and COPDs compared to NC. Similar pattern was also 
observed in the sub-epithelium d) M1 and e) M2. Percent change in 
macrophage phenotypes M0, M1 and M2 in c) Epithelium and f) Sub- 
expressed epithelium (Data in median and range; *p<0.05, **p<0.01).  
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Figure 5.2 
 
 
 
 
 
Figure 5.2 Representative micrographs of M1 macrophages dual stained for 
iNOS (brown) and CD68 (blue). a) Thin epithelium and thin walled normal 
control, b) thick epithelium and thick walled COPD-CS, counterstained with 
nuclear fast red (pink). ( ) Dual stained CD68+iNOS+ cells, ( ) only CD68+ 
cells. CD163 staining M2 macrophages c) NC d) COPD-CS.  
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Figure 5.3 
 
 
Figure 5.3 Regression analysis for tissue macrophage phenotypes with pack 
year history for NLFS and COPD-CS for a) epithelial M1 and b) sub-epithelial 
M2 macrophages. 
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 Arginase-1 (Arg-1) expression in the SA wall 
 
The small airways wall tissue of COPD-CS showed a marked overall non-
specific increase in tissue expression of Arg-1 in the small airway wall of COPD-
CS, both in the epithelium (p<0.01) and sub-epithelium (p<0.001) in 
comparison to normal controls (figure 5.4).  At this stage, we have not quantified 
this in non-COPD smokers, but descriptively the staining is present but less 
abundant. 
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Figure 5.4 
 
 
 
 
 
 
 
 
 
 
Figure 5.4 Pictorial representation of the Arginase-1 expression in the airway 
wall of a) NC compared to b) COPD-CS. A significant increase in Arginase -1 
expression was observed in both c) epithelium and d) sub-epithelium. (Data 
presented as median and range; group comparisons with Mann-Whitney two-
tailed t-test). 
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 AM phenotypes in the BAL 
 
When comparing the alveolar macrophages within the alveolar spaces (figure 
5.5 a-c) of resected lung tissue (also containing small airways) of COPD 
patients, we observed similarity in both morphological and  M1/ M2 expression 
patterns with luminal macrophages derived from BAL lumen (figure 5.6 b, d and 
f). However, we have provided here only the quantitative results from 
macrophages from the BAL samples. A two to three-fold increase in total BAL 
CD68+ AMs was found in NLFS (p<0.01) and COPD-CS (p<0.05), while in 
COPD-ES they were similar to normal levels (figure 5.7a). Unlike the tissue 
macrophage data, there was fewer undifferentiated percent M0 AMs across the 
groups (figure 7d). 
The BAL AMs in NC were predominantly M1 (median percentage 66.3%; range 
31.5-91.2) with essentially fewer M2s (median percentage 0% range 0.0-42.7) 
(figure 5.7d). There was a marked change in phenotype profiles in the clinical 
groups, with a decrease in the percent of M1 (median percentage 26.3%; range 
0.1-53.1) in NLFS, COPD-CS (median percentage 40.4%; range 6.2-82.5) and 
ES (median percentage 33.6%; range 4.0-80). Further, increases in M2 
macrophages was observed in (median percentage 49.5%; range 31.5-91.2) in 
NLFS, COPD-CS (median percentage 27.15%; range 0.2-71.9) and COPD-ES 
(median percentage 21.9%; range 1.3-72.7) (figure 5.7d). 
 Both total CD68+AMs (Spearman's rho (rs) = -0.35, p = <0.05) and M2 
AMs (Spearman's rho (rs) =-0.5, p <0.01) (figure 5.8 a, b) correlated negatively 
with FEV1/FVC.  
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Figure 5.5 
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Figure 5.6 
 
 
Figure 5.6 Representative pictures (400x) of M1 AMs dual stained for iNOS 
(brown) and CD68 (blue); a) Normal control, and b) COPD-CS, counterstained 
with nuclear fast red (pink). M2 phenotype macrophages stained brown with 
CD163 and arginase-1(ARG-1), (c, e) Normal controls and (d, f) COPD-CS 
respectively, with nuclear-stained hematoxylin (blue). 
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Figure 5.7 
 
Figure 5.7 AMs numbers in BAL. a) Total AMs, b) M1 and c) M2 macrophages 
in NC, NLFS COPD-CS, and ES. d) Represent percent of total macrophage for 
each phenotypic population (Data in median and range; *** p<0.001, *p<0.05). 
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Figure 5.8 
 
 
Figure 5.8. Regression analysis for BAL AMs with lung function in COPD 
groups. a) Total AMs and b) M2 AMs. 
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 BAL M2-associated cytokines were increased in COPD 
 
A marked increase in M2-related MDC/CCL22 and IL-4, IL-13, and IL-10 was 
observed in the BAL supernatants from NLFS and COPD subjects (figure 5.9a), 
with a decrease in the M1 cytokine IL-12p40 but not IFN-γ (figure 5.9b). We 
also found a significant increase of the pleiotropic cytokine IL-6 in all 
pathological (smokers and COPD) group (figure 5.9c). Further, a small but 
significant increase in proinflammatory IL-1β was observed in smokers but not 
in COPDs while for TNFα there was an increase in COPD-CS compared to 
normal controls (figure 5.9c).  An increase in the ratio of IL-12p40 to IL-4 
(M1/M2 cytokines) confirmed the switch to M2 dominance in BAL COPD-CS 
(figure 9d).  There was a positive correlation in COPD-CS between CCL22 and 
IL-4 and M2 macrophage numbers (figure 5.10 a, b). 
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Figure 5.9 
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Figure 5.10 
 
 
 
 
 
 
 
 
 
Figure 5.10. Positive correlation observed in M2 macrophage in COPD-CS for 
d) CCL22 and e) IL-4. 
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 Discussion 
This study is the first to phenotypically differentiate small airway wall and airway 
lumen macrophage subpopulations based on their M1 and M2 phenotypes in 
normal, smokers and COPD patients. My observations suggest dynamic 
differential switching in both the small airways and BAL AMs, but qualitatively 
these were quite different. In small airways, there was a switch towards 
predominantly an M1 phenotype in NLFS and COPD-CS, and in BAL AMs there 
was a switch towards M2 dominance. Further, cytokines in BALF from NLFS 
and COPD-CS have switched again to M2 characteristics.  
 M1 and M2 macrophages are considered to be functionally 
differentiated, with M1 more pro-inflammatory and M2 more pro-fibrotic. For the 
M1 phenotyping, I chose iNOS+ as a marker (Mills, 2012) with CD68 co-
staining to differentiate them from other iNOS producing cells such as dendritic 
and NK cells. For M2, I used CD163, which is a scavenger receptor that is 
upregulated in a more TH2 micro-environments (Kaku et al., 2014, Roszer, 
2015). Whether the different phenotypic skewing is a compartmental effect or 
caused by the movement of differentiated cells from wall to lumen needs further 
investigation. I believe that it is most likely the former as there was no gradient 
towards the lumen from sub-epithelium to epithelium, and there was no 
reciprocal decrease in wall cell numbers contributing to the significant increase 
in luminal macrophages.  
 The normal predominance of iNOS-expressing M1 macrophages occurs 
to fight pathogens through luminal production of nitric oxide (NO), an innate 
immune effector. However, such a response is non-specific, and when 
uncontrolled can cause considerable damage to host tissues and cells. My 
observation of reduced percent M1 macrophages in the airway wall in COPD 
current and ex-smokers compared to normal lung function smokers, therefore, 
suggests a reduced ability to fight infection (Budden et al., 2017). It may also 
reflect homeostatic adaptation to avoid excessive tissue damage. Recent 
evidence suggests that elevated levels of NO inherently suppress the M1 
phenotype (Lu et al., 2015).  
 Given the iNOS changes, I also wished to investigate the functionally 
reciprocal Arg-1. Interestingly, I found a higher non-specific expression of Arg-
1 throughout the airway wall mucosa including epithelium, sub-epithelium and 
 116 
alveolar septae in COPD-CS compared to normal non-smoker controls.  This 
overexpression of Arg-1 could be the consequence of increased cellular 
catabolic activity, associated with increased oxidative stress in smokers, 
catalyzing L-arginine to urea and L-ornithine via urea cycle. L-ornithine is a 
known precursor to L-proline, a key amino acid in the biosynthesis of collagen, 
and associated with wound healing (Benson et al., 2011). The excess 
deposition of collagen, however, leads to airway wall stiffness of the small 
airways, an important pathophysiological feature in COPD (Hogg  et al., 2004). 
Further, exhaled NO is also well known to be decreased in smokers, but the 
reason for this has been unclear (Maziak et al., 1998, Hynes et al., 2015).   
 The finding of an M2 predominance in the airway luminal macrophages 
in smokers with and without COPD is resonant of two previous studies, 
although they found an increasing percentage of M2 AMs only in COPD-ex 
smokers (Kunz et al., 2011, Kaku et al., 2014). One study (Kunz et al., 2011) 
lacked normal control BAL, and neither assessed the M1 phenotype 
populations. These findings are in line with the study by Shaykhiev et al., (2009) 
where gene expression analysis of cytokines and chemokines revealed more 
M2-polarised AMs in smokers and COPD compared to non-smoking controls. 
Further, our increase in both total AMs and especially M2 macrophage 
subtypes correlated to airflow obstruction, suggesting biological plausibility. 
 The BAL cytokine data reflected the cellular phenotype switching that I 
observed in that compartment. Invitro studies showed that both IL-4 and IL-13 
share a common receptor, IL-4Rα/IL-13Rα1, which signals via the JAK-
1/STAT6 pathway, to induce differentially-activated M2 macrophages (Gordon 
and Taylor, 2005). Again, studies by Rutschman et al., (2001), also showed 
that the induction of the STAT6 pathway by IL-4 and IL-13 suppressed iNOS 
expression, and so nitic oxide production, by post-transcriptional modification. 
Similar studies have also demonstrated that IL-4, IL-13, and IL-10 also 
synergistically upregulate Arg1 expression in macrophages (Munder et al., 
1998). Our current study indirectly corroborates with these findings, but in 
humans with the clinical disease.  
 I also observed an increase in CCL22 in BAL in NLFS and COPD. 
CCL22 is a regulatory chemokine secreted by M2 macrophages in response to 
TH2 polarized cytokines such as IL-4, IL-5, and IL-13, while it is downregulated 
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by the TH-1 cytokine IFNγ (Yamashita and Kuroda, 2002, Andrew et al., 1998). 
Importantly, given the common co-association of COPD and lung cancer, 
CCL22 has been implicated in tumorigenesis. Its active secretion by M2 tumor-
associated macrophages (TAMs), is known to promote malignancy by inhibiting 
suppressor T cell recruitment. Similar tumorigenic effects have been attributed 
to IL-6, which I also found to be elevated in smokers and COPD. Further, in 
vitro studies in macrophages also suggested that IL-6 promotes an M2 
phenotype and increased M2-associated markers such as Arg-1 (Fernando et 
al., 2014).  
 The differences in the polarization of macrophage subtypes between 
small airways and lumen are marked. This suggests a difference in the cytokine 
milieu in each anatomic microenvironment, promoting a shift towards the M1 
phenotype in the airway wall but towards M2 in the airway lumen. This may 
have important implications for the distinct pathologies observed in each site in 
COPD disease, i.e., infection and ROS-induced innate immune activation in the 
lumen, but fibrosis and thickening of the airway wall. However, there are 
limitations to the current study, with tissue originating from two separate patient 
groups: BAL cells came from volunteer groups designated COPD-CS, COPD-
ex-smokers, NLFS and NC, while small airway resections came from cancer 
patients with physiological categorisation being made on the basis of the lung 
function tests done for pre-operative work-up. Thus, it is possible that the 
macrophage phenotypes and cytokine profiles were possibly influenced by the 
presence of cancer, thought we have quantified the airway wall tissue 
macrophages well away from cancerous areas. Also, in the current study I have 
not confirmed M2 data with other potential macrophage sub-type markers such 
as CD206 and CD163, mainly because of lack of time and because I believe 
that I was using the best method currently accepted in the literature  
 CONCLUSION 
 
The major novel findings in this study are the reduction in M2 and increase in 
M1 macrophages in the airway wall of SAs in smokers and COPD. M1 are the 
strongest signal for innate inflammatory up-regulation I have seen in the airway 
wall to date. The finding of an M2 switch in BAL in smokers with and without 
COPD was in stark contrast to the macrophage phenotype in the small airway 
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wall. BALF cytokine profiling revealed promotion of an M2 phenotype. The 
switching was confirmed in lung tissue from a chronic smoking mouse model. 
The overall tissue expression of Arg-1 in the SA wall suggests increased 
catabolic activity, a sign of cellular senescence, but could also have implication 
for lung fibrosis and airway resistance. These novel findings are potentially 
important in understanding the pathophysiology of the respiratory tract`s 
response to smoking and in the aetiology of COPD; they need to be taken into 
account when considering mostly unexplained cellular functional phenomena 
associated with COPD, and the specific vulnerability of COPD sufferer to lung 
cancer. 
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  Enumeration of Mast cells and degranulating cells in the small 
airways of COPD patients 
 Introduction 
Mast cells (MC) play a crucial role in the innate immune response, recognizing 
possible pathogens and allergens. They are potentially granulating cells 
originating from hematopoietic stem cells in the bone marrow, which mature 
into mast cells in the target tissue (Drew et al., 2005). The granules released 
on activation from MC include mediators that are pro-inflammatory, pro-fibrotic 
and pro-angiogenic (Soltani et al., 2012). They have been classically 
associated with allergic reactions whereas they are activated by cross-linking 
of IgE molecules attached to specific surface receptors by their Fc fragment, 
but it is now known that there are other ways that degranulation can also be 
stimulated (Erjefält, 2014, Galli et al., 2011). 
 
In chapter 4, I described the variability in key immune cells in the airway wall, 
including both innate and adaptive populations. Previously our group reported 
an increase in the MC population (Soltani et al. 2012) in the large airways of 
COPD patients in both the reticular basement membrane and lamina propria in 
endobronchial biopsy samples. In this chapter, I will further discuss the 
contribution of MCs, and other degranulating cells, in the small airway wall of 
COPD subjects. Further, I will also be providing information on overall 
abnormality in the cellular expression of lysosome-associated membrane 
protein 1 (LAMP-1), which has been used as a marker for active cell 
degranulation (Hennersdorf et al., 2005, Eskelinen, 2006), although it may also 
represent a somewhat more complicated phenomenon with links to autophagy 
(Eskelinen, 2006).   
 
LAMP-1 is a transmembrane lysosomal glycoprotein, which is expressed on 
activation lysosomes and endosomes and has been used as a marker for 
degranulation. The lamp-1 expression is known to be increased in MCs when 
activated with IgE (Grützkau et al., 2004). Further, LAMP-1 has also been 
demonstrated to be activated in CD8+ lymphocytes; suppression of CD8+ cells 
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in COPD with inhibition of activation of CD8+ lymphocyte degranulation was 
associated with a LAMP-1 reduction (Aktas et al., 2009).  
 
Our group has also reported previously that smoking decreased large airway 
sub-epithelial lamina propria total cellularity in mild to moderate COPD patients 
(Sohal et al., 2013a), while paradoxically MC was increased in that situation. 
However, MCs numbers in the small airway were not enumerated in that study. 
Thus, this chapter will investigate if there is a similar increase in MC numbers 
in the small airway wall and further estimate their degranulation capacity, which 
has not previously been attempted in any comprehensive way. 
 Overview of materials and methods 
The subjects involved are detailed on page 66 in the method section. I 
employed dual immunohistochemical staining methods to evaluate total MCs 
as well as degranulated MCs in the small airways of normal controls and the 
clinical groups (as detailed in Chapter 3 page 75, 76). Further, the enumeration 
of MCs, degranulated MCs and total degranulated cells were evaluated and is 
detailed in chapter three, page 81. It is also important to notify here that I have 
used correlation analysis for mast cells with parameters including collagen-1, 
fibronectin index, airway wall lamina propria, smooth muscle layer thickness, 
all of which have been analyzed and presented in Chapter 7. 
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 Results 
 Total Mast cells (MCs) 
 
In the small airway sub-epithelium, there were much more MCs than in the 
corresponding epithelium. There was a significant decrease in the total number 
of MCs in the small airways of both ex- and current-smoker COPD (p<0.05) 
than in the normal controls with again normal smokers being intermediate. In 
the epithelium, in contrast, an increase in the number of MC was observed in 
COPD-CS (p<0.01) compared to NLFS and NC, while in ex-smokers their 
numbers tended back to normal (Figure 6.2). 
 
Figure 6.1 
 
 
 
 
 
 
Figure 6.1 Representative images (50x) for dual stained mast cells (mast cell 
tryptase and LAMP-1+ cells) in the small airway of a) Normal controls and b) 
COPD-CS. Enlarged images of cells captured from the analysed tissue, c) mast 
cell tryptase+ cells. d) Only LAMP-1+ (degranulated) cells e) Dual stained mast 
cell tryptase+LAMP-1+ cells.   
a)  b)  
c)  d)  e)  
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Figure 6.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2. Total number of mast cells in the small airway as examined in: a) 
epithelium; b) sub-epithelium. 
 
 Degranulating Mast cells 
 
In the epithelium, a slight increase in the absolute number of LAMP-1+ 
(degranulating) MCs was observed in COPD-CS patients (p<0.05) but there 
was no change from normal in the smoker COPD group in the sub-epithelium 
in this regard (Figure 6.3 a, b). In percentage terms, there was similarly no 
change between groups in degranulating MCs in either the epithelium or sub-
epithelium (Figure 6.3 c, d).  
 
 
 
 
 
 
 
 
 
 
 
 
 
a) b) 
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Figure 6.3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3. Degranulated LAMP-1+ mast cell numbers and their percentage of 
total mast cells the small airway: a) and c) epithelium; b) and d) sub-epithelium. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a) b) 
c) d) 
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 Total Degranulated cells 
 
The total number of degranulated (LAMP-1 positive) cells in the epithelium was 
approximately double the number of degranulated MCs, but with no change 
between the groups. In the sub-epithelium, the density of degranulating cells 
overall in the normal was about tenfold higher than in the epithelium but was 
markedly reduced in COPD subjects (p<0.05).  
 
Interestingly, and rather paradoxically, degranulating MCs as a percentage of 
all degranulating cells were increased in both smokers and COPD subjects in 
both epithelium and sub-epithelium, although of borderline significance, for the 
most part, suggesting that degranulating NK/CD8 cells are likely to be even 
more reduced. 
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Figure 6.4.  
 
  
Figure 6.4. Graphical representation of the total LAMP-1+ degranulated cells 
as examined in the small airway wall and the percent contribution of 
degranulating mast cells to the total LAMP-1+ cell population a) and c) 
epithelium, and b, d) sub-epithelium. 
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 Regression analysis for Mast Cells 
 
 Correlation to smoking history 
 
An increase in smoking history (pack-years) correlated directly to the decrease 
in both total MCs and degranulated MCs in COPD-CS but not in the NLFS 
subjects (Figure 6.5), suggesting a COPD specific effect. 
 
Figure 6.5 
 
Figure 6.5 Correlation analysis between smoking history (pack-years) and a) 
Total mast cells b) Degranulated mast cells in NLFS subjects and COPD-CS 
patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a) b) 
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 Correlation with lung physiology parameters 
 
A positive correlation was observed between COPD groups MC numbers 
versus large and small airway obstruction (FER and FEF25-75, respectively) 
(Fig 6.6, a, b). A less strong and non-significant positive relationship was also 
observed between total degranulating cells and lung function (Figure 6, c and 
d). 
 
Figure 6.6  
 
 
Figure 6.6 Correlation analysis between lung physiology parameters 
(%FEV1/FVC and FEF25-75%) and a) Total mast cells b) Degranulated 
LAMP-1+ cells in COPD groups. 
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 Relation to airway remodelling 
 
For the COPD groups, there was a strong relationship between decreasing total 
numbers of sub-epithelial (lamina propria) MCs and indices of small airway 
remodelling:  increased thickening of the small airway wall LP (analyzed as the 
area between the Rbm and start of smooth muscle layer and deposition of 
collagen I and fibronectin ECM. In contrast, however, the relationship with the 
smooth muscle layer was positive, i.e. more MCs, thicker the muscle layer 
(Figure 6.7).  
Note- Features such as airway wall thickness, collagen, and fibronectin index 
and smooth muscle thickness have been analyzed and presented in the 
following chapter.  
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Figure 6.7 
 
Figure 6.7 Correlation analysis between total mast cell numbers in the small 
airway wall and a) airway wall thickness b) Collagen-1 index c) Fibronectin 
index and d) Smooth muscle thickness in the COPD group 
 
 
 
 
 
 
 
a) b) 
c) d) 
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 Discussion 
This is the first study to evaluate MC numbers, their percentage of total 
cells, and their functional degranulating status in the epithelium and lamina 
propria of small airways of COPD patients. The major finding of this study was 
a decrease in MC numbers in these compartments, while there was no change 
in their degranulating activity in the sub-epithelium of COPD patients. To 
complicate the picture, the degranulating activity of other airway wall cells 
seems even more depressed, so that as a percentage of total actively 
degranulating cells, those that are marked as MCs are paradoxically increased. 
Regarding actual mast cells, the current data were in contrast to the previous 
observation by our group (Soltani et al., 2012) who assessed the large airway 
wall where there was an increase in the number of in COPD, assessed in 
bronchial biopsy tissue. Interestingly, MCs in the large airway wall were 
primarily associated with vascular structures, and in the context of both hypo-
cellularity and hypo-vascularity (Eapen et al., 2017). The small airway wall too 
is hypo-cellular including for MCs, but these are not mainly focused around 
vessels. 
 
The current observation of reduced MCs in the sub-epithelium LP of 
COPD patients is comparable to reports by  Andersson et al., (2010) who found 
a similar decrease in MCs in the sub-epithelial region of the small airways of 
COPD patients across GOLD stage I-IV subjects, which negatively correlated 
with severity of the disease. My current study provides additional information in 
COPD ex-smokers where the levels of MCs remained low even after the 
subjects had quit smoking, suggesting that the effect observed is mainly COPD 
driven. Moreover, when correlated with smoking history in currently smoking 
COPD and NLFS group, the suppressions of total MCs and degranulating MCs 
were more significant in the COPD-CS group, again suggesting that 
susceptibility to airflow obstruction in addition to smoking influences this 
pathological MC outcome. Similar to Anderson et al. my finding also showed 
that the decrease in MCs negatively associated with the lung function, but 
additionally it was related to decreased small airway calibre as measured by 
FEF25-75% in the COPD group. It is difficult and inherently speculative to say 
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what the meaning of this relationship of induced MCs with airflow obstruction 
is, but it is unlikely to be causative but more likely that both are related to 
another more fundamental process. 
My observation of an increase in epithelial mast cells numbers in COPD 
are similar to those of Grashoff et al., (1997) who also observed an increase in 
MCs in the small airway epithelium of COPD patients; however, in contrast, 
they found no change within the sub-epithelium LP. They had no data on MC 
activation. The increase in epithelial numbers could potentially be explained by 
their active migration from the wall into the airway lumen (Persson and Uller, 
2010a). Fate-mapping studies with MCs in an animal model of COPD may well 
be worth doing to follow this up.  
 
Literature evidence suggests that both tryptase and chymase expression 
are reliable markers for MCs. In the current study, I used tryptase only as the 
marker to identify MCs, as these are more specifically located in the airway 
mucosa when compared to chymase-expressing MCs that are present more in 
the adventitial connective tissue (Ballarin et al., 2012, Krishnaswamy and Chi, 
2006, Galli et al., 2011). 
 
Consistent with my findings, Gosman et al., (2008) found that MCs are 
concentrated towards the peripheral small airways compared to central airways 
in both COPD and control groups and suggested that this could be crucial in 
small airway remodelling in COPD. Interestingly, and perhaps paradoxical to 
this suggestion, in the current study the reduction in tryptase-positive MCs in 
the sub-epithelium of COPD patients was quite strongly negatively correlated 
with airway wall thickening as well as my indices of ECM remodelling changes 
in collagen-1 and fibronectin. Again, the negative relations  would suggest that 
the MC is not, in fact, driving the remodelling process, in fact quite the opposite, 
but again that both phenomena are driven by another more fundamental 
process. However, the current findings may complement earlier observations 
in other diseases, which have demonstrated the importance of MC tryptase in 
maintaining tissue homeostasis through the degradation of excessive ECM 
collagen deposition, indirectly by degrading MMP-9 activity (Wernersson and 
Pejler, 2014a, Fajardo and Pejler, 2003). Furthermore, MC tryptase is also 
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known to activate pro-MMP-3 and pro-MMP-13, both of which are crucial for 
the digestion of ECM proteins such as collagen and fibronectin (Magarinos et 
al., 2013). Thus, the observed suppression of tryptase-positive MCs in the 
airway wall of COPDs could perhaps be related to the aberrant accumulation 
of ECM protein and airway remodelling. It is also interesting that there was a 
positive relationship between MC numbers in the LP and thickness of the 
smooth muscle layer, suggesting that there may be some (perhaps mutual) 
trophic relationship between them.    
 
 MCs contains granules (secretory lysosomes) that hold the immense 
capacity to hold an array of lysosomal proteins such as acid hydrolases (e.g., 
β-hexosaminidase) (Wernersson and Pejler, 2014b, Schwartz et al., 1979) and 
biogenic amines such as histamine and serotonin. They also store and secrete 
extracellularly mature forms of serine and other proteases, which includes 
tryptase, chymase-1, cathepsin G, granzyme B, and carboxypeptidase among 
others (Moon et al., 2014). Based on their content MC secretory lysosomes are 
characterized into three sub-types. Specifically, LAMP-1 marks the more 
mature or active ‘type-1 and type-2’ secretory lysosomes that are ready to be 
exocytosed and containing one or more of these fully active mediators. In 
COPD research, there are few previously published data on degranulating 
markers, especially the crucial LAMP-1 (Grutzkau et al., 2004). The previous 
estimates of mast cell degranulation by Gosman et al., (2008) used 
morphological and cellular conformational analysis based on the secretion 
pattern of tryptase by MCs. The limitation of this approach, however, lies in 
differentiating the pre-formed MC tryptase from its mature form that is stored in 
secretory lysosomes granules ready for release. In the current study, I provide 
specific evidence on degranulating activity in MCs by dual staining them for 
LAMP-1 and mast cell tryptase. I found that the degranulating LAMP-1+ MCs 
in the LP constituted approximately 15-20% of the total mast cells population, 
though this was not different overall from normal in spite of some smokers 
having quite a lot relatively. This was in contrast to the epithelium, where 
COPD-CS had a significant increase in degranulating MCs though not in 
percentage terms of total mast cell numbers in the small airway epithelium.  
Currently, no firm conclusion can be drawn of the role of LAMP-1 or MC 
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lysosomal exocytosis in COPD, and this is a complex process that may involve 
multiple types of lysosomes (Moon et al., 2014). 
 
The decrease in LAMP-1 expression that I have described in the COPD 
airway seemed to be related to an overall cellular dysfunction in potentially 
degranulating cells and was not limited to just mast cells. McKendry et al., 
(2016) also recently reported that CD8 cells from COPD patients had a reduced 
degranulating capacity, also using the LAMP-1 expression, when ex-vivo lung 
slices were exposed to influenza virus.   Indeed, an advantage of using LAMP-
1 is that it has been described as a general degranulation marker that can 
assess the total degranulating cell population in tissue such as the small airway 
(Hennersdorf et al., 2005).  
 
There is some limitation to my observation. There were fewer subject 
tissue sample numbers available per clinical group at this stage in my research, 
though my findings seem statistically robust and consistent, without likely Type-
1 or Type-2 errors. Also, as stated above, LAMP-1 alone may not be sufficient 
to determine the granulation capacity or activity of MCs, and thus more 
lysosomal markers will be required to be tested as this work goes forward, but 
I believe that I have shown enough to make this worthwhile (though perhaps 
more in epithelium than MCs alone). The current study made inferences about 
non-MCs, and further study needs to do double-staining for LAMP-1 and other 
specific cell types such as CD8, NK cells, and macrophages that are all granular 
cells and capable of degranulation on activation. Finally, the current data was 
mainly obtained using small airways from surgically resected tissue derived 
from cancer patients; it is conceivable that the presence of cancer in the lungs 
of these patients affected the MC populations and their activity, although all cell 
assessments were conducted on airways well away from the cancerous region. 
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 Conclusion 
 
To summarize, the data provided in this Chapter show that MCs are reduced in 
number in the lamina propria of the small airway which is congruent with my 
findings (Chapter 4) of more general hypocellularity. Further, the overall percent 
change of mast cells to overall cellularity remained unchanged between COPD-
CS and normal controls, as did the number and percentage of active MCs, as 
indicated by LAMP-I positivity indicating degranulation. The data on LAMP-1 
staining also indicated a more general decrease in degranulating activity across 
the range of cell types potentially involved in such processes. These decreases 
in mast cell numbers in smokers/COPD showed a direct relation to increasing 
in small airway wall thickening and ECM protein remodelling changes, perhaps 
pointing to an active role in maintaining normal tissue homeostasis and 
indirectly, perhaps by default, involvement in airway remodelling.  
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   Enumeration of Myofibroblasts in the small airways of 
smokers and COPD patients 
 
 Introduction 
 
In Chapter 4, I highlighted that the airway wall in both large and small airway 
complements was relatively hypocellular, but in both areas, the ‘stromal’ cell 
population may well be the largest cell component. As part of my thesis work, I 
wished to evaluate this stromal cell population further, but unfortunately, due to 
time constraints, I have been able to advance this only as far as quantitating 
the myofibroblast population. However, I felt that this was a priority, as it would 
help to advance and, in some ways, complete the work of my research group 
that has been ongoing for a decade. Thus, in addition to straight quantitation, 
and to placing these cells anatomically within the airway, I wished also to relate 
them to EMT activity in the corresponding epithelial basal cells, as expression 
of alpha-smooth muscle actin (αSMA) by transitioning mesenchymal cells has 
long been described as a late feature in EMT(Kalluri and Neilson, 2003, LeBleu 
et al., 2013). I also wanted to relate changes in the myofibroblast population to 
airway wall thickness and deposition of strategic representative ECM proteins. 
I have focused on small airway tissue for these analyses as the site of functional 
airflow changes in COPD, and because of this, my analysis has had a 
strong emphasis on relating all these pathological small airway changes to 
measures of airflow obstruction.   
  
Myofibroblasts are motile and contractile cells, which are 
related to the increased expression of alpha-smooth muscle actin (αSMA) 
myofilaments, which form “stress fibers.” Previous studies in COPD based on 
this protein marker for myofibroblasts using human bronchi and bronchiolar 
tissue have been once again variable. Lofdahl et al., (2011) in their histological 
staining of large and small airway  tissue from operative resections, showed an 
increased expression in αSMA positive cells in the lamina propria of the large 
airway in COPD patients when compared to non-smoker controls, although 
similar differences in the expression level was not observed in small 
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airway wall . In contrast, findings from invitro studies with fibroblasts isolated 
from the distal end of the airway from COPD patients showed 
increased contractile properties associated with increased 
myofibroblast numbers (Hallgren et al., 2012). These findings suggest 
myofibroblast may be important in both airways.   
  
In the current study, I will be using αSMA to identify the myofibroblast 
population, but with care to dissociate them from smooth muscle bundles. I will 
descriptively analyze the localization of these cells in the small airway wall 
tissues. As mentioned, I will also analyze whether the changes in these cell 
types have likely direct implications for airflow limitation in 
COPD through airway wall tissue remodelling and scarring, i.e., re-organization 
of the extracellular matrix (ECM). These changes in the ECM are known to 
have profound effects, the most important being the gradual obliteration of the 
small airway. My hypothesis is that all of these potentially inter-related 
processes are driven by active EMT.   
  
 
 Overview of materials and methods 
 
The subjects involved in this study are detailed in page 66 in the method 
section. I employed immunohistochemical methods to stain for αSMA positive 
cells, collagen-1, and fibronectin in the small airway wall. Details on the staining 
methodology of the tissue can be referred to in Chapter 3 page 78-80). Further, 
this chapter evaluates small airway wall thickness, myofibroblast numbers, and 
ECM deposition, all of which is detailed again chapter 3 pages 82, 83) 
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 Result 
 Airway wall thickness in Small Airways 
 
Both the adventitia and the LP were thicker in COPD subjects, with the latter 
showing at least a tenfold change compared to normal controls, whereas in the 
former (the adventitia) there was “only” a 2-3-fold increase change observed 
(figure7.1). Also, the muscle layer was thickened too, but only slightly so. All of 
these changes in aggregate are reflected in a substantial increase in total small 
airway thickness in COPD.  
It is noteworthy that increased thickness of these compartments also occurred 
in smokers with apparently normal lung function, and indeed, in the adventitia 
the change was uniform across smoker/COPD groups. For the LP, the effect 
was greatest in the COPD subjects. However, there was substantial within-
group variability which is likely to reflect real anatomic variability along the 
airways in the process involved, both within subjects as well as between 
individuals, given the scrupulous way that we selected airways for quantification 
(see Methods chapter). 
 
Figure 7.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a) b) 
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Figure 7.1 (cont…) 
  
 
 
Figure 7.1 Representative images of the airway thickness, myofibroblast 
population (as marked with arrows within the LP area) in the small airway wall 
of: a) NC and b) COPD-CS (50x magnification). An increase in thickness was 
observed in the clinical groups in the c) LP, d) Adventitia and e) smooth muscle 
layer.  
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 Correlation of airway thickening to physiological function in 
COPDs 
 
There was a significant correlation between increased small airway LP 
thickening and decrease in airflow-related lung function in the COPD groups 
combined. 
Figure 7.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.2 Correlation between airway wall thickness and lung function 
indices a) %FEV1/FVC and b) FEF25-75% (small airway more specifically) in 
the COPD groups combined.   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a) b) 
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 αSMA positive myofibroblast in Small Airways. 
 
Significant increases in small airway αSMA positive myofibroblasts were 
observed throughout the airway wall in the smokers and COPD groups, but 
most consistently in the latter. The density and increase in myofibroblasts were 
especially striking in the LP and in actively smoking COPD. Again, there was a 
great deal of real within-group variability. 
Figure 7.3 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 7.3 Increase in αSMA+ myofibroblast cells were observed in all three 
compartments of the sub-epithelial areas of the small airway wall, i.e. a) Rbm, 
a) b) 
c) 
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b) LP and c) Adventitia Correlation to αSMA with physiological parameters and 
small airway wall LP thickening 
 
Figure 7.4 is complex but is an attempt to show together the relationships 
between myofibroblast numbers in the LP and the Rbm against airflow 
obstruction in the three clinical groups. Although numbers are rather small, 
there was a significant or near significant correlation between myo-fibroblasts 
versus decreases in lung function (airflow, both as %FEV1/FVC and FEF25-
75%) in COPD groups but not in the NLFS (Figure 7.4). Relationships were 
most consistently between airflow obstruction and myofibroblast density in the 
currently-smoking COPD group. 
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Figure 7.4 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.4 Correlation analysis between αSMA+ myofibroblast in the (a, c) Rbm 
and (b, d) LP of the three clinical group (NLFS, COPD-CS, and ES) and lung 
function parameters (a, b) %FEV1/FVC and (c, d) FEF25-75%. 
 
 
 
a) b) 
c) d) 
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 Correlation to αSMA with smoking history (pack-years) and small 
airway wall LP thickening 
 
Regression analysis between increases in myofibroblasts SA wall LP thickness 
in all pathological groups (Figure 7.5) showed a very similar picture, i.e., quite 
strongly suggesting both smoking and COPD effect. There was also a positive 
correlation found between smoking history (pack-years) and density of αSMA 
positive cells in the small airway LP in COPD-CS and NLFS, suggesting some 
if not mostly a current smoking effect on this. 
 
Figure 7.5 
 
 
 
 
 
 
 
 
 
Figure 7.5 Correlation analysis between αSMA+ myofibroblast and a) smoking 
(pack-years) in NLFS and COPD-CS, b) airway wall thickness in the LP area of 
all clinical groups. 
 
 
 
 
 
 
a) b) 
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 ECM deposition in Small Airway 
 
This analysis provided here are percentage calculation based on objects per 
area of tissue staining (detailed in methods) in the specified (LP, Adventitia) 
region evaluated, however, does not take into account staining intensity which 
would have provided more information on how much protein deposition there 
was. Even so, there was an overall increase in the key “scar” ECM proteins, 
Collagen-1 and Fibronectin in the airway wall, with fibronectin changes being 
the most pronounced. 
 
 Collagen-1 deposition in LP and Adventitia. 
 
Increase in collagen-1 was observed in both the LP and adventitia. However, 
in comparison to percent collagen-1 expression in the LP (1.5 folds), the 
increase in adventitia were greater (5-6 folds) in smokers and COPD patients 
compared to NC. Compared to smokers and COPD-CS, in the adventitia the 
relative expression of collagen-1 deposition was reduced, though still higher 
than normals. 
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Figure 7.6 
 
Figure 7.6 Representative images of collagen-1 deposition in the airway wall 
of a) NC and b) COPD patients, Increase in percentage collagen-1 expression 
observed in pathological groups in both the c) LP and d) Adventitia.   
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 Fibronectin deposition in LP and Adventia 
 
A significant and similar increase in percent fibronectin expression was 
observed both in the LP and adventia region of the small airway wall of smokers 
and COPD subjects. Again, similar to collagen-1 exprssion patterns, the levels 
in ex-smokers COPD were slightly lower compared to pathological groups, but 
were higher than normal controls. 
 
Figure 7.7 
 
 
 
 
 
Figure 7.7. Representative images of Fibronectin deposition in the airway wall 
of a) NC and b) COPD patients. Increase in percentage fibronectin expression 
observed in pathological groups in both the c) LP and d) Adventitia.  
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 Total ECM index in small airway LP and Adventitia  
 
Interestingly and consequentially, on measuring the ECM (Collagen-1 and 
fibronectin) index, which is the product of total ECM protein change and 
thickness of the corresponding region of the small airway wall, I observed a 
significantly higher fold change especially with collagen-1 index in LP area and 
the adventitia. Similar, increase was also observed in fibronectin index 
deposition in all pathological groups in comparison to normal controls.  
 
Figure 7.8 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.8. Collagen and Fibronectin index in small airway wall a, c) Lamina 
Propria and b, d) Adventitia  
 
 
 
a) b) 
c) d) 
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 Correlation of percent Collagen-1 and Fibronectin to lung function, 
smoking history and SA wall LP thickness of pathological groups. 
 
The percent by area tissue collagen-1 expression was significantly and 
positively correlated with LP thickness in COPD (both CS and ES) patients, but 
in contrast to the data given above in this chapter, this was not the case in the 
normal lung function smokers although their LP thickness was increased as I 
have shown (Figure 6.9 a). Notably, and contrary to collagen-1 expression, 
fibronectin percentage positively correlated to increasing smoker airway LP 
thickness only and not in the COPD groups (Figure 7.9 b). 
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Figure 7.9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.9 Correlation analysis between airway wall thickness and percent a) 
collagen-1 and b) fibronectin for all three-clinical group (NLFS, COPD-CS, and 
ES). An increase in percentage c) collagen-1 was found to correlate with 
smoking history pack years but not with d) fibronectin.   
  
 
 
 
 
 
a) b) 
c) d) 
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Further, there was a strong correlation between smoking history and collagen-
1 percentage deposition in small airway LP, which was again absent with 
fibronectin (Figure 6.9 a, b).   
  
A significant correlation was seen between collagen-1 deposition and lung 
function in the COPD-CS but was absent in for the ex-smoker group (Figure 
6.10 a). I found no correlation between fibronectin deposition in small airway 
LP and either smoking history or lung function (Figure 6.10 b).  
 
Figure 7.10 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.10 Correlation analysis between lung function and percentage a) 
collagen-1 and b) fibronectin expression in COPD-CS and COPD-ES. 
 
 
 
 
 
 
a) b) 
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 Correlation of αSMA positive my fibroblast to percent ECM 
changes in the SA wall of COPD group 
On evaluating the clinical groups, I found significant positive correlations 
between the density of αSMA+ myofibroblasts in both Rbm and LP with percent 
expression of both collagen-1 (Figure 6.11 a, b) but not with fibronectin (Figure 
6.11 c, d) suggesting that myofibroblast could be the main contributor to 
collagen-1 deposition 
Figure 7.11 
 
Figure 7.11 Correlation analysis between airway myofibroblast 
and percent collagen-1 and fibronectin expression in Rbm (Figure 7.11 a, c) 
and LP (Figure 7.11 c, d) for all three clinical group (NLFS, COPD-CS, and 
COPD-ES). 
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 Correlation of EMT marker expression in the basal epithelium 
versus airway thickening in COPDs 
I further evaluated whether changes in S100A4 positive cells as an index of 
EMT activity, expression of which has been previously shown by our group to 
be increased in both basal epithelial cells and Rbm cells (Mahmood et al., 
2015). I further evaluated weather EMT marker expression are associated with 
αSMA positive myofibroblasts in the SA wall of smokers and COPD groups. 
αSMA cell expression is also thought to represent a late manifestation of the 
epithelium to mesenchymal transition. Notably, there was a strong positive 
correlation between the numbers of the two cell types, especially for basal 
epithelial cells against LP myofibroblast data. 
 
Figure 7.12 
 
 
Figure 7.12 Correlation analysis between EMT marker S100A4 expression in 
the a) basal epithelial cells and b) Rbm with myofibroblast within the Rbm. 
 
 
 
 
 
 
 
a) b) 
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  Correlation of EMT marker expression in the basal epithelium 
versus airway Lamina Propria thickening in COPDs 
 
Further, a positive association was also observed between the increase in 
mesenchymal cell markers for both vimentin and S100A4 and increase in 
lamina propria thickness.  
 
Figure 7.13 
 
Figure 7.13 Correlation analysis between small airway wall LP thickness with 
EMT marker a) S100A4 and b) Vimentin expressed in basal epithelial cells. 
 
 
 
 
 
 
 
 
 
 
 
a) b) 
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 Discussion 
 
Perhaps the major novel finding in the current chapter is an increase in some 
αSMA positive myofibroblasts in the SA wall of COPD patients and its direct 
association with an increase in the airway wall thickness in the small airway LP 
and a decrease in lung function reflecting airway caliber. These changes in the 
myofibroblast population were also directly related to pathological changes in 
ECM protein, namely collagen-1 and fibronectin. I have also been able to 
correlate my data with previous observations from our group, by finding that the 
increase in mesenchymal markers in basal epithelial cells and Rbm cells of 
COPD patients, interpreted as representing active EMT, were significantly 
correlated with both the increase in the number of airway wall myofibroblasts 
as well as the increase in airway wall thickness. It is reasonable to interpret 
these data, I believe, as strong evidence that EMT is “an” if not “the” driver of 
myofibroblast proliferation and activity; that the myofibroblasts are active in 
producing new and pathological ECM; that this, in turn, is related to airway wall 
thickening and so reduction in small airway luminal calibre and so airflow. This 
confirms EMT and these flow-on effects from that as having a central place in 
small airway damage, and ultimately destruction as the core pathology in 
COPD airway disease as we and others have previously suggested (Sohal et 
al., 2017a, Sohal et al., 2017b).  
 
It has been accepted that one of the principal causes for airflow limitation in 
COPD is the airway wall tissue remodeling/scarring though re-organization of 
the extracellular matrix (ECM). However, as I have pointed out earlier, the 
evidence for that has not been strong. In the current study, I analyzed two 
important markers of ECM pathology, collagen-1, and fibronectin, both already 
described as co-localized to areas with increased proliferation of myofibroblasts 
(Harju et al., 2010). I also observed an increase in both collagen-1 and 
fibronectin in the airway wall of COPD patients compared to smokers and 
normal controls. Although significant differences were observed the percent 
expression of both these ECMs, there were more marked changes for 
fibronectin compared to collagen-1. However, since collagen-1 was profoundly 
expressed throughout the sub-epithelium, i.e., both in the LP and adventitia, 
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the overall relative collagen index that I have devised (to take into account 
thickening of the airway wall compartments; described earlier), was significantly 
higher for both collagen-1 and fibronectin, in the smoker/COPD pathological 
groups compared to normal controls. Interestingly, though I observed the 
relative differences greater in collagen-1 compared to fibronectin, on adding the 
airway wall parameters, which again is suggestive of collagen-1 being the main 
contributor to airway wall thickness. 
 
My current observation of an increase in collagen-1 is in agreement with the 
earlier studies done  by Harju et al., (2010) in small airway tissues where an 
overall increase in both collagen I and III subtypes in the early stages COPD 
(GOLD stage I and II) were observed in the small airway LP. At the same time, 
my data contrast to observations by Annoni et al. (2012) who suggested a 
decrease in collagen-1 deposition in mild-moderate COPD patients, although 
they too found an increase in fibronectin in the small airways of both smokers 
and COPD.  
 
Interestingly, the excess deposition of collagen-1 in the LP, which related 
positively to the small airway LP thickness, was specific to the COPD groups, 
while remaining unchanged in smokers with normal lung function. This provides 
further evidence for pathophysiological relevance for collagen-1 changes in 
COPD. In contrast and interestingly, fibronectin changes were not related to 
airway thickness, smoking history or lung function in the way that collagen-1 
was; this suggests that it is not involved in physical remodelling but that its 
cellular immune-modulatory roles may be more important. Furthermore, ECM 
changes in COPD in relation to lung function were only significant in current-
smoking COPD and not ex-smokers. I found an increase in collagen expression 
in current smokers affected their lung function while remaining unchanged in 
ex-smokers suggesting a probable reversal in physiological functionality in the 
group. 
 
ECM producing myofibroblasts, which may derive from fibroblasts, have a 
spindle-shaped morphology and are highly contractile. The contractile nature 
of myofibroblasts is directly related to their expression of αSMA myofilaments, 
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which form so-called “stress fibers.” Surprisingly, there have been few reports 
so far that the current data could be compared to. My finding of an increase in 
αSMA positive myofibroblast is in contrast to Karvonen et al., (2013) who 
showed a decrease in expression αSMA cells in the bronchioles of COPD 
patients compared to non-smoker controls. The differences in the findings are 
likely due to the counting strategy and area under consideration. Thus, while 
Karovnen et al., (2013) counted αSMA positive cells in the whole of the sub-
epithelial wall, in the current study I took into consideration αSMA positive cells 
between the whole Rbm and the muscle layer, i.e., the true LP (Figure 6.1). 
Further, I also separately measured αSMA positive cells in the Rbm itself just 
below the epithelium, which could be suggestive of an EMT source. My finding, 
however, was similar to that of Harju et al., (2010) who provided a descriptive 
analysis of the tissue and evidence of co-localization of αSMA positive cells 
with collagen subtypes as well as mesenchymal marker such as vimentin in the 
SA wall. Their conclusion was similar; giving evidence that αSMA positive 
myofibroblast could be responsible for the increased accumulation of collagen-
1 and fibronectin in the small airway LP of COPD patients. Indeed, 
myofibroblasts may well be responsible for airway wall thickening secondary to 
their activation and consequent excessive secretion and accumulation of ECM. 
Further, my observation of the decline in lung function and reduced airway 
caliber with the increased presence of myofibroblast suggest an active 
involvement of this cell type in airway remodeling and resulting pathological 
airway stiffness associated with COPD patients.    
 
As mentioned, our group’s previous data has suggested that the underlying 
mechanism for airway wall remodeling is through the induction of epithelial-
mesenchymal transition (EMT) (Sohal et al., 2010), with a strong relationship 
between markers of EMT activity such as S100A4 and vimentin with decreased 
lung function and airway obstruction (Mahmood et al., 2015, Sohal et al., 2010). 
EMT in COPD is potentially driven by the canonical TGFβ pathways via nuclear 
transcription factor such as pSMAD2/3 while reducing the inhibitory SMAD7 
(Mahmood et al., 2017), with these SMADs strongly correlating with decreased 
lung function parameters and airway obstruction (Sohal et al., 2014).  
Interestingly, TGFβ1 is also known to play a crucial role in the development of 
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myofibroblast from fibroblasts, also through phosphorylation of the same SMAD 
pathway (Gu et al., 2007, Harris et al., 2013).  
 
There is however some limitation to this study; there were fewer individual 
subject tissue samples available per clinical group at this stage through bio-
bank attrition and lack of time to obtain and process more, though my findings 
seem statistically robust and consistent, without likely Type-1 or Type-2 errors. 
Further, for some end-points, especially the EMT markers, I took the 
opportunity of using sections already stained for these by a previous Ph.D. 
student (Dr. Malik Mahmood) as part of his work, but the overlap between his 
subjects and mine were more limited than would have been ideal. Also, as a 
generic problem, the current SA tissues were obtained from cancer patients 
and thus some confounding by this disease pathology in some way cannot be 
ruled out, but all analysis of the tissue was done well away from the cancer-
affected areas, and this seems unlikely.  
 
While the contribution of myofibroblasts was for me a central issue, in fact, my 
study lacks specific information on the origin of the fibroblast in the airway wall 
and the relative contribution of EMT, which I can only speculate on from indirect 
evidence. I had hoped to analyze fibroblast-specific markers with double-
staining, such as NG2 for pericytes, and fibroblast/myofibroblast activation 
markers such as PDGFRα/β, CD44, and Thy-1 among others to further 
delineate this further, but essentially ran out of time. 
 
Finally, regarding limitations, there is the whole issue of the airways in these 
COPD tissue samples being essential “survivors.” In other words, we now know 
from the work of Hogg (Kirby et al., 2017) that a significant number, even 
perhaps a majority, of airways will have been destroyed by the time the patients 
reached the degree of airflow obstruction. It is quite likely that the processes 
that are involved here do indeed represent this destructive process, but it 
seems even more interesting that the regression analyses were productive. My 
conclusion here reflects not only acute pathology relevant to this point in time 
that the airways were sampled but also in some profound way represent the 
whole history of the pathological process probably going back over many years. 
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The fact that there was so much pathology already present in apparently 
physiologically normal individuals would back this up very strongly.  
 
 Conclusion 
 
In this chapter, I have provided comprehensive numerical estimates of the 
myofibroblast population in the small airways of COPD patients, and some 
estimate of their activity. Thus, their close (if in some ways complex) 
relationships to ECM deposition, airway remodelling and pathophysiology 
suggest that they do have an important and even a critical role in the core 
disease process in COPD airways and its progression.  
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Summary and Conclusions 
 
 Overview of results 
 
COPD is now known to be a globally devastating disease, mainly caused by 
cigarette smoking worldwide and certainly in more developed countries. The 
disease prevalence is 210 million persons affected worldwide, and it causes at 
least 3 million deaths annually, which corresponds to 5% of total mortality 
(Schluger and Koppaka, 2014). The disease is characterized primarily by slowly 
progressive airway narrowing with only partial reversibility at most. Vulnerable 
smokers develop in particular the core pathology of small airway fibrosis that 
leads to luminal narrowing and ultimately obliteration, accompanied by 
“bronchitis” and structural changes throughout the airway tree. Up to fifty 
percent of the patients go on to suffer also from varying degree of 
parenchymatous lung destruction (emphysema) which adds to airflow 
obstructions and associated symptoms. 
 
Airway inflammation is widely said to be central to COPD airway pathology, but 
what this means is somewhat enigmatic and probably over simplistic. Indeed, 
over the years, the literature has reported increases in both innate and adaptive 
cells in the airway lumen in COPD with convincing increases in both 
bronchoalveolar lavage (BAL) and sputum samples in COPD (Pesci et al., 
1998a, Rutgers et al., 2000b, Pesci et al., 1998b). However, there are 
substantial contradictions about the actual picture of inflammation, if it exists at 
all, in both the large and small airway wall (Di Stefano et al., 1998a, Di Stefano 
et al., 2001, Saetta et al., 1999). In my literature survey in chapter 2, I have 
provided a comprehensive analysis of the inconsistencies in the prevailing 
dogma about COPD at least as it applies to the crucial airway compartment. 
Thus, in this thesis I have provided a comprehensive cross-sectional 
reassessment of the total and differential inflammatory cells in the airway wall; 
it is this overall cellularity in the airway wall of COPD patients that is crucial. 
This has been detailed in chapter 4, and only the broad overview is discussed 
here. Further, in chapter 5, I provide a more in-depth analysis on the 
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understudied subtypes (M1 and M2) of macrophage, for both the airway wall 
and the lumen. In chapter 6, I evaluate the presence of another key 
inflammatory cell type, Mast Cells, in the small airway wall and provided 
evidence of dysfunctionality both specific to MCs but also a more generalized 
abnormality with a reduction in degranulation capacity of cells in the airway wall. 
In chapter 7, I assessed the myofibroblast population in the airway wall, studied 
their potential contribution to airway wall thickness and ECM changes, and 
further explored their relation to EMT activity in basal epithelial and Rbm cells. 
I also provide further evidence on the possible contribution of EMT to the fibrotic 
changes, airway thickness and remodeling, and presence of airway obstruction. 
 Assessment of airway wall cellularity and inflammation 
 
In tune with my stated aims, I began by revaluating the cellular composition of 
the airway wall, and this followed on from our research group`s previous 
observations of likely hypo-cellularity in the large airway of COPD patients 
(Sohal et al., 2013a). Thus, in chapter 4, I have made a comprehensive 
assessment of cellularity in both the large and small airways. I observed that 
both large and small airways areas were hypo-cellular in COPD patients when 
compared to a normal control group. Interestingly, this decrease in airway wall 
cellularity in COPD patients reflects reductions in both innate and adaptive 
inflammatory cells such as neutrophils, macrophage, CD4 and CD8 cells in 
large airways, and in the small airway except CD8 lymphocytes.  All cells types 
evaluated in the small airways were either reduced or at best remained 
unchanged from normal. Further, in this chapter, I have also questioned the use 
of CD68 expression alone as a marker for detecting macrophages after having 
observed that they also tag more fibroblastic looking cells. Finally, there was 
the novel contribution that classic inflammatory cell types alone constituted only 
20-30% of the overall cellularity, which formed the basis of further investigation 
on the role of other cell types in the airway wall, which I believe, are largely 
stromal cells (Figure 8.1). 
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Figure 8.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.1 Summary of percent inflammatory cell component to the total cells 
in the large and small airways of non-smokers (NC) and COPD-CS (Neu- 
Neutrophils, Mac- CD68+ Macrophages, Fibro (CD68+fibroblast like cells), MC- 
Mast cells, Eos- Eosinophils, CD4 and CD8 cells). 
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 Abnormal switching in the M1 and M2 macrophage phenotypes in 
small airway wall and the lumen of COPD patients (Chapter 5) 
 
Another novel and somewhat paradoxical finding were that macrophages in the 
airway lumen are skewed towards an anti-inflammatory/ pro-fibrotic phenotype 
while M1 pro-inflammatory macrophage is more common in the airway wall. 
Indeed, in my work, this was the only evidence that there may be an 
inflammatory process in this compartment. This is the first time that such 
phenotype switching has been described and to that extent, at least, this 
change may underlie downregulation of macrophages function that has been 
described in luminal cells, e.g., in efferocytosis. Further, I provide evidence that 
this switching of macrophages may be influenced by the luminal 
microenvironment of the region, which again was found to be skewed towards 
an M2/TH2 phenotype. Another notable observation was the generalized 
excessive expression of the enzyme arginase-1 in the airway wall of COPD 
current smokers both in their epithelium and sub-epithelium areas. Such an 
increase of arginase-1 is known to tilt the balance of tissue homeostasis by 
again promoting a more fibrotic phenotype through inducing collagen formation 
and thus airway stiffness. This change from an iNOS dominance is also likely 
to explain why in smokers and COPD nitric oxide production from the 
respiratory tract is reduced, which has been known for some time; in turn this 
my may underlie a defect in microbial killing.  
 Evaluation of mast cells, degranulated mast cells and 
degranulated cells in the airway wall of COPD patients 
 
In chapter 6, I also evaluated the presence of mast cells and their degranulating 
capacity in the airway wall of COPD patients. Indeed, as all other inflammatory 
cells described earlier, I found that there was a decrease in the number of mast 
cells in the sub-epithelium of COPD patients. This was again in contrast to the 
previous report from our group which found that an increase in mast cell in a 
similar area as in the large airways. Further, this is the first reported use of 
LAMP-1, a lysosomal marker to evaluate degranulation capacity in mast cells. 
While the only slight decrease was observed in the degranulating mast cells, 
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the overall degranulating capacity of the cells in COPD patients was found to 
be significantly lower in when compared to normal control. This could thus 
suggest a decrease in the overall functionality of the cells. However, the 
description of the degranulation provided in this chapter is generalized and thus 
warrants more investigation, specific to individual cell types.  
 Extensive evaluation of small airway fibrosis 
 
This is the first time than anyone has systematically “dissected,” using immune-
pathological methods on resected lung tissue, the dimensions of the small 
airway wall in smokers and COPD patients compared with normal controls. 
Given that we know that the pathophysiology in COPD airways is focused in 
this area, this has been a remarkable gap in respiratory research. The core 
finding related to COPD is of thickening of all compartments in the small airway 
wall, i.e., Rbm, LP, ASM layer, and adventitia, but the changes in LP are the 
strategically the most specific to COPD, while other changes may be more of a 
smoking effect. Indeed, the degree of pathology that was found in apparently 
physiologically “normal” smokers was quite striking. All of these clinical tissues 
came from cancer resections and it is possible that they represent the end of 
the normal lung function smoker range, but they are still not being picked up by 
conventional spirometry airflow methods.  
 
Myofibroblast in the airway wall, specifically in the LP, were dramatically 
increased in COPD and statistically related to airway thickness. Similarly, the 
airway wall depositions of collagen-1 and fibronectin, the ECM proteins related 
to fibrosis that I measured, were increased, but only the collagen was closely 
related to airway wall thickening and to airflow obstruction. Driving all these 
changes is likely to be EMT activity in the basal epithelial cells. Given the 
relationships found, this is likely due to their transition directly into 
myofibroblasts, though it is conceivable that the myofibroblast change could be 
indirect through EMT-related activity stimulating stromal cells, pericytes or 
endothelial cells to transition; this, however, is highly speculative at this stage, 
and a direct effect of EMT is most consistent with the data now provided.  
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 Concluding remarks 
 
I believe that this work presented here advances the understanding of the core 
pathology in smokers and COPD substantially and somewhat by directly adding 
to the early work of Macklem and colleagues who describe the small airways 
as the site of both increase airway resistance in smokers and probably 
enhanced “fibroblast” activity as the likely pathology.  
 
The focus of most pathogenic research in COPD over the past 40 years has 
been on airway luminal innate immune activation (“inflammation”) and the 
drivers of this (and emphysema) including disturbance of protease/anti-
protease balance and oxidant/anti-oxidant balance. There has been limited 
follow up on the seminal work of pathologists Lynne Reid and Michael Dunnill 
describing abnormal epithelium in COPD. Only until recently work by Ronan 
Crystal`s group demonstrated the significance of the abnormality in basal 
(stem) cell genetic programming in the airway epithelium and their 
consequence to airway pathology. Parallel to this was our group’s observation 
that one of the consequences of such reprogramming in these basal cells is 
active EMT. I have taken this observation a significant step further by showing 
the EMT activity in the epithelium is strongly related to myofibroblast expansion 
in the sub-epithelial LP of the airway wall and what reasonably seem to be 
consequential changes in airway thickness, ECM changes and airway 
obstructive changes 
 
The finding that the airway wall in COPD is essentially NOT an inflammatory 
milieu but is indeed hypo-cellular and fibrotic is especially important. At the 
expense again of slightly exaggerated language, my picture of the airways in 
COPD is one of a “dying tissue,” which fits in well with the vital observations by 
the Hogg’s group of the disappearance of small airways being such a dramatic 
early feature of this disease process. 
 
Finally, I have made some rather more preliminary and provisional 
observations: on macrophage phenotype switching in the airways which may 
well underlie important known functional changes in this cell population; on a 
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switch from iNOS to arginase dominance in the airway tissues in COPD; on 
dysfunction in degranulating cells in the airway wall; and indeed even more 
preliminary observations of likely protein-handling/lysosome and autophagy 
abnormalities in the COPD epithelium. This latter has not been included in the 
thesis because they are not yet sufficiently mature, although recently presented 
at national and international conferences. I mention this feature now only 
because these new observations open potentially new avenues for COPD 
research and potential advances in integrative pro-fibrotic (and pro-malignant) 
understanding of fundamental COPD pathogenesis which have been sorely 
absent for much of the last 40-50 years, with some crucial exceptions which I 
have tried to highlight. 
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